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ABSTRACT: The four-membered oxetane ring has been increasingly exploited for its
contrasting behaviors: its inﬂuence on physicochemical properties as a stable motif in
medicinal chemistry and its propensity to undergo ring-opening reactions as a synthetic
intermediate. These applications have driven numerous studies into the synthesis of new
oxetane derivatives. This review takes an overview of the literature for the synthesis of
oxetane derivatives, concentrating on advances in the last ﬁve years up to the end of
2015. These methods are clustered by strategies for preparation of the ring and further
derivatization of preformed oxetane-containing building blocks. Examples of the use of
oxetanes in medicinal chemistry are reported, including a collation of oxetane derivatives
appearing in recent patents for medicinal chemistry applications. Finally, examples of
oxetane derivatives in ring-opening and ring-expansion reactions are described.
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1. INTRODUCTION
Oxetanes, as strained cyclic ethers, present a fascinating
combination of stable motifs for medicinal chemistry and
reactive intermediates for further synthesis. These features
make them attractive motifs for an ever-increasing range of
applications in the chemical sciences. In medicinal chemistry,
oxetanes have received enormous interest as replacement
groups for gem-dimethyl and carbonyl groups with improved
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physicochemical properties. The small, polar nature of the
heterocycle has led to its incorporation as a pendant motif to
improve “druglike” properties, in particular solubility, and also
to oﬀer intellectual property advantages. As a result, these units
have been widely adopted in medicinal chemistry programs in
recent years. These recent studies have relied on both
established synthetic methods and development of numerous
new methodologies for oxetane synthesis and incorporation.
Accordingly, a number of novel methods have been developed
to access oxetane-containing compounds. At the same time,
there have been signiﬁcant advances in utilizing the reactivity of
oxetanes in the synthesis of complex molecules. The strain in
the small ring facilitates opening with nucleophiles, rearrange-
ments, and ring expansions. Here, we review and collate the
synthetic methods and reactivity of oxetanes, as well as
commenting on the relevance to medicinal chemistry programs.
Advances up to late 2015 are included, concentrating on more
recent developments but also detailing older work that still
remains powerful in the synthesis of varied oxetane derivatives.
Section 2 will introduce structural features of the oxetane
ring and properties that the ring can impart in a medicinal
chemistry context. The following sections then examine
oxetane synthesis through ring-closing approaches, with the
cyclization step forming a C−O or C−C bond (section 3), and
(formal) [2+2] cycloadditions forming both C−C and C−O
bonds (section 4). Selected transformations of oxetane-
containing products are discussed in each section to illustrate
the stability of the ring to chemical transformations, as are
selected applications of biologically active products. Section 5
examines strategies available for the incorporation of intact
oxetane motifs, including the use of Carreira’s oxetan-3-one and
other small oxetane-containing building blocks that maintain
the small ring. This section also includes a survey of the use of
these building blocks in medicinal chemistry applications, with
selections covering primary literature and also patent literature.
Section 6 continues the functionalization of intact oxetane
derivatives through metalation. Section 7 focuses speciﬁcally on
2-exo-methyleneoxetanes and their synthesis and functionaliza-
tion, in both ring-opening reactions and methods that maintain
the ring structure leading to functionalized oxetane derivatives.
Section 8 reviews ring-opening and ring-expansion reactions of
oxetanes, where the four-membered ring is modiﬁed to
generate new structural types. Readers are also directed to
other notable and complementary reviews incorporating varied
aspects of oxetane chemistry from Carreira and co-workers,1,2
Abe,3 D’Auria and Racioppi,4 De Kimpe and co-workers,5
Mahal,6 Malapit and Howell,7 Sun and co-workers,8 and
others.9−11 The extensive use of oxetane motifs in other ﬁelds,
including polymer chemistry as a monomer12−18 and a cross-
linker19,20 and, for example, in catalytic reaction with CO2 to
generate cyclic carbonates,21−27, is outside the scope of this
review and will not be considered.28−30
2. PROPERTIES AND NATURAL OCCURRENCE OF
OXETANES AND THEIR INFLUENCE ON
BIOLOGICALLY RELEVANT PHYSICOCHEMICAL
PROPERTIES
2.1. Physical Properties of Oxetanes
Oxetane itself is a four-membered ring containing an oxygen
atom with an inherent ring strain of 106 kJ·mol−1 [epoxides 112
kJ·mol−1; tetrahydrofurans (THFs) 25 kJ·mol−1].31,32 The ring
adopts an essentially planar structure with a puckering angle of
only 8.7° at 140 K (10.7° at 90 K) as indicated in an X-ray
crystal structure of the parent heterocycle (Figure 1a).33,34 The
planar structure minimizes the strain in the ring, and due to the
presence of the heteroatom, there are considerably fewer
gauche interactions, which are reduced by puckering, than in
cyclobutane (cf. 30° puckering for cyclobutane).35
The introduction of substituents onto the oxetane ring can
increase the unfavorable eclipsing interactions, resulting in a
more puckered conformation. For example, X-ray crystallo-
graphic investigations showed that the puckering angle of the
biodegradable insecticide EDO was 16° (Figure 1b).36 The
carbon−oxygen bond length in unsubstituted oxetane is 1.46 Å
and the carbon−carbon bond length is 1.53 Å, which results in
bond angles of 90.2° (C−O−C), 92.0° (C−C−O), and 84.8°
(C−C−C), by X-ray at 90 K.34 The strained C−O−C bond
angle exposes the oxygen lone pair of electrons, allowing the
oxetane to act as an excellent hydrogen-bond acceptor as well
as Lewis base.37 As required for hybridization in small rings,
there is increased p-character to the bonds in the ring, and exo-
cyclic substituents have increased bond angles. The increasing
s-character of the oxygen lone pairs as the ring size of the cyclic
ether decreases does not have a signiﬁcant inﬂuence on the H-
bonding ability until three-membered epoxides. Consequently,
oxetanes form more eﬀective H-bonds than other cyclic
ethers.38,39 Similarly, oxetanes compete as H-bond acceptors
with the majority of carbonyl functional groups (aliphatic
ketones, aldehydes, and esters),40,41 with only amides providing
better acceptors.42,43 These structural features are important for
many of the advantageous properties of substituted oxetanes.
2.2. Oxetanes in Natural Products
The oxetane ring appears in relatively few natural product
structures, but when it is present, there is important biological
activity that is often reliant on the ring (Figure 2). Perhaps the
most well-known example is paclitaxel, or Taxol, ﬁrst isolated in
1971 from the stem bark of the western yew (Taxus brevifolia)
and used in cancer chemotherapy.44 Taxol acts by binding to
microtubules and stabilizing them during cell division.45
Computational studies concluded that the oxetane acted as a
conformational lock, rigidifying the structure,46 or alternatively
as a hydrogen-bond acceptor.45 Although lower activity was
observed when the oxetane was replaced with related
alternative ring structures,45,47,48 very recent studies have
shown that the oxetane is not in fact essential for biological
activity.49 In the purported biosynthesis of taxol, cyclization
occurs via an enzyme-mediated epoxy ester/oxetane ester
rearrangement mechanism. Three separate mechanisms for this
transformation have been proposed: a neutral-concerted
Figure 1. Structural properties of oxetane and puckering of the
substituted oxetane ring in EDO.
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pathway (Figure 3a),50 an acid-catalyzed route (Figure 3b),51
and a dissociative pathway (Figure 3c).52 Computation studies
by Willenbring and Tantillo53 were unable to ﬁnd evidence to
conclusively distinguish among the three mechanisms.
Various other oxetane-containing compounds have been
isolated from natural sources. Oxetanocin A was ﬁrst isolated
from the soil bacteria Bacillus megaterium and inhibits the in
vivo replication of human immunodeﬁciency virus (HIV).54
Oxetin was isolated from a broth of Streptomyces sp. OM-2317
and has antibacterial and herbicidal eﬀects.55 It was reported to
inhibit Bacillus subtilis and Piricularia oryzae in minimal media,
as well as showing herbicidal activity, inhibiting glutamine
synthetase from spinach leaves. Both maoyecrystal I and
mitrephorone A were shown to be cytotoxic.56,57 Thromboxane
A2 has prothrombotic properties, and the oxetane is very short-
lived in the body due to the acetal structure.58 Merrilactone A
was ﬁrst isolated in 2000 from the pericarps of the Illicium
merrillianum plant and was shown to stimulate the growth of rat
neurons.59 Dictyoxetane is a marine diterpene isolated from the
brown alga Dictyota dichotome whose biological properties are
currently not understood.60 This pentacyclic structure has been
subject to a synthetic model study targeting the unusual
tricyclic heterocyclic portion.61 Finally, bradyoxetin, produced
by the soil bacterium Bradyrhizobium japonicum, has two
pendant oxetane rings.62
2.3. Oxetanes as Replacement Groups
In 2006, Carreira, Rogers-Evans and co-workers63−65 (Hof-
mann-La Roche) published a highly inﬂuential report on the
use of 3,3-disubstituted oxetanes as replacement groups for
gem-dimethyl groups in medicinal chemistry (Figure 4). gem-
Dimethyl groups have commonly been used in medicinal
chemistry to block metabolically vulnerable methylene sites.
However, their introduction results in an increase in
lipophilicity, which itself may have adverse eﬀects on the
pharmacokinetic properties of a compound.66 This work
exploited the similar molecular volume of the oxetane and
gem-dimethyl groups67,68 to propose the oxetane motif as a
considerably more polar equivalent of a gem-dimethyl group
with the same spacial arrangement. The replacement aﬀorded a
reduction in lipophilicity (cLogP), which can give an associated
reduction in metabolic liability.
To probe the eﬀect of the replacement of a gem-dimethyl
unit with an oxetane, the t-butyl group of a model compound,
1, was replaced with a methyl-substituted oxetane, 2 (Figure
5).63 The parent compound chosen was both lipophilic and
amphiphilic, but it became considerably more polar and more
soluble upon introduction of oxetane. In addition, the
metabolic stability was improved as indicated by reduced
intrinsic clearance rates (CLint; microliters per minute per
Figure 2. Oxetane-containing natural products.
Figure 3. Three proposed pathways for biosynthesis of the oxetane
ring of taxol.
Figure 4. 3,3-Disubstituted oxetanes as replacement group for gem-
dimethyl.
Figure 5. Eﬀects of replacing a gem-dimethyl group with oxetane.
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milligram) measured in human (h) and mouse (m) liver
microsomes. Oxetane-containing compound 2 was also shown
to be have reduced hERG (human ether-a-go-go-related gene)
inhibition (hERG IC50 35 μM for 2 vs 7.5 μM for 1) due to the
reduction in lipophilicity.63,65
The strong σ-electron-withdrawing properties of the oxetane
ring were shown to attenuate the basicity of nearby amines.
Through an “oxetane scan”, the greatest eﬀects were seen when
the oxetane was in α-position to the amine, but interestingly, a
decrease of 0.3 pKa unit was still observed when the oxetane
was in δ-position to the amine compared to the parent
compound (Figure 6). The chemical stability of these
compounds, including 2−6, was shown to be high in aqueous
buﬀers over the pH range 1−10 for 2 h at 37 °C.63
In a subsequent series of papers, Carreira and co-work-
ers1,2,65,69 investigated various properties of oxetanes as
replacement groups, resulting in a number of advantageous
changes. In particular, the use of oxetanes as replacements for
carbonyl groups has been of considerable interest due to similar
dipoles and H-bonding properties (Figure 7).69 Whereas
carbonyl compounds (aldehydes, ketones, and esters) are
vulnerable to enzymatic attack and α-deprotonation/epimeriza-
tion of stereogenic centers, oxetane derivatives are stable to
both of these concerns. As a replacement, the main diﬀerence
between an oxetane and carbonyl motif is the length of the
group. Fujishima et al.70,71 employed this strategy and the
increased size of the oxetane to improve the binding aﬃnity of
1,25-dihydroxyvitamin D3 analogues for bovine thymus vitamin
D receptor.
Carreira and co-workers69 studied the physiochemical and
biological properties of various matched pairs of oxetane-
containing spirocyclic compounds and their corresponding
carbonyl-containing heterocycle derivatives (Table 1). In both
the pyrrolidine and piperidine derivative pairs, 7/8 and 9/10,
incorporation of the oxetane ring decreased solubility.
However, opposing eﬀects on lipophilicity were observed. On
the other hand, metabolic stability was considerably improved
for oxetane spirocycles 8 and 10 compared to 7 and 9 in terms
of the intrinsic clearance rate.
Morpholine rings are often incorporated into drug scaﬀolds
to improve aqueous solubility, but they can also undergo
undesirable oxidative metabolism. Due to similar structural
properties, the spirocyclic oxetane motif 12 was suggested as a
morpholine replacement. When compared to morpholine 11,
spirocyclic oxetane 12 had increased aqueous solubility and
decreased lipophilicity while remaining metabolically stable
toward oxidation (Table 1). In recent years, Carreira and co-
workers have also reported spirocyclic structures as structural
analogues of heterocycles, including piperazine72 as well as
piperidine and thiomorpholine analogues,73 and other
spirocyclic small-ring heterocyclic systems targeting drug
discovery.74−78
In 2008, Duncton et al.79 examined the stability of a series of
oxetane derivatives on incubation with human liver microsomes
in the presence of glutathione and nicotinaide adenine
dinucleotide phosphate (NADPH), to screen for reactive
metabolites (Figure 8). Glutathione conjugates were observed
for fewer than half the derivatives tested, which was interpreted
as providing evidence that the oxetan-3-yl chemotype could be
attractive for medicinal chemistry.
In 2013, Carreira and co-workers80 explored the eﬀects of
structural modiﬁcation of thalidomide and lenalidomide.
Infamously, while the R-isomer of thalidomide functions as
an anti-emetic and sedative, the S-isomer is a teratogen.
Crucially, these readily interconvert under physiological
conditions. When the imide CO was replaced by an oxetane,
an increase in solubility and decrease in lipophilicity, and no
Figure 6. Eﬀect of oxetane motif on amine basicity.
Figure 7. Comparison between carbonyl and oxetane functional
groups, representing similar arrangement of lone pairs and change in
size.
Table 1. Physicochemical and Biological Properties Demonstrating the Eﬀects of Replacing a Carbonyl Group with an Oxetane
Ringa
aIntrinsic clearance rates were measured in human (h) and mouse (m) liver microsomes.
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unfavorable diﬀerence in the intrinsic clearance rates in human
microsomes, was observed (Table 2).80 Oxetanothalidomide 13
was shown to be conﬁgurationally stable to racemization in
human blood plasma after an incubation period of 5 h, thereby
showing that oxetanes as replacements of carbonyl groups can
alleviate epimerization at adjacent stereocenters.
Dowling et al.81 at AstraZeneca compared 3-aminooxetane
motifs with other small rings through a series of matched pairs
(Figure 9). It was found that introduction of oxetane lowered
logD by ∼0.8 unit in comparison to aminocyclopropane and
aminocyclobutane derivatives. In addition, the oxetane
derivative signiﬁcantly decreased the fraction of compound
bound by human plasma proteins, increased metabolic stability
(rat liver microsome and hepatocyte), and reduced hERG ion
channel binding.
While 3-substituted oxetanes have now been relatively well
explored in this manner and have been exploited accordingly
(see section 5), there remain fewer examples and little data on
other oxetane substitution patterns being examined in any
detail in this context. The most notable study that compared
oxetane substitution patterns, from Stepan et al.82 (Pﬁzer),
studied the eﬀect of diﬀerent carbocyclic and oxygen
heterocylic derivatives on a series of N-substituted arylsulfona-
mides. Progression from carbocyclic rings to six- and ﬁve-
membered oxygen heterocycles and eventually oxetane rings
gave an improvement in metabolic stability without reduction
in potency (Figure 10). Across THF derivatives, the 3-
substituted example was more stable to human liver micro-
somes (HLM) than the 2-substituted derivative; similarly, the
3-monosubstituted oxetane was more stable than the 2-
monosubstituted derivative. Metabolite identiﬁcation studies,
which initially identiﬁed N-alkyl substituents as metabolically
labile, were able to identify sites of oxidative metabolism. For
the 2-monosubstituted oxetane derivative, the compound
underwent ring scission, forming hydroxy acid and diol
metabolites. For the 3-monosubstituted oxetane derivative,
the major metabolic route was oxidation of the bridging
methylene carbon leading to N-dealkylation. Incorporation of
gem-dimethyl substitution at the oxetane 4-position gave the
most stable derivative (CLint 25.9 mL·min
−1·kg−1), whereas a
gem-dimethyl group at the 3-position aﬀorded a considerably
Figure 8. Examples of oxetanes tested with human liver microsomes and glutathione.
Table 2. Comparison of Physicochemical Properties of
Thalidomide and Oxetanothalidomide
Figure 9. Matched-pair analysis of logD for 5-anilinopyrazolo[1,5-
a]pyrimidine inhibitors of CK2 kinase.
Figure 10. Comparison of metabolic stability of N-substituted arylsulfonamides. CLint,app is total intrinsic clearance obtained from scaling in vitro
HLM half-lives.
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less stable example (CLint > 293 mL·min
−1·kg−1). This study
concluded that introduction of an oxetane could increase the
overall drug likeness of molecules. Further studies examining
oxidative metabolism showed this was largely due to CYP3A4
and that metabolic stability was directly linked to intrinsic
lipophilicity.83,84 As such, oxetane derivatives beneﬁted from
their increased polarity compared to other cyclic ethers.
Bull and co-workers85 have reported studies into the
chemical and metabolic stability of 2-sulfonyloxetanes, which
were designed as novel fragments for fragment-based drug
discovery. Selected compounds were shown to be stable across
the pH range 1−10, with half-lives in the region of 4−5 days at
25 °C. Similarly, the intrinsic clearance of 2-(2-pyridylsulfonyl)-
oxetane was investigated in rat hepatocytes and shown not to
present a metabolic liability. Oxetane δ-amino acid scaﬀolds,
synthesized by Wessel and co-workers86−88 at Roche, were used
to generate an oxetane-based library of oxadiazoles and
triazoles.89 Typical physicochemical properties were calculated
for the oxetane library, and found to be within desirable ranges
for medicinal chemistry (Figure 11). Metabolic properties, in
particular the oxetane derivatives’ susceptibility toward
degradation in human and mouse microsomes, were evaluated
for a selection of substrates. All oxadiazoles tested displayed
medium to low clearance in either human or mouse
microsomes.
Wipf and co-workers90,91 recently developed an oxetane-
containing neutral solubilizing group by adapting an oxetanyl
dimethyl sulfoxide (DMSO) derivative that had proved
eﬀective as an additive to enhance aqueous solubility of small
organic molecules. The oxetanyl sulfoxide motif was incorpo-
rated into poorly soluble drugs or drug candidates, particularly
those containing an ionizable group (Figure 12).90 For
example, carboxylic acids were transformed into oxetanyl
sulfoxide ester derivatives, and amines, used as the hydro-
chloride salt to improve solubility, were converted into the
corresponding oxetanyl sulfoxide carbamates. For a naproxen
derivative, oxetanyl sulfoxide derivative 14 showed a >10-fold
increase in solubility and also a signiﬁcant increase in cell
permeability. A similar increse in solubility was achieved by
converting free amines to oxetanyl sulfonyl carbamates. A
bioactive mitochondrial-targeted nitroxide, JP4-039, currently
in development, saw a very large (76-fold) solubility increase
when the t-butyl carbamate was converted into oxetanyl
sulfoxide derivative 15.
These studies and the presence of oxetanes in biologically
active compounds have established the oxetane motif as an
intriguing structure in medicinal chemistry. Introduction of an
oxetane can beneﬁcially inﬂuence solubility, metabolic stability,
and lipophilicity of a compound as well as inﬂuence the basicity
of proximal amines. The small polar core may provide the
possibility to increase steric bulk without increasing lip-
ophilicity.63 As a result of these desirable properties, oxetanes
have recently received signiﬁcant interest from the pharma-
ceutical industry, often being employed as bioisosteres and to
improve the physicochemical properties of druglike compounds
(see section 5 particularly).92−94 Recent trends in medicinal
chemistry have sought to incorporate motifs that are more sp3-
rich, that reduce planarity and improve solubility and other
physicochemical properties, without a signiﬁcant increase in
molecular weight;95−97 the small, polar oxetane motif may oﬀer
opportunities toward these goals (this section and section 5).
The deﬁned three-dimensional “scaﬀolding” properties of
oxetanes have been exploited as sugar mimics (sections 3.1.4
and 7), and oxetanes have been investigated as amide
replacements in unnatural peptides (section 3.1.2 and section
5.1). The subsequent sections will cover the synthesis of varied
oxetane derivatives, with examples of the exploitation of the
property changes brought about through oxetane incorpo-
ration, and also the reactivity of oxetane derivatives.
3. SYNTHESIS OF OXETANE DERIVATIVES BY
INTRAMOLECULAR CYCLIZATION
The inherent ring strain in oxetane products makes cyclization
a fundamental synthetic challenge, and the kinetics of
cyclization to form four-membered saturated cyclic ethers are
signiﬁcantly slower than for three-, ﬁve-, and six-membered
analogues.98 Hence anions and good leaving groups are
commonly required to achieve acceptable yields for the
cyclization of functionalized acyclic precursors to oxetane
derivatives. The most common disconnection forms the C−O
bond through an intramolecular etheriﬁcation reaction, which
has been achieved by several approaches (section 3.1),
complemented by few but increasing C−C bond-forming
methods (section 3.2).
3.1. Cyclization through C−O Bond Formation
3.1.1. Intramolecular Etheriﬁcation. Williamson ether-
iﬁcation describes a general approach to ether synthesis by a
base-mediated nucleophilic substitution reaction between an
alcohol and an aliphatic carbon center in a 1,3-relationship for
oxetane synthesis. Intramolecular cyclization generally provides
the desired oxetane products; however, the yields can be
modest due to undesirable side reactions, such as Grob
fragmentation of the halo-alkoxide into an aldehyde and an
alkene.99,100 Consequently, intramolecular Williamson ether-
iﬁcation as a method for oxetane synthesis is rather substrate-
dependent. This approach was ﬁrst used for the synthesis of
oxetane in 1878 by Reboul101 and remains most commonly
Figure 11. Examples from Wessel’s oxetane library.
Figure 12. Wipf’s oxetane-containing neutral solubilizing group.
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employed in the synthesis of complex oxetane-containing
structures.102−105
Nelson and co-workers106,107 reported a stereocontrolled
synthesis of 2,4-substituted oxetanes from 1,3-diols (Scheme 1).
The syn- and anti-diols 16 and 20 were synthesized from the
same aldol precursor by stereoselective reduction.108,109
Selective synthesis of acetoxybromides 17 and 21 from the
1,3-diols was achieved with inversion of stereochemistry by
conversion to the ortho esters followed by treatment with
acetyl bromide. The required 1-hydroxy-3-bromo relationship
present in intermediates 18 and 22 was established by use of
diisobutylaluminium hydride (DIBAL) to cleave the acetyl
group. Intramolecular cyclization to oxetanes 19 and 23 was
then achieved with complete inversion of stereochemistry by
use of sodium hydride in THF, resulting in overall retention of
stereochemistry (through double inversion at the benzylic
center) over three steps from the 1,3-diol. Interestingly, with a
methyl in the 3-position of the oxetane product, a mixture of
diastereoisomers was observed, which was speculated to be due
to formation of a benzylic cation (not shown). A one-pot
procedure for conversion of 17 to 19 was also developed,
removing the need for DIBAL reduction, by addition of 1 equiv
of MeOH and excess base.
An important enantioselective synthesis of oxetanes was
reported in 1986 by Soai et al.110 Three examples of
enantioenriched 2-aryl-substituted oxetanes were prepared
through enantioselective reduction of β-halo ketones followed
by Williamson ether cyclization promoted by KOH. Enantio-
meric excesses of 79−89% were achieved by enantioselective
reduction with a chiral reducing catalyst, generated in situ from
lithium borohydride and chiral ligand 24. Acetylation followed
by subsequent ring closure aﬀorded oxetanes without
racemization (Scheme 2a).
More recently, Lo and Fu111 demonstrated the preparation
of enantioenriched oxetanes by the same approach from
enantioenriched γ-chlorohydrins. These were, in turn, synthe-
sized from β-chloroketones via an asymmetric reduction with
(+)-B-chlorodiisopinocampheylborane [(+)-DIP-Cl; Scheme
2b].112 The cyclization used KH, and while the yield was
moderate, the enantiomeric excess (ee) was retained. Dussault
et al.113 reported the preparation of enantioenriched oxetanes
via cyclodehydration of enantioenriched 1,3-diols, generated
from 2,3-epoxy alcohols by ring opening with sodium bis(2-
methoxyethoxy)aluminum dihydride (RedAl) or dimethyl
cuprate (Scheme 3). The use of KOtBu in THF for both
monotosylation and cyclization gave the oxetanes in high yield,
either as a one-pot reaction or through isolation of the
monotosylate.
In 2006, Mandal and co-workers114 reported one-pot
synthesis of a variety of cyclic ethers, including oxetanes,
using a Williamson etheriﬁcation protocol. Starting from the
desired diol, conversion of the primary alcohol to the iodide
through an Appel reaction, followed by treatment with base,
generated oxetanes 25 and 26 in 82% and 78% yield,
Scheme 1. Stereocontrolled Synthesis of Oxetanes 19 and 23 from the Corresponding Diols
Scheme 2. Asymmetric Synthesis of 2-Aryloxetanes by Use of a Chiral Catalyst
Scheme 3. Stereocontrolled Synthesis of Oxetanes from
Epoxy Alcohols
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00274
Chem. Rev. XXXX, XXX, XXX−XXX
G
respectively (Scheme 4). [See sections 3.1.3 and 3.1.4 for
oxetane-containing sugar derivatives and nucleoside analogues.]
The ﬁrst synthesis of oxetin employed a traditional
Williamson etheriﬁcation with a tosylate leaving group to give
the oxetane ring motif with the desired stereochemistry. Omura
and co-workers115 synthesized the natural product and its three
stereoisomers, using a sugar as a chiral auxiliary (Scheme 5a).
From aldehyde 27,116 a Wittig reaction aﬀorded both cis- and
trans-alkenes with poor selectivity (1.3:1 cis/trans), but they
could be separated by chromatography. Reduction of the ester
moiety with DIBAL accessed both allylic alcohols in good
yields, and epoxidation of the cis-allylic alcohol with m-
chloroperoxybenzoic acid (m-CPBA) gave both possible
stereoisomers of epoxide 28a/b. Regio- and stereoselective
ring opening of epoxide 28a with NaN3 aﬀorded a single
product with an excellent 81% yield. Selective tosylation of the
primary alcohol, followed by Williamson etheriﬁcation with
KOtBu, aﬀorded oxetane 29 in good yield. Functional group
manipulation aﬀorded the natural product 30, which was
puriﬁed by ion-exchange chromatography. The remaining three
stereoisomers 31−33 (Scheme 5b) were all prepared by the
same synthetic route. Subsequently, all four stereoisomers of
oxetin were tested against B. subtilis, but only the natural
product oxetin 30 showed any activity.
Synthesis of oxetanocin was achieved by Yamamura and co-
workers117 by use of Williamson etheriﬁcation for the oxetane-
forming step (Scheme 6). A sodium hydride-mediated
cyclization was utilized to synthesize the oxetane scaﬀold of
oxetanocin in a good yield of 84% with a mesylate leaving
group. Interestingly, the 2-hydroxymethyl substituent could be
replaced at C2 with adenine over a sequence of steps involving
conversion to the methyl ketone and Baeyer−Villiger oxidation
to form the 2-acetate derivative,118 followed by displacement
with protected adenine.
Total syntheses of taxol have primarily formed the oxetane
ring midway through the sequence by an intramolecular
Williamson etheriﬁcation (Scheme 7).119−129 The majority of
total syntheses use base-mediated approaches for formation of
the oxetane on similar intermediates, with the leaving group
commonly being either a mesylate, triﬂate, or halide.
Interestingly, mild acidic conditions with catalytic camphorsul-
fonic acid (CSA) enabled oxetane formation in the sequence of
Nicolaou et al.,121 delivering the desired oxetane in just 10 min.
The intermediate of Danishefsky et al.127 diﬀered considerably
as the oxetane was introduced in step 13 of 49, considerably
earlier than, for example, in the work of Nicolaou et al.121 (step
31 of 37) or in the total synthesis of Wender et al.119 (step 40
of 44). Danishefsky stated that this strategy would be important
for an analogue program. Treatment with ethylene glycol at
reﬂux allowed the cyclization to occur, and it was speculated by
Danishefsky et al.127 that this transformation involved a
hypervalent silyl ether to trigger the displacement of the
required triﬂate. Wender et al.119 and Kuwujima and co-
workers123 both utilized a halide leaving group, which allowed
conversion to the oxetane in good yields of 95% and 86%,
respectively, in a single step. A base-mediated cyclization step
with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) is a common
and enduring approach, with Holton et al. (1994),125,126
Kuwujima and co-workers (2000),123 Takahashi and co-
workers (2006),120 and Nakada and co-workers (2015)129 all
using closely related conditions from very similar intermediates
(for Nakada’s recent example, see Scheme 7). In all cases the
proximity of the required leaving group to the primary alcohol
allowed the etheriﬁcation reaction to proceed in good yield
under a variety of conditions. Various synthetic studies have
been reported on taxol mimics.130−132
In 2009, Fan and co-workers133 reported oxidative cyclization
of malonate Michael adducts with chalcones to selectively
Scheme 4. Synthesis of Oxetanes 25 and 26 through an
Iodination−Williamson Etheriﬁcation Pathway
Scheme 5. (a) Synthesis of the Natural Product Oxetin from
D-Glucose and (b) Unnatural Stereoisomers
Scheme 6. Synthesis of Oxetanocin by Use of Williamson
Etheriﬁcation for the Key Cyclization Step
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access cyclopropanes and oxetane derivatives with high
diastereoselectivity (Scheme 8). Cyclization was observed
only when iodosobenzene (PhIO) and tetrabutylammonium
iodide (Bu4NI) were utilized. During optimization, cyclo-
propanes were synthesized in shorter reaction times when
alcoholic solvents were used. Conversely, when the reaction
was conducted in an open-air system with water, the oxetane
was formed as the major product. Substrates bearing electron-
rich aryl groups gave improved yields and selectivity for oxetane
products, as did addition of SiO2 and Na2CO3.
Two years later, Yang and co-workers134 reported a similar
iodine-mediated conversion of Michael adducts of malonates
with enones to either α-hydroxymalonate derivatives (34),
cyclopropanes (35), or oxetanes (36) with high diastereose-
lectivity (Scheme 9). The oxygen atoms in α-hydroxymalonates
34 and oxetanes 36 were derived from atmospheric O2, and
substoichiometric amounts of I2 (0.2 equiv) could be used.
Each of the three reactions proceeded well when both R1 and
R2 were aryl groups, with the nature of substituents on the aryl
ring having no signiﬁcant impact on the reaction.
A radical mechanism was proposed that involved initial
iodination of the Michael adduct to give key intermediate 37
(Scheme 10). This intermediate could undergo a DBU-
mediated cyclization in the absence of O2, to give cyclopropane
38, or cleavage of the C−I bond and reaction with oxygen and
an iodine radical, to give iodoperoxide 39 and then hypoiodide
40. Iodine abstraction with the starting material would give α-
Scheme 7. Selected Examples of the Oxetane-Forming Step in Taxol Total Syntheses
Scheme 8. Solvent-Controlled Synthesis of Cyclopropanes
and Oxetane Derivatives from Michael Adducts of Malonates
Scheme 9. Selective Synthesis of α-Hydroxymalonates,
Cyclopropanes, and Oxetane Derivatives from Michael
Adducts
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hydroxymalonate 41 and regenerate key intermediate 37.
Treatment of 41 with I2 and Na2CO3 would give iodide 42, and
a simple Williamson etheriﬁcation would aﬀord oxetane 43.
Alternatively, intramolecular electrophilic attack of the
hypoiodide would also give iodide 42, with a ﬁnal C−O
bond-forming step.
Recently, Smith and co-workers135 developed an enantiose-
lective formal [2+2] cycloaddition to form highly substituted,
ﬂuorinated β-lactones 44 from ﬂuorinated ketones and α-
aroyloxyaldehydes, using chiral N-heterocyclic carbene (NHC)
catalyst 47. Reduction to diols 45 with LiBH4 and activation of
the primary alcohol with TrisCl, followed by Williamson
etheriﬁcation, aﬀorded the substituted ﬂuorinated oxetanes 46
with excellent diastereomeric ratio (dr) and ee (Scheme 11).
Following Carreira’s studies on the properties of 3-
substituted oxetanes (see section 2), there has been
considerable interest in developing approaches to function-
alized 3-substituted oxetanes. Carreira’s approach used oxetan-
3-one, the chemistry of which is covered in section 5 of this
review. Carreira and co-workers63 developed a four-step
synthesis of the cyclic ketone that involved an intramolecular
cyclization to form the oxetane (Scheme 12). Dihydroxyace-
tone dimer 48 was converted into the corresponding
dimethylketal 49. Monotosylation with TsCl followed by
deprotonation with NaH prompted the intramolecular
cyclization, forming oxetane 50. Acidic cleavage of the ketal
provided oxetan-3-one 51 in a yield of 62%. This motif has
been widely used as a building block to prepare oxetane
derivatives and is now commercially available from many
suppliers.
Use of solid-phase synthesis for preparation of 3,3-
disubstituted oxetanes 53 and 55 was reported by Hailes and
co-workers136 in 2005. Polystyrene and a novel PEG 3400 resin
were used with a sulfone linker. Polymer-bound precursors
were synthesized from polymer-bound sulfonyl chlorides and
the desired diols 52 and 54, with bead staining providing
evidence for incorporation. Cyclization with sodium hydride
proved unsuccessful, but treatment with KOtBu resulted in
much improved yields over two steps when compared to
solution-based synthesis for both resins and substrates used
(Scheme 13a).
Vigo et al.137 reported the synthesis of 3,3-disubstituted
oxetanes with hydroxy, amino, and carboxylic acid residues
suitable for further functionalization. From diol 56, through a
route of cyclization, nucleophilic substitution, and then
Scheme 10. Proposed Mechanism for Conversion to Cyclopropane, α-Hydroxymalonate, and Oxetane Products
Scheme 11. Synthesis of Oxetanes via NHC-Catalyzed
Formal [2+2] Cycloaddition of Fluorinated Ketones and α-
Aroyloxyaldehydes
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functional group manipulation, a variety of functionalized
oxetanes were prepared (Scheme 13b).
Development of a three-step route from diol 57 via cyclic
carbonate 58 allowed access to 3-benzyloxetane 59 in moderate
yield (Scheme 13c).137 Previous cyclization strategies and
functional group manipulation had proved unsuccessful for this
synthesis.
Further examples of medicinally relevant 3,3-disubstituted
oxetanes were reported in 2014 by Boyd and Davies138
(AstraZeneca). 3,3-Disubstituted oxetanes were synthesized
from the relevant substituted dimethyl malonates with
installation of a protected hydroxymethyl group, double ester
reduction to the diol, tosylation, base-mediated cyclization, and
ﬁnally removal of the silyl protecting group with tetra-n-
butylammonium ﬂuoride (TBAF; Scheme 13d). Yields for the
Williamson etheriﬁcation were reported between 59% and 87%.
Scope included various substitution at the 3-position with aryl,
allyl, alkyl, and halide substituents tolerated.
Synthesis of a large number of spirocyclic oxetanes has been
examined in recent years, often by Williamson etheriﬁcation in
particular incorporating a 3-linked oxetane. An excellent review
from Carreira and Fessard2 on this subject appeared in 2014;
we will not replicate their material here but only highlight a
small selection of examples. Synthesis and biological testing of
an analogue of ciproﬂoxacin 61 containing a spirocyclic oxetane
motif is an excellent demonstration of both the synthetic
strategy that has been widely employed for this class of
compounds and the potential application of spirocyclic
oxetanes in medicinal chemistry.69,73 Spirocyclic building
block 60 was synthesized in two steps from 3-bromo-2,2-
bis(bromomethyl)propan-1-ol (Scheme 14a). Synthesis of
ciproﬂoxacin analogue 61 was achieved in a yield of 68% by
use of KOtBu in DMSO at 130 °C (Scheme 14b). Oxetane
analogue 61 was then compared against an azetidine analogue
and the parent ciproﬂoxacin in a number of biological assays.
Comparable activities were seen for the two spirocyclic
Scheme 12. Synthesis of Oxetan-3-one by Intramolecular
Cyclization
Scheme 13. Synthesis of 3,3-Disubstituted Oxetanes from Diols
Scheme 14. Spirocyclic Building Block 60 and Use in a
Ciproﬂoxacin Analogue
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analogues, and additionally there was no observable metabolism
in human microsomal assays.
Carreira and co-workers74 also reported the synthesis of 2-
substituted spirocyclic oxetane azetidines (Scheme 15). The
addition of furyllithium to azetidine aldehyde 62, synthesized in
three steps from tribromopentaerythritol, aﬀorded cyclization
precursor 63 with the required 1,3-relationship between the
alcohol and electrophilic carbon. Cyclization to the desired
spirocyclic oxetane 64 occurred successfully under mild basic
conditions (K2CO3 in MeOH). This work highlighted how the
conditions employed for cyclization can be important in
determining the reaction outcome; when KOtBu in THF was
used, Grob fragmentation occurred to give 3-exo-methylenea-
zetidine 65 in a 53% yield. The likelihood of Grob
fragmentation occurring appeared to depend on the thermody-
namic stability of the oleﬁn formed. Additionally, both the
solvent and base utilized have an eﬀect on the probability of
Grob fragmentation occurring.139
Recently Davis and Bull140 prepared an unusual bis-
spirocyclic oxetane derivative (Scheme 16). Reduction of an
oxetane diester to the diol with LiBH4 proceeded in high yield.
Treatment with BuLi and TsCl, followed by a second treatment
with BuLi in a separate step, formed the second oxetane ring.
Epoxides have also been used as leaving groups for the
synthesis of oxetanes via intramolecular etheriﬁcation. Kato and
co-workers141,142 demonstrated the synthesis of oxetanocin
analogues involving base-mediated ring opening of cis-epoxides
of homoallylic epoxides by KOH to aﬀord oxetanes (61−66%
yield) along with the THF product (3.5:1 to 14.5:1 ratio,
oxetane/THF). Interestingly, trans- and terminal epoxides gave
only the THF product. Additionally, stoichiometric tributyltin
methoxide was used by Chung et al.143 in 1996 for ring opening
of a terminal epoxide by a hydroxy group to give 4-
[(benzyloxy)methyl]oxetan-2-ylmethanol in 32% yield. Sub-
sequently, Carreira and co-workers69 used this methodology for
synthesis of a bridged bicyclic morpholine; it was also used
elsewhere.144 This disconnection has also been achieved under
acidic conditions. In 2002, Birman and Danishefsky145 ﬁrst
devised this Payne-type rearrangement from the relevant α-
epoxide to yield the desired oxetane motif as a last step in the
synthesis of merrilactone A. Treatment of α-epoxide 66 with
tosic acid in dichloromethane at room temperature yielded
merrilactone A with the correct stereochemistry. These
conditions have been replicated as the ﬁnal step in a number
of merrilactone A syntheses, yielding approximately 80% in all
reports (Scheme 17).146−150
3.1.2. Epoxide Ring Opening/Ring Closing. Epoxides
can be ring-expanded to oxetanes: as a variant of the
Williamson etheriﬁcation, the cyclization precursor has been
accessed by opening an epoxide with nucleophiles bearing
leaving groups. In 1980, Servrin and Krief151 opened epoxides
(2-hexyloxirane, 2-hexyl-2-methyloxirane, or 2-methyloxirane)
with a selenomethyllithium reagent in THF/HMPT at −78 °C,
which was then warmed to 20 °C to aﬀord ring-opened
hydroxyselenide 67 (Scheme 18). These intermediates were
converted to halides that could be cyclized with a base such as
KOtBu or MeMgBr to access the oxetane. Selenoethyl- and
selenopropyllithium were also successful to introduce addi-
tional Me/Et groups at the oxetane C4 position.
In 1983, Okuma et al.152 reported a similar method to access
the oxetane cyclization precursor by ring opening of epoxides
with a sulfoxonium ylide generated in situ from trimethylox-
osulfonium iodide. Attack of a 2-substituted or 2,2-disubstituted
epoxide with the sulfur ylide accessed the ring-opened
intermediate 68, which subsequently cyclized directly in the
same reaction ﬂask with release of dimethyl sulfoxide to aﬀord
2-substituted oxetanes in excellent yields of 83−99% (Scheme
19). Aromatic and alkyl substituents were tolerated; however,
Scheme 15. Preparation of Spirocyclic Oxetane Azetidines
Scheme 16. Preparation of a Bis-spirocyclic Oxetane
Derivative
Scheme 17. General Procedure for Synthesis of the Oxetane
Ring in Merrilactone A via Payne Rearrangement-type
Mechanism
Scheme 18. Oxetane Formation through Epoxide Opening
with Selenoalkyllithium
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examples were limited to Ph, p-ClC6H5, Me, or H substituents
and an example with cyclohexanone.
Okuma et al.152 demonstrated that by increasing the
equivalents of trimethyloxosulfonium iodide, the oxetane
motif could be accessed from the corresponding carbonyl
compound through initial formation of the epoxide followed by
ring opening. A related method was reported that used the
sodium anion of an NTs-sulfoximine.153,154 Fitton et al.155
expanded the scope of oxetanes accessed through this method
to incorporate alkyl substituents that could be further
manipulated to access a range of oxetane derivatives. Treating
monosubstituted epoxides with dimethyloxosulfonium methyl-
ide resulted in oxetanes 69 in good yields (Table 3). The useful
2-hydroxymethyloxetane motif was formed in 74% yield
following acetal deprotection (from entry 1, Table 3), and
the vinyl derivatives (entries 2 and 4) successfully underwent
bromination with Br2 or epoxidation with m-CPBA.
Fokin and co-workers156 modeled the ring expansion of an
unsubstituted epoxide computationally at the density functional
theory MP2 level of theory, utilizing a polarizable continum
model to account for solvent eﬀects and determining that
formation of the oxetane ring from an epoxide required 13−17
kcal·mol−1 activation energy; therefore, moderate heating was
required. Subsequent ring-expansion barriers were calculated
for oxetane to THF at 25 kcal·mol−1 and THF to
tetrahydropyran (THP) at 38 kcal·mol−1. For 2-methyl- and
2,2-dimethyloxirane, the methylenation of epoxides with
dimethylsulfoxonium methylide was modeled and shown to
proceed via an SN2 transition structure and was sensitive to
epoxide substitution. Experimental ﬁndings were consistent
with computational results, whereby enantioenriched chiral
oxetanes were accessed from enantioenriched epoxides with full
retention of enantiomeric purity (Table 4). 2-Alkyl- and 2,2-
dialkylepoxides had similar reactivity when treated with
dimethylsulfoxonium methylide; however, the 2,3-disubstituted
epoxide was unreactive, resulting in only trace amounts of
product (Table 4, entry 5). Consecutive ring expansion was
performed, treating chiral oxetanes with dimethylsulfoxonium
methylides to form chiral tetrahydrofurans (THFs), also with
conservation of ee. Recently, Carreira and co-workers75 applied
this approach to N-Boc-azetidin-3-one, where this trans-
formation was successful in the generation of a spirocyclic
azetidine-oxetane. Aggarwal and McGarrigle and co-workers157
reported the cyclization of a related intermediate to form a 2,2-
disubstituted oxetane through conjugate addition of a hydroxy
malonate to a vinyl sulfonium salt, forming an ylide, which
underwent proton transfer and cyclization.
Shibasaki and co-workers158 developed a powerful one-pot
enantioselective synthesis of 2,2-disubstituted oxetanes involv-
ing an asymmetric Corey−Chaykovsky epoxidation reaction,
followed by ring expansion of the resulting chiral epoxides to
chiral oxetanes. Excellent levels of ee were obtained, with
reinforcing enantioinduction leading to partial kinetic reso-
lution and ampliﬁed ee. The starting methyl ketone 70 was
treated with 1.2 equiv of dimethyloxosulfonium methylide, 5
mol % catalyst 71, and phosphorus oxide additive 72 in the
presence of molecular sieves to aﬀord the corresponding chiral
epoxide, which was then treated with a further equivalent of the
sulfur ylide and 15 mol % catalyst and additive to compensate
for the slow reaction rate (Scheme 20). Chiral 2,2-disubstituted
oxetanes were accessed in good to excellent yields of 58−88%
with up to 99.5% ee, employing both alkyl and aryl methyl
ketones. When ethyl ketones such as propiophenone were
employed, the epoxide intermediate was produced in 88% ee;
however, the subsequent ring expansion provided the oxetane
in 91% ee with only a 26% yield, demonstrating that the
reaction was sensitive to ketone substitution.
3.1.3. Synthesis of Oxetanes from Sugar Derivatives.
Saccharides have been used extensively as starting materials for
the synthesis of oxetanes, due to the repeating 1,3-functionality
and the opportunity to access enantioenriched and diaster-
eomerically deﬁned oxetanes.159 Similarly, these starting
materials have been used in the synthesis of small oxetane-
containing natural products, though typically this approach can
be lengthy. In this manner, sugars have been used extensively
by Fleet and co-workers160,161 as starting materials for the
synthesis of enantioenriched oxetanes through ring contraction
Scheme 19. Oxetane Formation through Epoxide Opening
with Trimethyloxosulfonium Ylide
Table 3. Expanded Scope of Oxetanes Accessed through
Epoxide Ring Opening with Trimethyloxosulfonium Ylide
entry R yield (%)
1 CH2OCH(CH3)OC2H5 70
2 CH2OCH2CHCH2 65
3 CH2OC6H5 83
4 CH2CH2CHCH2 56
5 CH(OC2H5)2 59
Table 4. Assessing Chiral Oxetanes from Ring Expansion of Chiral Epoxides with Dimethylsulfoxonium Methylide
entry R R1 R2 R3 conditions yield (%) ee (%)
1 C6H5 H H H NaH, DMSO, 70 °C 85 >98
2 n-hexyl H H H t-BuOK, t-BuOH, 80 °C 91 >98
3 H CH2OCH2Ph H H t-BuOK, t-BuOH, 80 °C 80 >98
4 C6H5 Et H H NaH, DMSO, 110 °C 88 >98
5 C6H5 H H Me t-BuOK, t-BuOH, 120 °C trace nd
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of the triﬂates of α-hydroxy-γ-lactones (Scheme 21). These
were formed from the corresponding α-hydroxy-γ-lactones,
which are in turn prepared from compounds derived from
sugars.162−164 Certain nucleophiles attack the lactone carbonyl,
leading to ring opening of the lactone, followed by displace-
ment of the triﬂate to form the oxetane. When lactone 74,
derived from glucuronolactone 73, was treated with benzyl-
amine or K2CO3 in methanol, ring contraction occurred to
form oxetanes 75 and 76, respectively, in good yield.161
Only one stereoisomer was formed with benzylamine with a
yield of 81%, and no reaction was observed when OTf was
replaced with OMs. On the other hand, an epimeric mixture
was observed when K2CO3 in methanol was used (61%, ratio
2:1), with the major product having retention of conﬁguration
at the oxetane C2 position due to epimerization prior to
oxetane formation. Treatment of ester oxetane 76 with
benzylamine and hydrazine hydrate aﬀorded the corresponding
amide oxetanes, and reduction was achieved by use of LiAlH4;
both reactions proceeded without epimerization.161
The synthesis of an unusual but stable α-chlorooxetane 78
was achieved by Fleet et al.166 through a Barton modiﬁcation of
the Hunsdiecker reaction (Scheme 22).165 Ester 76 was
converted to the chloride with a yield of 27% through
hydrolysis to the sodium carboxylate salt 77, formation of the
acid chloride, and reaction with N-hydroxypyridine-2-thione
sodium salt under reﬂux in CCl4. The structure of this
fascinating chlorooxetane was proven by an X-ray crystal
structure.166
In subsequent work, Fleet et al.167 showed that α-
chlorooxetanes could be converted into oxetane nucleoside
analogues through displacement of the chloride with adenine
(Scheme 23). A separable 1:1 mixture of C2-epimers 79 and 80
was obtained, which may indicate nucleophilic displacement
had signiﬁcant SN1 character.
A few years after the reaction with bicyclic lactones, Fleet and
co-workers168 expanded the scope of ring contraction of α-
hydroxy-γ-lactones to all four diastereoisomers of 3,5-di-O-
benzylpentono-1,4-lactones. These lactones were prepared
from 1,2-O-isopropylidinepentofuranose sugars (Scheme 24).
Triﬂates 81−84 were prepared in four steps from the readily
available diols of D-xylo, D-ribo, D-arabino, and L-lyxo sugars
with yields between 48% and 64%.
Ring contraction was conducted on each example under
previously reported conditions (dry K2CO3 in anhydrous
MeOH), aﬀording methyl oxetane-2-carboxylates 85−88 in
yields of 70%−82% (Table 5). Interestingly, for D-xylono and
D-arabinono triﬂates 81 and 83, the expected inversion of
conﬁguration occurred, whereas for D-ribono and L-lyxono
triﬂates 82 and 84, retention of conﬁguration at C2 of the
lactone resulted. The major product of each ring contraction
has a trans relationship between the C2 and C3 substitutents
on the oxetane ring. No deuterium incorporation was observed
when the reaction was conducted in methanol-d4, which
implied that the stereochemical outcome of these reactions was
not a consequence of equilibrium of the oxetane products.
Scheme 20. Asymmetric Synthesis of 2,2-Disubstituted
Oxetanes via One-Pot Sequential Addition of Sulfur Ylides
to Ketones
Scheme 21. Sample Ring Contraction of α-Hydroxy-γ-
lactone Triﬂates
Scheme 22. Synthesis of α-Chlorooxetane 78 through Barton
Modiﬁcation of the Hunsdiecker Reaction
Scheme 23. Synthesis of Oxetane Nucleoside Analogue from
α-Chlorooxetane 78
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Unfavorable interactions during SN2 ring closure in the open-
chain 4-hydroxy-2-O-triﬂate esters when the substituents of the
resulting oxetane are cis-conﬁgured were cited as a possible
reason for this stereochemical outcome. Epimerization of the
hydroxy triﬂate intermediate therefore occurs more rapidly than
cyclization, which favored the trans conﬁguration.
Fleet and co-workers169 later demonstrated that ring
contraction occurred with C3-deoxy 3-substituted oxetane
products (Scheme 25). In this case, inversion of conﬁguration
was observed for both D-ribono (89) and D-arabinono (91)
substrates upon ring contraction. Yields for 3-alkyloxetanes 90
and 92 were generally lower than those for previously reported
3-ether-substituted oxetanes due to the increased tendency of
alkyl triﬂate lactones to undergo elimination reactions rather
than ring contractions.
This ring contraction strategy enabled synthesis of the
natural product oxetanocin and its α-epimer (Scheme 26).170
From the triﬂate lactone, derived from D-xylo 93, ring
contraction with K2CO3 in MeOH aﬀorded oxetane 94 with
inversion of conﬁguration. The epimer of oxetane 94 could be
formed from the same triﬂate lactone in three steps; treatment
with sodium triﬂuoroacetate and MeOH gave the inverted α-
hydroxy-γ-lactone (D-arabinonolactone), followed by conver-
sion to the triﬂate and ring contraction. Radical decarboxylative
chlorination gave an unstable α-chlorooxetane, which was
immediately trapped as the sulﬁde with PhSK to be puriﬁed.
Regeneration of the α-chlorooxetane was conducted with Cl2 in
CHCl3, followed by addition of benzoyl adenine to give
protected adenine oxetane 95 as an epimeric mixture in 23%
yield. Separation and subsequent deprotection aﬀorded
oxetanocin and α-oxetanocin in 71% and 60% yields,
respectively.
Scheme 24. Synthesis of Triﬂate Lactones 81−84 from Pentofuranose Sugars
Table 5. Synthesis of Oxetanes 85−88 by Ring Contractiona
aInv = inversion of conﬁguration at C2 upon cyclization. bRet =
retention of conﬁguration upon cyclization.
Scheme 25. Synthesis of 3-Alkyloxetanes 90 and 92
Scheme 26. Synthesis of Oxetanocin and Its α-Epimer
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Through an almost identical route, Fleet and co-workers171
synthesized both epimers of norooxetanocin in 15 steps from
diacetal glycose. Both α- and β-norooxetanocin were inactive
against HIV-1 (up to a concentration of 100 μg·mL−1).172 In an
improved sequence, epinorooxetanocin was prepared from
lactone triﬂate 96, itself prepared in two steps (Scheme 27).172
Ring contraction under standard conditions aﬀorded oxetane
97. To access α-chlorooxetane 98, hydrolysis of the ester,
followed by treatment with N-chlorosuccinimide (NCS) and
lead tetraacetate, gave a single stereoisomer in 58% yield. The
chloride was displaced with adenine to give nucleoside oxetane
99 as a single epimer, which was subsequently deprotected with
triﬂuoroacetic acid (TFA), aﬀording epinorooxetanocin with an
80% yield. In vitro studies of epinoroxetanocin showed
signiﬁcant activity against HIV-1 (IC50 = 0.5−1.5 μg·mL−1),
which was similar to the activity of oxetanocin (IC50 = 0.5−1.5
μg·mL−1).
In 1992, Saksena et al.173 developed the use of mesylate and
tosylate groups for ring contraction under aqueous hydrolytic
conditions to form oxetanecarboxylic acids with high yields.
Gumina and Chu174 used the conditions reported by Saksena in
their synthesis of the enantiomer of oxetanocin. They achieved
this in 16 steps, starting from L-xylose with an overall yield of
2.8%, in a route otherwise similar to that reported by Fleet and
co-workers.170
Oxetanes constructed by these strategies have provided
important building blocks for further functionalization to
provide enantioenriched oxetanes with varied substitution
patterns, especially at the 3- and 4-position of the oxetane
ring. In sections 3.1.3.1 and 3.1.3.2, we report some of the
transformations that may be valuable in accessing function-
alized oxetane derivatives and for applications in medicinal
chemistry.
3.1.3.1. C3 Functionalization and Applications of
Oxetanes Derived from Sugars. Fleet and co-workers175
showed that oxetane 2-esters could undergo a variety of
transformations at C3, particularly nucleophilic displacements.
Deprotection of the benzyl protecting groups in oxetane 86
proceeded by hydrogenolysis with H2 and Pd/C with a good
yield of 86% (Scheme 28a). After selective silylation of the
primary hydroxy group, the secondary alcohol at the C3
position of the oxetane ring could be converted to the triﬂate
with Tf2O, and triﬂate 100 could be displaced with inversion by
a variety of nucleophiles. Initially this was achieved by use of
NaN3 to form oxetane 101, and no competing elimination
reactions were observed. Oxetane 102, prepared from L-
rhamnose in four steps,176,178 was used to access a range of 3-
azidooxetanes 103−105 in a similar manner through reduction
of the acetal protecting group, triﬂate formation, and SN2
displacement with NaN3 (Scheme 28b).
177−179 A similar
sequence was conducted with D-xylose.177
3-Hydroxyoxetane 106 was converted to a single isomer of
ﬂuorooxetane 107 through the use of diethylaminosulfur
triﬂuoride (DAST), which proceeded with inversion (Scheme
29).175 Recently, Wessel and co-workers86 used DAST in the
synthesis of 3-ﬂuorooxetane δ-amino acids as interesting new
rigid scaﬀolds for use in medicinal chemistry. Fleet and co-
workers175 converted ﬂuorooxetane and azidooxetane deriva-
tives to analogues of oxetanocin, and while the azido analogue
showed signiﬁcant antiviral activity against HIV-1 (IC50 = 6 μg·
mL−1), it was less than the activity of oxetanocin itself.
In 1997, Sakya et al.180 synthesized oxetane-3-thiols from
oxetane 108 (Scheme 30). Selective tosylation of the primary
alcohol occurred with good yield. This tosyl group could not be
displaced by either NaN3 or amines; instead, retro-aldol and
decomposition products were isolated. However, the secondary
alcohol could be converted to thiol 109 through triﬂate
Scheme 27. Synthesis of Epinoroxetanocin
Scheme 28. Synthesis of Azidooxetanes
Scheme 29. Synthesis of Fluorooxetane 107 by Use of
Diethylaminosulfur Triﬂuoride
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00274
Chem. Rev. XXXX, XXX, XXX−XXX
P
formation followed by displacement with KSAc, selective for
the secondary triﬂate, and deprotection.
These oxetanethiols were subsequently used in synthesis of a
variety of oxetane carbapenems 110 and to determine their
antibacterial structural activity relationship against both Gram-
positive and Gram-negative bacteria (Table 6). The oxetane
carbapenems tended to have less activity against Gram-positive
bacteria (such as Staphylococcus aureus) compared with the
broad-spectrum antibiotic imipenem,181 but they showed
similar activity against Gram-negative bacteria (Escherichia coli
and Pseudomonas aeruginosa). Oxetane carbapenem 110a was
also shown to be more stable to hydrolysis by hog kidney
dehydropeptidase (DHP) than imipenem.
3.1.3.2. C4 Functionalization and Applications of
Oxetanes Derived from Sugars. Oxetane derivatives have
been developed as isosteres for dipeptides.182 Toward this aim,
Fleet and co-workers183 incorporated an azide group at the C4
position by two routes: a Mitsunobu reaction with PPh3, diethyl
azodicarboxylate (DEAD), and diphenylphosphorylazide
(DPPA) and also a displacement reaction of an alkyl bromide
using sodium azide (Scheme 31).
Toward novel oxetane amino acids, Wessel and co-
workers86,87 from Roche reported that the azide moiety could
be incorporated through displacement of a triﬂate (Scheme 32).
These primary azides were subjected to hydrogenolysis
followed by in situ protection with Boc2O to give protected
primary aminooxetane 111 in good yields.
Wessel and co-workers86 achieved hydrolysis of the methyl
esters using 1 N LiOH in THF with quantitative yield, and it
could also be achieved enzymatically with pig liver esterase
(Scheme 33). Acidic aqueous workup led to degradation of
oxetane 112; therefore, the reaction was screened in micro-
aqueous reaction systems (organic solvents with a small
amount of water added). It was shown that lipase L2 from
Candida antarctica provided the best activity, and oxetanecar-
boxylic acid 112 could be isolated by ﬁltering oﬀ the enzyme
followed by evaporation of the solvent. This enzymatic
hydrolysis was conducted on a gram scale, and an excellent
Scheme 30. Synthesis of Oxetanethiol 109
Table 6. Structure−Activity Relationships of Oxetane Carbapenems
minimum inhibitory concn (μg·mL−1)
organism strain imipenem 110a 110b 110c
E. coli ATCC 25922 0.12 0.25 0.12 0.12
P. aeruginosa ATCC 27853 2 128 16 64
S. aureus ATCC 28213 ≤0.06 1 0.12 0.12
relative hydrolysis to hog DHP 100 <1
Scheme 31. Synthesis of Alkylazidooxetanes
Scheme 32. Synthesis of a Protected Amino Acid Oxetane
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yield was obtained. A related oxetane monomer was
incorporated into a β-turn region of cyclodecapeptide
gramicidin S, which caused a well-deﬁned cyclic hairpin
structure in solution.184
While investigating the preferred secondary structures of
homooligomers of oxetane amino acids,185 oxetane-azido ester
scaﬀolds were converted to β-amino acid monomers and
coupled to form a range of β-amino acid oligomers (dimers,
tetramers, and hexamers). For example, the δ-2,4-cis-oxetane
azido ester scaﬀold 113 underwent hydrolysis to aﬀord oxetane
acid 114. Fleet showed that transesteriﬁcation to the isopropyl
ester allowed for successful hydrogenolysis of the azide to the
free amine 115 in good yields. This transesteriﬁcation avoided
intramolecular lactamization and oligomerization, which was
observed with hydrogenolysis of methyl ester 113.186 Treat-
ment of these two monomers with TBTU [N,N,N,N′-
tetramethyl-O-(benzotriazol-1-yl)uronium tetraﬂuoroborate]
gave oxetane dimer 116 in 89% from isopropyl ester oxetane
115. This dimer was subjected to the same iterative process,
and homooligomers up to the hexamer were successfully
synthesized. Hexamer 117 was built up over ﬁve steps with a
very good yield of 64% from dimer 116 (Scheme 34).
Conformational analysis of these oxetane β-amino acid
oligomers by IR and NMR spectroscopy, involving nuclear
Overhauser eﬀect (NOE), total correlation (TOCSY), and
rotating-frame nuclear Overhauser eﬀect (ROESY) spectra,
indicated that well-deﬁned secondary structures were adopted
in solution.185,187 The major conformation was dictated by an
internal 10-membered hydrogen-bonded motif, which is
comparable to a conventional α-amino acid peptide β-turn.
On the other hand, the trans-oxetane amino acid oligomers did
not show any deﬁned secondary structures. By contrast, trans-
oxetane amino acid oligomers with a bulky 3-(tert-
butyldimethylsilyl)oxy (3-OTBS) substituent did display a
deﬁned conformation in chloroform and 2,2,2-triﬂuoroethanol,
enforced through steric interactions without the inﬂuence of H-
bonding.188 Cyclic tetrameric derivatives have also been
prepared.189
Oxetanes have also been incorporated as side chains in β-
amino acids for the synthesis and conformational analysis of the
foldamers they might adopt in solution.190 Novel oxetane β3-
amino acids 119a,b were prepared from sugar-derived diol 118
in 14 steps with overall yields of 1.4% and 3.7%, respectively
(Scheme 35). Oxetane formation was achived via Williamson
etheriﬁcation with NaH in THF. The amine stereocenter was
introduced by an aza-Michael addition. Oxetane β3-amino acid
119a was incorporated into tri- and penta-α,β-peptides under
standard peptide coupling conditions191 with L-Ala derivatives.
Conformational analysis by NMR, molecular dynamics, and
circular dichroism indicated the presence of a well-deﬁned
folded conformation that involved hydrogen bonding.
3.1.4. Synthesis of Oxetane-Containing Nucleoside
Analogues. Nucleoside analogues have been developed as
eﬀective classes of novel antiviral and cancer therapeutics. Their
mode of action stems from an ability to disrupt nucleotide
metabolism and DNA replication, thus leading to apopto-
sis.192,193 Examples include idoxuridine, the ﬁrst marketed
antiviral nucleoside for treatment of herpes simplex virus;194
zidovudine (AZT),195 approved in 1987 as a treatment for
HIV; and more recently entecavir196 (approved in 2005) and
sofosbuvir197 (approved in 2013) as treatments for hepatitis B
and C, respectively (Figure 13).
Toxic side eﬀects and development of resistance to existing
therapies198,199 means there has been a continued drive in this
area to ﬁnd novel nucleoside-based therapeutics with optimal
physicochemical properties. Several groups in recent years have
investigated incorporation of oxetanes, in addition to other
functionalities, toward this goal.200 Wengel and co-workers,201
in 1998, evaluated the thermal stabilities of duplexes comprising
several oxetane-containing modiﬁed oligonucleotides (ONs)
against the complementary single-stranded DNA and RNA.
The synthesis of the desired bicyclic oxetane-containing
nucleoside 121 was completed in 12 steps from the known
ulose 120 in overall 8.5% yield, with the key cyclization step
being intramolecular etheriﬁcation between the secondary
alcohol and primary mesylate group. This was achieved in
93% yield over the mesylation and cyclization steps (Scheme
36). Subsequent steps allowed synthesis of the corresponding
3′-O-phosphoramidite building block 122 for incorporation
into ONs.
Several modiﬁed 14-mer ONs were synthesized along with a
9-mer variant, and the thermal stabilities of their duplexes with
single-stranded DNA and RNA were determined by melting-
point analysis and compared to that of unmodiﬁed ON (Table
7).201 It was found that the majority of modiﬁed 14-mer ONs
resulted in decreased thermal stability against both DNA and
RNA, with lower melting points being reported. However, 5′-
X13T was the notable exception, showing a signiﬁcant increase
in thermal stability against both DNA and RNA (Table 7, entry
7). Additionally, the 9-mer example showed small increases in
thermal stability against the reference ON (Table 7, entry 8 vs
entry 9), thus demonstrating the potential in incorporating an
oxetane into ONs in order to deliver superior physical
properties.
In 2001, Nielsen and co-workers202 published a study
exploring the anti-HIV activity of a conformationally restricted
nucleoside analogue of AZT featuring an oxetane motif.
Scheme 33. Hydrolysis of Oxetane Ester by Use of Candida
antarctica Lipase L2
Scheme 34. Synthesis of Oxetane Hexamer 117
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Starting from the cheap and readily available D-arabinose, both
anomeric conﬁgurations of the desired oxetane-containing
nucleoside, 124a,b, were synthesized in 12 steps (Scheme
37). A modiﬁed Corey−Link reaction furnished an α-azido
methyl ester stereoselectively, which was followed by stereo-
selective reduction of a ketone, ester reduction, and conversion
to the mesylate to give oxetane precursors 123a,b. Sodium
hydride-mediated etheriﬁcation delivered the oxetane function-
ality. However, when the antiviral activity of both anomeric
conﬁgurations 124a,b was then tested against HIV-1 in MT-4
cell lines, in both cases, no anti-HIV activity was observed at
300 μM.
In 2004, Sharma and Nielsen203 reported the synthesis of
oxetane-containing [3.2.0]bicycloarabinonucleoside 129, of
interest for potential in antisense and antigene technology,
from alkene 125 (Scheme 38). The key step of the synthesis
involved oxidative cleavage of the terminal alkene to give
alcohol 126 by use of in situ formed RuO4 (from RuCl3·xH2O
and NaIO4). In the second step of this oxidative cleavage,
addition of NaBH4 reconverted the α-ketol (formed from
overoxidation) back to the diol as well as reducing any active
Ru species. After protecting group manipulation, thymine was
used to displace the acetate at the anomeric center.
Deprotection of the benzoyl and acetyl protecting groups
followed by mesylation aﬀorded dimesylate 127. Selective
hydrolysis of the primary sulfonate ester of the primary
mesylate, followed by Williamson etheriﬁcation, aﬀorded
oxetane bicycle 128. Benzyl deprotection gave oxetane 129.
Chattopadhyaya and co-workers204,205 explored the synthesis
and antisense eﬀects of 1′,2′-locked oxetane-containing nucleo-
sides. Extensive studies on the eﬀects of replacing either
thymine or cytosine residues in antisense oligonucleotide
(AON)−RNA duplexes with nucleoside 130 or 131,
respectively, were performed, with a focus on examining the
eﬀect on RNase H cleavage (Figure 14). With nucleoside 130,
singly, doubly, and triply modiﬁed AON−RNA duplexes were
found to be similarly good substrates for RNase H as the
unmodiﬁed duplex. The modiﬁed duplexes also exhibited
improved protection toward endonuclease, with stability
increasing with increasing levels of modiﬁcation. The
modiﬁcations led to a loss in thermodynamic stability, which
Scheme 35. Synthesis of Novel β3-Amino Acids and Penta-α,β-peptide
Figure 13. Examples of marketed nucleoside antivirals.
Scheme 36. Synthesis of Oxetane Nucleoside
Phosphoramidite 122 from Ulose 120
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could be improved by introduction of a dipyridophenazine
(DPPZ) moiety.204 For nucleoside 131, singly and doubly
modiﬁed AON−RNA duplexes were again found to be good
substrates for RNase H. Michaelis−Menten kinetics indicated
catalytic activity close to that of the native duplex. Target
aﬃnity for AON−RNA duplexes modiﬁed with nucleoside 131
was signiﬁcantly improved compared to those modiﬁed with
nucleoside 130.205
In 2005, Chattopadhyaya and co-workers206 developed
routes to oxetane-containing 1′,2′-locked nucleosides from
protected furanose derivatives. The oxetane ring-forming step
involved base-mediated Williamson etheriﬁcation with either a
mesyl or tosyl leaving group: for example, the synthesis of uracil
derivative 132 is shown in Scheme 39. Synthesis of guanine and
adenine derivatives was achieved via a similar strategy, which
allowed the synthesis of oxetane-containing nucleosides on a
multigram scale.206 In 2014, Komsta et al.207 prepared uridine
and guanosine 1′,2′-locked oxetane derivatives, with anti-HCV
activity; a 1′,2′-oxetane guanosine 6-triphosphate derivative was
found to be a modest inhibitor of HCV NS5B polymerase (IC50
= 10 μm).
Interest in nucleosides including an oxetane moiety as
antivirals for treatment of hepatitis C virus (HCV) has led to a
number of studies being published in this area. The synthesis
and anti-HCV activity of 3′,4′-oxetane nucleosides was reported
by Du and co-workers208 in 2010. Initially, six examples of the
nucleoside with a 4′-hydroxymethyl group were synthesized
(133−137), with varying groups known to be compatible with
anti-HCV activity at the 2′-position. Synthesis of the cytosine-
based analogues was achieved in 12 steps from the
corresponding uridine nucleosides (Scheme 40a), whereas the
adenine example 138 was synthesized in 10 steps directly from
2′-deoxy-2′-β-ﬂuoroadenosine (Scheme 40b). In both cases, the
key ring-forming cyclization was a base-mediated displacement
Table 7. Melting Point Experiments To Determine Thermal
Stability of Modiﬁed Oliglionucleotidesa
Tm (°C)
entry oligonucleotide ssDNA duplex ssRNA duplex
1 5′-T14b 36.0 34.0
2 5′-T7XT6 36.0 33.5
3 5′-T6X2T6 34.5 33.0
4 5′-T6XTXT5 35.5 32.5
5 5′-T5X4T5 31.5 37.0
6 5′-T3(TX)4T3 35.5 31.5
7 5′-X13T 58.0 49.0
8 5′-GTGATATGCb 26.0 26.5
9 5′-GXGAXAXGC 34.5 34.5
aThermal stability is compared to that of the unmodiﬁed reference
oligonucleotide and is measured at 260 nm in medium-salt buﬀer: 1
mM ethylenediaminetetraacetic acid (EDTA), 10 mM Na3PO4, and
140 mM NaCl, pH 7.2. Concentration of each strand was 2.5 μM. G =
2′-deoxyguanosine monomer; A = 2′-deoxyadenosine monomer; C =
2′-deoxycytidine monomer; Tm = melting point, determined as
maximum of the ﬁrst derivative of absorbance vs temperature curve.
bReference oligonucleotide.
Scheme 37. Overall Synthetic Strategy for Synthesis of
Nucleosides 124a,b
Scheme 38. Synthesis of Bicyclic Oxetane 129 from Sugar-
Derived Alkene 125
Figure 14. Structures of 1′,2′-locked oxetane-containing nucleosides
130 and 131.
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of a triﬂate (Scheme 40a) or a cyclic sulfate group (Scheme
40b).
When subjected to the subgenomic replicon assay, none of
the oxetane derivatives showed signiﬁcant antiviral activity
compared to several related non-oxetane-containing analogues.
This lack of activity was postulated to be due to an inability of
the modiﬁed nucleosides to be anabolized to the triphosphate
derivative, an essential step for antiviral eﬃcacy. Therefore, the
triphosphate derivatives of 134−136 were prepared and their
activity relating to inhibition of HCV polymerase (NS5B) was
explored and compared to that of a known inhibitor, PSI-6130.
In this case, inhibition of HCV polymerase was observed, albeit
at higher concentrations than PSI-6130 (Table 8),208
demonstrating that phosphorylation might be the inhibiting
factor for activity in whole-cell replicon studies.
In 2014, both Du et al.209 and Jonckers et al.210 published
anti-HCV data for nucleosides furnished with a pendant
oxetane group at the 2′-position. The study by Jonckers et al.210
indicated disappointing results for 4′-hydroxymethyl derivatives
142−144, as signiﬁcantly reduced inhibition of HCV
replication was seen compared to other derivatives in a
luciferase assay in Huh-7 replicon cells (Table 9).
In a similar study by Du et al.,209 several 2′-oxetane
derivatives were compared, unfavorably, to the 2′-tetrahydro-
furan derivatives in a luciferase-based genotype 1b replicon
assay in Lunet cells (Table 10). Only one example, 143,
indicated any anti-HCV activity, and this was signiﬁcantly lower
than the best 2′-tetrahydrofuran example. In the two studies,
diﬀerent anti-HCV activities were calculated for nucleoside
143; this was likely due to the diﬀerent assays used in the
studies.
In both studies, by Du et al.209 and Jonckers et al.,210 a
prodrug strategy was successfully exploited to bypass the
restrictive phosphorylation steps. In the study by Jonckers et
al.,210 25 phosphoramidate derivatives were prepared from the
4′-hydroxymethyl derivative, by use of N-methylimidazole
(Scheme 41). The anti-HCV activity of each compound was
investigated, and generally very promising EC50 values in the
low micromolar range were observed. Additionally, cytotoxicity
up to a 98 μM concentration was observed in only one
compound.
Du et al.209 also prepared a number of prodrug derivatives
151 and 152 (via an analogous method to that shown in
Scheme 41) with similarly positive results against a HCV
replicon assay using ET-Lunet cells (Table 11). Once again, no
cytotoxicity was observed up to concentrations of 100 μM. As
with the 2010 study of Du and co-workers,208 triphosphate
derivatives 153 and 154 were also prepared. These examples
Scheme 39. Synthesis of 1′,2′-Locked Oxetane Nucleoside
Scheme 40. Synthesis of Cytosine and Adenine Oxetane-
Containing Nucleoside Analogues
Table 8. Inhibition of HCV Polymerase (NS5B) Activity in
Vitro by Oxetane-Containing Triphosphate Nucleosides
Compared to Known Inhibitor PSI-6130
nucleoside IC50 (μM)
139 30.96 ± 4.75
140 78.91 ± 5.68
141 32.76 ± 5.36
PSI-6130 5.37 ± 0.50
Table 9. Selected Results Comparing the Anti-HCV Activity
of Oxetane-Containing Nucleoside Derivatives to That of a
Cyclopropane Analogue
nucleoside EC50 (μM)
142 >98
143 17.1
144 7.3
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demonstrated more promising results than the corresponding
tetrahydrofuran-containing analogues and the 4′-hydroxymeth-
yl derivatives against NS5B polymerase and its S282T mutant
(Table 12).209
Prasad and co-workers211 identiﬁed oxetanoribonucleosides
as potentially interesting antiviral agents, and in 2014 they
developed a synthesis of C-4′-spiro-oxetanoribonucleosides
utilizing a diastereoselective Novozyme-435-catalyzed deacyla-
tion step. In just seven moderate- to high-yielding steps, both
thymine and uracil spironucleoside derivatives 155 and 156
could be formed (Scheme 42).
3.1.5. Oxetane Synthesis through Electrophilic Hal-
ocyclization of Alcohols. Intramolecular haloetheriﬁcation
has been shown to be a viable strategy for the synthesis of
oxetanes but has received relatively little investigation.
Throughout the 1980s and early 1990s, a variety of 4-exo-trig
electrophilic cyclizations to form oxetanes were discovered
largely by use of N-bromosuccinimide (NBS) and often with
constrained structures. In 1980, Ehlinger and Magnus212 found
that vinyl silane 157 favored an exo cyclization process, giving
adamantyloxetane 158 in a very good yield of 92% (Scheme
43). The THF that would result from endo cyclization, the
desired product in this study, was not observed. A few years
later, in the process of determining the stereochemistry of cis-
clerodane diterpenes, Manabe and Nishino213 formed oxetane
159 in quantitative yield by use of NBS (Scheme 44). The same
reaction was used by Paquette et al.214 in the synthesis of a
[5.9.5] tricyclic system closely related to jatrophatrione.
In the late 1980s, bis(sym-collidine)iodine perchlorate
[I(coll)2ClO4] reagent was used to synthesize β-iodooxetanes
by a 4-exo-trig cyclization.215 This reagent, which was generated
in situ from iodine and bis(sym-collidine)silver(I) perchlorate,
Table 10. Anti-HCV Activity of Pyrimidine Nucleosides
Scheme 41. Synthesis of Oxetane-Containing Nucleoside
Prodrugs
Table 11. Anti-HCV Activity Data for Prodrug Nucleoside
Analoguesa
aStudied by Du et al.209.
Table 12. Anti-HCV Activity Data for Triphosphate-
Containing Nucleosides
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could provide three- to seven-membered ring ethers by use of
unsaturated alcohols. Four oxetane examples were demon-
strated, which indicated that tertiary alcohols helped the exo
cyclization, though relatively high yields were also achieved if
the double bond was substituted (Scheme 45). The methyl
group altered the charge distribution on the iodonium
intermediate, which made it more electrophilic at the C3
position. Finally, when an unsubstituted unsaturated alcohol
was used, an inseparable 1:1 mixture of oxetane and THF was
observed (no yield given). Stepan et al.82 used this approach to
develop the γ-secretase inhibitors discussed in section 2.
Oxetane 161 was formed from alcohol precursor 160, and the
crude material was used to form the alkylated sulfonamide
products, obtained in low yields (Scheme 46).
Jung and Nichols216 used this 4-exo-trig haloetheriﬁcation
cyclization strategy to synthesize racemic oxetanocin A
analogues, predicting that the aryl and vinyl groups on the
alcohol substrate 163 would be enough to promote oxetane
formation. Cyclization from alcohols 163a−c occurred via in
situ formation of bis(collidine)iodine(I) perchlorate from the
silver salt to aﬀord good yields and selectivity (oxetane/THF)
for each substrate (Scheme 47). Trans-substituted oxetanes 164
were the major products, as determined by NOESY experi-
ments, but reductive deiodination of 164a with LiAlH4
indicated that all four possible isomeric oxetane products
formed in a ratio of 10:2:1.5:1. Oxetanes 164 and the respective
THFs 165 could be separated after displacement of the alkyl
Scheme 42. Seven-Step Synthesis of C-4′-Spiro-
oxetanoribonucleosides 155 and 156
Scheme 43. Synthesis of Adamantyloxetane through NBS-
Mediated 4-exo-trig Cyclization
Scheme 44. Synthesis of Oxetane-Containing Diterpene
Derivative
Scheme 45. Synthesis of Iodo-Substituted 2-Alkyloxetanes
via 4-exo-trig Cyclization
Scheme 46. Synthesis of γ-Secretase Inhibitor 162 via
Iodonium-Mediated Oxetane Cyclization
Scheme 47. Accessing Oxetanocin A Analogues via
Iodonium-Mediated Oxetane Cyclization
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iodide with acetate; ozonolysis followed by reduction gave
oxetanocin A analogues.
In 1997, an asymmetric variant of this process was achieved
through incorporation of an oxazolidinone auxiliary.217 With
the Evans auxiliary a variety of substituted alcohols underwent
the cyclization successfully, and only oxetane products 166
were observed. However, the oxetane bearing a phenyl group
readily decomposed (Table 13). Interestingly in a previous
study, use of methyl esters preferentially gave THF products.218
Good facial selectivity was observed in the cyclization step,
proposed to be due to minimizing a 1,3-transannular
interaction between the iodomethyl and R groups in the
developing oxetane ring. The selectivity went down as the size
of R increased, suggesting the transition state to the major
product may experience allylic strain (A1,3 strain) between the
terminal vinyl hydrogen and imide group (Scheme 48).
Exo cyclization of vinylsilanes was later investigated by
Rousseau and co-workers219 (Scheme 49). The nature of the
counterion in the halide reagent was important, with best
results obtained with hexaﬂuoroantimonate. Tertiary alcohols
that were unsubstituted on the double bond gave only one
diastereoisomer (167a) upon reaction with the bromonium
reagent Br(coll)2SbF6, and Z- and E-alkenes gave diﬀerent
oxetane diastereoisomers. When secondary alcohols were used,
mixtures of cis- and trans-2,4-disubstituted oxetane isomers
were obtained (167b). Substituents on the CC double bond
led to mixtures of diastereomers (167c), which could not be
identiﬁed. Finally, reactivity of the iodonium salt, I(coll)2SbF6,
was investigated but a reduced yield was obtained (167d).
Similar transformations have been reported by exo
cyclization using electrophilic S and Se reagents to generate
oxetanes. The electrophilic addition of PhSe, by use of PhSCl,
and etheriﬁcation was ﬁrst reported as an unwanted side
reaction in the synthesis of a cis-hydrindenone, a bicyclic natural
product scaﬀold.220 Arjona et al.221 shortly afterward reported
electrophilic addition using both PhSCl and PhSeCl with a
variety of 7-oxanorbornenic substrates. The use of PhSCl was
more eﬀective at promoting etheriﬁcation and gave oxetane
168a as the major product, whereas the use of PhSeCl gave the
addition of chloride as the major product. Improved selectivity
and yields for the oxetanes could be achieved if the temperature
of the reaction was lowered, though tertiary alcohols were
required to gain high yields for cyclization (Table 14).222
Synthesis of four-membered rings from a 4-endo-trig
cyclization is much less common than a 4-exo-trig cyclization,
due to the strain in the transition state. However, Homsi and
Rousseau223 showed that oxetanes (as well as other four-
membered rings) could be synthesized in reasonable yields
from cinnamic alcohols through a 4-endo-trig cyclization by use
of bis(collidine)bromine(I) hexaﬂuorophosphate (Scheme
50a). The E- and Z-alkenes gave the same oxetane, with the
Table 13. Iodine-Mediated Cyclization of Enantioenriched
Oxetanes through Incorporation of an Evans Auxillary
entry R yield 166 (%) ratio a:b
1 Me 63 >98:<2
2 Et 90 82:18
3 iPr 77 81:19
4 Ph 85 a
aDecomposition occurred in this case.
Scheme 48. Possible Transition States Explaining the Facial
Selectivity of Cyclization
Scheme 49. Electrophilic Halocyclization of Functionalized
Vinylsilanes
Table 14. Investigations into Electrophilic Cyclization of a 7-
Oxanorbornenic Substrate
entry
electrophile
(EX) solvent temp (°C) yield 168 (%) ratio a:b
1 PhSCl CHCl3 rt 4:1
2 PhSCl CH2Cl2 −50 93 1:0
3 PhSeCl CHCl3 rt 1:4
4 PhSeCl CH2Cl2 −78 84 9:1
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stereochemistry determined to be trans due to a coupling
constant of 6 Hz (expected to be larger for cis).
Examination of the inﬂuence of substituents on cyclization
revealed that primary and secondary alcohols mainly gave low
yields of oxetanes and signiﬁcant degradation, and tertiary
alcohols gave oxetanes in good yields (Scheme 50b).223,224 A
tertiary alcohol with an α-phenyl group led to oxetane
formation in moderate yield (55%). When R ≠ R′, mixtures
of diastereoisomers were observed. These oxetanes were further
functionalized in order to access oxetin derivatives, for example,
through oxidative cleavage of the phenyl group with NaIO4 and
catalytic RuCl3 (not shown).
3.1.6. Other C−O Bond-Forming Cyclization Ap-
proaches. In 2014, Dussault and co-workers225 reported the
synthesis of cyclic ethers through a C−O bond formation with
reversed polarity. Unlike the traditional Williamson ether-
iﬁcation (oxyanion and electrophilic carbon), carbanions as
enolate anions and electrophilic oxygen in the form of a
peroxide were used. Cyclization proceeded rapidly in the
presence of KOtBu or KH in THF, giving oxetanes, THFs, and
tetrahydropyrans (THPs) in high yields (Scheme 51a). The
transformation was also achieved in an intermolecular fashion
with t-butyl iodoalkyl peroxides and cyclohexanone to give the
spirocyclic ether derivatives (Scheme 51b).
Commonly, oxetan-3-ones have been formed by intra-
molecular OH insertion of diazo compounds, which has been
previously reviewed.5,226 In 2010, Zhang and co-workers227
reported an alternative, whereby a gold carbene was generated
from an alkyne that formed oxetan-3-ones from propargylic
alcohols in one step, with Au(I) as catalyst (Scheme 52).
Functionalized secondary and tertiary propargylic alcohols were
successfully employed though they required a slight mod-
iﬁcation to the catalyst and pyridine N-oxide additives.
Sharma and Williams228 demonstrated the formation of
oxetan-3-ones in a two-step sequence from allenes (Scheme
53). Double epoxidation of the allene and then halide or
thermally induced rearrangement of the spirodiepoxide gave
the desired oxetan-3-one analogues. Diﬀerent conditions for the
rearrangement gave diﬀerent diastereomers as the major
product.
3.2. Cyclization through C−C Bond Formation
The formation of oxetanes via C−C bond formation is
relatively unexplored, but there are increasing examples of
this as an eﬀective and complementary strategy. In the 1990s,
Craig et al.229,230 reported the use of a C−C bond-forming
cyclization for the stereoselective synthesis of bicyclic
ketooxetanes 170 and 172 by intramolecular C-glycosidation
(Scheme 54). Silver triﬂate mediated the cyclization of
thiopyridyl glycosides 169 and 171 in moderate yields through
addition of the silyl enol ether side chains to the generated
Scheme 50. Oxetane Synthesis via 4-endo-trig
Haloelectrophilic Cyclizationa
a(a) Initial result with cinnamic alcohols. (b) Substrate scope
accessing highly substituted oxetanes.
Scheme 51. Synthesis of Oxetane, Tetrahydrofuran, and
Tetrahydropyran Rings through Reverse C−O Bond
Formation
Scheme 52. Au(I)-Catalyzed Cyclization of Propargylic
Alcohols to Oxetan-3-ones
Scheme 53. Synthesis of Oxetan-3-ones in Two Steps from
Allenes
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oxocarbenium intermediate. The stereoselectivity was rational-
ized as resulting from minimization of unfavorable steric
interactions between the bulky nucleophilic side chain and the
ring system in the transition state. Extension of this
methodology to more complex bicyclic systems from sugar
derivatives was achieved by variation of the leaving group and
cationic activator, either under the original conditions or with
thiophenyl glycosides with tin chloride or ethylaluminium
dichloride.231,232
Intramolecular cyclization with epoxide opening through C−
C bond formation has been used to form oxetanes. First
reported in 1976 by Still,233 trans-epoxy allylic ether 173 was
treated with sBuLi in THF/hexamethylphosphoramide
(HMPA) at −78 °C to form vinyl oxetane 174 regioselectively,
via stereospeciﬁc cyclization of the resulting allyloxycarbanion
(Scheme 55). Formation of the more strained four-membered
ring over the isomeric ﬁve- or six-membered rings was favored
due to the lower strain necessary in the transition state to
obtain the required alignment of the carbanionic center and the
epoxide C−O bond. The trans isomer of 173 was required for
intramolecular epoxide ring opening: when the cis isomer was
treated with sBuLi, 2-cyclohexenol was formed. The addition of
4% HMPA was required to prevent the oxetane ring opening of
174 through further reaction with sBuLi.
Bird and Hormozi234 reported a similar outcome upon
treating allyl glycidyl ethers with sBuLi in THF/HMPA at −78
°C; the four-membered oxetane or seven-membered oxepane
products were favored over the isomeric THF or THP. In
general, the oxepane product was favored, but two examples
gave the oxetane as the major product due to substitutent
eﬀects. In 1983, Williams and Grote235 reported the intra-
molecular epoxide ring opening of substrates bearing a benzyl
substituent to aﬀord various cyclic ethers. For oxetane
examples, treatment of epoxides with 3 equiv of lithio-2,4-
dimethylpiperidide (LiDMP) and 3 equiv of HMPA in THF at
−78 °C, followed by warming to 22 °C for 2 h, resulted in
cyclization (Scheme 56). Good stereocontrol was observed,
with the phenyl ring preferring orientations that minimized
unfavorable steric interactions.
Mordini et al.236 further explored the reactivity of benzyl
epoxides as precursors to access oxetanes by treating benzyl
epoxy ethers with 2 equiv of LiDAKOR (lithium diisopropyl-
amine and potassium tert-butoxide) in THF at −50 °C for 15 h.
Cyclization of the benzylic anion by attack at the epoxide
formed 2,3-disubstituted oxetanes with complete anti selectivity
between the C2 and C3 substituents, but yields were low due to
a competing elimination reaction to form vinyl ethers 176
(Scheme 57a). The electronics of the aryl group were
important in determining reaction outcomes. With electron-
rich examples, migration of the lithiated anion from the
benzylic position occurred, resulting in formation of the vinyl
ether product (Y = OMe, Me, and tBu). Electron-withdrawing
substituents favored oxetane formation unless the anion was
too stable; the p-nitro substituent gave no reaction. When a
phenyl ring was present (Y = H), the oxetane could be accessed
as the only product in 70% yield. When benzyloxy ether 177
was treated with LiDAKOR and a large excess of nBuLi at
higher temperature (25 °C), Z-alkene diol 178 was formed due
to further reaction with excess base (Scheme 57b).237 The
lithiated oxetane underwent ring opening to form a carbene
intermediate, which, following an alkyl 1,2-shift, aﬀorded the
observed diol. The same process was reported for more
functionalized alkoxymethyl derivatives; all substrates cleanly
Scheme 54. Intramolecular C-Glycosidation Route to
Oxetanes
Scheme 55. Vinyl Oxetane Formation via Intramolecular
Epoxide Ring-Opening Cyclization
Scheme 56. Intramolecular Cyclization of Epoxy Ethers
Bearing a Benzyl Substituent
Scheme 57. Oxetane Formation from Cyclization of Benzyl
Epoxides
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converted to the oxetanes in good yields of 50−75% upon
treatment of the epoxides with LiDAKOR.238 Subsequent
treatment with nBuLi (4 equiv) resulted in diol formation with
stereocontrol.
α-Substituted epoxy ethers 179 prohibited migration of the
anion, resulting in trisubstituted oxetanes 180 as the sole
products.239 Treating benzyloxy epoxides, prepared by a
Sharpless kinetic resolution, with LiDAKOR or LiCKOR
(butyllithium and potassium tert-butoxide) in THF at
−50 °C resulted in excellent yields of the trisubstituted
oxetanes (Table 15, entry 1).
In 1997, Mordini et al.240 expanded these studies to access
amino alcohols bearing an oxetane moiety. Benzyl epoxy ethers
derived from valine, leucine, and serine were treated with
LiDAKOR at −50 °C to generate the amino alcohol-substituted
oxetanes (Scheme 58). Employing the E isomers of 181
resulted in formation of the anti conﬁguration of oxetane 182.
However, when a Z isomer of the benzyl epoxy ether derived
from serine was employed (protected as an oxazolidine), the
oxetane was formed in 65% yield and a mixture of syn and anti
(30:70) conﬁgurations was observed.
Trisubstituted oxetanes with a hydroxymethyl substituent
could be generated from monosubstituted epoxides. Terminal
epoxy α-substituted ethers 183, upon treatment with LiCKOR
or LiDAKOR at −50 °C, aﬀorded 184 (Table 16).241 When Y
was a phenyl ring or an alkyne, 2-phenyl- or 2-alkynyloxetanes
were the major products, demonstrating preferred formation of
the four-membered ring over the isomeric THF. The relative
stereochemistry of the oxetane products at C2/C3 was
determined by consideration of the stereochemistry of epoxy
ether substrates and selectivity for the anti conﬁguration of Y
and hydroxymethyl substituents (Table 16, entries 1−4).
Oxepanes 185 were formed instead when allyl epoxy ethers
were employed (Table 16, entries 5−7). Enantioenriched cis-
substituted epoxides were also converted to enantioenriched
epoxides.242 A synthesis of oxetanocin used this strategy with
lithiation of allyl ether and epoxide opening; however,
selectivity and yield for the desired oxetane were low.243,244
Fujioka and co-workers245 developed a C−C bond-forming
route to highly substituted 2-phosphonatooxetan-3-ones by
intramolecular ester condensation (Scheme 59). Cyclization
precursors such as 186 were prepared from the corresponding
methoxymethyl ether with trimethylsilyl triﬂate (TMSOTf) and
P(OMe)3, and the cyclization was then promoted with lithium
diisopropylamide (LDA) in the presence of tetramethylethyle-
nediamine (TMEDA) to form oxetanone 187. The phospho-
nates could then be used in Horner−Wadsworth−Emmons
reactions to generate the substituted exo-methyleneoxetane
188. A one-pot process gave similar yields to the two-step
procedure.
In 2014, Bull and co-workers246 reported an anionic
substitution cyclization reaction to form 2-functionalized
oxetanes, forming the C2−C3 bond. 2-Sulfonyl oxetanes were
targeted as unusual fragments for fragment-based drug
discovery but presented unsuitable substrates for C−O bond-
forming cyclization approaches.85 This prompted more
extensive investigation of a C−C bond-forming approach.
The required cyclization precursors 189 were accessed in three
steps from readily available chloromethyl aryl sulﬁdes. Treat-
ment of aryl sulfones 189 with lithium bis(trimethylsilyl)amide
(LiHMDS) resulted in formation of a carbanion, stabilized by
the sulfone, which eﬀected cyclization to aﬀord 2-sulfonyl
oxetane 190 (Scheme 60). The reaction proceeded in high
yield in just 1 h at 0 °C and was successful on a gram scale. The
aryl group could be readily varied to build a collection of 2-
sulfonyl oxetanes. The sulfonyl oxetane fragments were further
Table 15. Stereoselective Synthesis of Trisubstituted
Oxetane through Intramolecular Epoxide Ring Opening
entry Y 2,3-syn:2,3-anti yield 180 (%)
1 C6H5 13:87 80
2 p-F−C6H5 12:88 81
3 CH2CH 2:98 80
4 C6H5S 78:22 86
Scheme 58. Regio- and Stereoselective Synthesis of Amino
Alcohol-Substituted Oxetanes
Table 16. Stereoselective Synthesis of Hydroxyoxetanes through Cyclization of Epoxy Ethers
entry R Y 184 (syn/anti):185 (syn/anti) yield (%)
1 C5H11 C6H5 98 (5/95):2 53
2 CH2OSiMe2tBu C6H5 98 (2/98):2 55
3 C5H11 CHC 98 (20/80):2 55
4 CH2OSiMe2tBu CHC 98 (15/85):2 50
5 H CH2CH 2:98 (98/2) 45
6 C5H11 CH2CH 2:98 (98/2) 65
7 CH2OSiMe2tBu CH2CH 2:98 (98/2) 53
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derivatized through deprotonation on the ring, aided by the
sulfonyl group (section 6), as well as cross-coupling reactions
through the aryl substituent, maintaining the oxetane ring
intact.246,85 Furthermore, the chemical and metabolic stability
of the fragments, relevant to fragment-based drug discovery,
was assessed.85 This approach to oxetane synthesis was
extended to sulﬁnyl oxetanes, which cyclized under modiﬁed
conditions upon deprotonation adjacent to the sulfoxide.247
The C−C bond-forming strategy was extended to a two-step
approach to 2,2-disubstituted oxetane derivatives.140,248 A
rhodium acetate catalyzed O−H insertion between ethyl
diazomalonate and β-bromohydrins rapidly constructed suitable
cyclization precursors 191 (Scheme 61). Cyclization forming
the C−C bond [NaH in N,N-dimethylformamide (DMF) at
0 °C for 1 h] was very eﬀective to generate 2,2-disubstituted
oxetanes 192. Substituents were incorporated at the 4-position
by use of substituted bromohydrins, and the ee of
enantioenriched bromohydrins was transferred to the oxetane
product. Varied substituents could be incorporated at the 4-
position, and chlorides were also eﬀective as leaving groups.
More highly substituted oxetane examples were prepared from
tertiary alcohols and 1,2-substituted bromohydrins, including
cyclic systems to generate fused oxetanes. These diester oxetane
derivatives were further elaborated in order to generate a range
of oxetane-containing fragments and building blocks.
The use of other diazo compounds gave a series of novel
functionalized oxetane motifs. From the corresponding diazo
compounds, varied functional groups were introduced into the
oxetane products, including amides, nitriles, phosphonates, and
sulfones (Scheme 62).249 More substituted examples were also
demonstrated, with low to good diastereoselectivity. Through
the use of donor−acceptor diazo compounds, aryl rings could
also be introduced onto the oxetane ring. With these examples,
deprotonation with LiHMDS in THF gave better conversions.
Scheme 59. Synthesis of Oxetan-3-ones by Intramolecular Ester Condensation
Scheme 60. Synthesis of 2-Sulfonyl Oxetanes
Scheme 61. Oxetane Synthesis by O−H Insertion/C−C Bond-Forming Cyclization
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Ester hydrolysis was again demostrated, and amide coupling
with nitrile- and aryl-substituted examples accessed new amide
derivatives.
4. [2+2] AND FORMAL [2+2] CYCLOADDITIONS
This section will consider recent examples in the synthesis of
oxetanes where both the C−C and C−O bonds are formed in a
single operation. Given the comprehensive reviews in recent
years on the topic of the Paterno−̀Büchi reaction,3,4,250−252
here selected examples of photochemical [2+2] reactions will
be presented, including continuous-ﬂow approaches and other
formal [2+2] reactions, focusing on recent advances. See
section 7 for examples of [2+2] reactions involving allenes to
form 2-alkylideneoxetanes.
4.1. Paternò−Büchi [2+2] Photocycloaddition
Over many years, the light-induced Paterno−̀Büchi reaction
between carbonyls and oleﬁns has been exploited for oxetane
synthesis. High yields are often achieved for suitable substrates,
frequently aﬀording highly substituted oxetanes. Reaction
between the alkene and a photoexcited singlet or triplet
carbonyl derivative proceeds to the oxetane by either a
nonconcerted or concerted pathway. Where the reaction occurs
through the triplet-state carbonyl, the reaction is nonconcerted
and proceeds through a C,C-biradical intermediate, ﬁrst
forming the C−O bond. However, reaction of the singlet
carbonyl is more complex and can occur through either a
concerted mechanism or nonconcerted mechanism.3,4,253−256
While regio-, site-, and stereoselectivity can be challenging, such
selectivities have been achieved, for example, in the extensive
work by Bach et al., targeting 3-silyloxy257,258 and 3-
aminooxetane derivatives259−263 (Scheme 63).264,265 In this
work, reactions were conducted by irradiating aryl aldehydes
and silyl enols or N-acyl enamines with ultraviolet light, and
high diastereoselectivity was obtained, with a cis conﬁguration
favored between the aryl group and the silyl ether/amine.
Recently, Griesbeck et al.266 have formed fused oxetaneisox-
azolines by a Paterno−̀Büchi reaction of methyl-substituted
isoxazoles with aryl aldehydes with high regioselectivity and exo
diastereoselectivity. Zhang and co-workers267 reported the
[2+2] cycloaddition reaction of oxazoles with isoquinoline-
1,3,4-trione to form spiroisoquinolineoxetanes, which under-
went an acid-catalyzed hydrolysis to give spiroisoquinolineox-
azoline products. Furthermore, the Paterno−̀Büchi reaction has
been conducted on designed chiral templates with dihydropyr-
idones,268,269 with 8-phenylmenthol as an auxiliary,270 and
directed by chiral hydroxy groups.271 Additionally, the synthesis
of a variety of natural products, for example, oxetanocin272 and
merrilactone A,273 successfully utilized the Paterno−̀Büchi
reaction as the oxetane-forming step.
There are certain substitution patterns around oxetanes that
have only been prepared through [2+2] approaches, one such
example being 3,3-diaryl-substituted oxetanes. In 2001, Xu and
co-workers274 reported the synthesis of a 3,3-diphenyloxetane
in 98% yield by a Paterno−̀Büchi reaction (Scheme 64). Prior
to this work 3,3-diaryloxetanes were not known in the
literature.
Subsequently, Inoue and co-workers275,276 used [2+2]
photocycloaddition methods for the synthesis of 3,3-dipheny-
loxetanes from chiral cyanobenzoates and diphenylethene.
Interestingly, the diastereoselectivity was entirely dependent on
the mode of excitation (direct excitation of acceptor or selective
activation of the charge-transfer band). Nonintercovertible
diastereomeric pairs of excited-state complexes were generated
with diﬀerent ratios depending on excitation, and the dr was
Scheme 62. Synthesis of Functionalized Oxetanes from Unsymmetrical Diazo Compounds
Scheme 63. Synthesis of (a) 3-Silyloxyoxetanes and (b) 3-
Aminooxetanes via Paternò−Bu ̈chi Photochemical [2+2]
Cycloadditions
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carried through to the oxetane products. The mode of
excitation was controlled by simply changing the irradiation
wavelength.275,276
D’Auria and co-workers277 examined the Paterno−̀Büchi
reaction with alkenyl boronates and benzophenone. When
pinacol boronate 193 and benzophenone were irradiated in
benzene at 310 nm, the product oxetane 194 was observed in a
30% yield (Scheme 65a). Interestingly, when the N-
methyliminodiacetic acid (MIDA) boronate derivative 196
was submitted to the same conditions, allylic alcohol 197 was
observed in 66% yield, resulting from hydrogen abstraction at
the allylic position (Scheme 65b). Computational studies
indicated that the Paterno−̀Büchi reaction was likely to proceed
via C,C-biradical intermediate 195. This diﬀered from the
previous hypothesis that electron-poor alkenes proceeded
mainly by a C,O biradical intermediate. Further computational
studies suggested that both observed products were the
kinetically favored products and not thermodynamically
preferred.277
Photochemical reactions, although often powerful as a
synthetic tool, may involve long irradiation times that can
lead to reduced yields of the product due to undesired reactions
over the extended time period. In recent years, reactions in
continuous ﬂow have been described as a strategy to achieve
more eﬃcient and uniform irradiation.278 The ﬁrst example of a
[2+2] cycloaddition in a microﬂow system was published in
2004; enones and vinyl ethers were reacted to give the
corresponding cyclobutane, by use of a 300 W mercury lamp
and a residence time between 2 and 3.2 h.279 The equivalent
reaction on a model substrate in a batch process gave a
signiﬁcantly lower yield (8% vs 88%), demonstrating the
potential of this approach.279 Subsequently, this methodology
has been applied to the Paterno−̀Büchi reaction for synthesis of
oxetanes. In 2011, Ryu and co-workers280 demonstrated that
using either a 15 W black light (BL) or a 300 W mercury lamp
in a microﬂow photoreactor system with a residence time of 1.2
or 4 h converted benzophenone and prenyl alcohol to the
desired oxetane in excellent yields of 84% or 91% (Scheme 66).
The 15 W black light required an extended residence time to
achieve comparable yields, but the energy eﬃciency was still far
superior to the batch process, which yielded only 51% of
product after 92 h.280
A single example of a Paterno−̀Büchi cycloaddition in ﬂow
was published by Booker-Milburn and co-workers281 in 2014
(Scheme 67). After 3 h, the batch process (run at a 0.3 M
concentration) gave 14.05 g of product (67% yield). Under
optimized ﬂow conditions at a ﬂow rate of 3 mL·min−1, 20.52 g
of product was isolated after 3 h (72% yield), representing an
increase in productivity of 50%.
In 2014, Kakiuchi and co-workers282 investigated the
Paterno−̀Büchi reaction, using slug ﬂow technology to increase
the eﬃciency of the system, which involves two interspersed
phases in the ﬂow microsystem. Three diﬀerent modes of ﬂow
were investigated and compared to batch reaction: normal ﬂow,
slug ﬂow with substrate solution/N2, and slug ﬂow with
substrate solution/H2O. Both normal ﬂow and slug ﬂow
approaches gave a considerable increase in reaction eﬃciency
compared to the batch reaction (Table 17).282 The slug ﬂow
approach with substrate solution/H2O combination gave the
highest eﬃciency. Suggested reasons for the increase in
eﬃciency include light dispersion eﬀects and a stirring eﬀect
caused by movement of the second layer, as well as a thin-layer
eﬀect leading to a short pathway for irradiation. All conditions
gave the same diastereoselectivity.
Scheme 64. Synthesis of 3,3-Diphenyloxetane by Paternò−
Büchi Reaction
Scheme 65. Photochemical Reactions of Electron-Poor Alkenyl Boronates with Benzophenone
Scheme 66. First Example of Paternò−Büchi Cycloaddition
in Flow
Scheme 67. Example of Paternò−Bu ̈chi Cycloaddition in
Flow Compared to Batch Processa
aBooker-Milburn and co-workers.281
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4.2. Formal [2+2] Cycloadditions
In 2011, Mikami et al.283 reported a Lewis acid-catalyzed
asymmetric formal [2+2] cycloaddition to form 2-triﬂuorome-
thyloxetanes from triﬂuoropyruvate and activated alkenes
(Scheme 68). This transformation was achieved by use of
either Cu(II) or Pd(II) complexes depending on the vinyl
substrate: silyl ethers required Cu−bis(oxazoline) complex A,
whereas Pd−BINAP complex B [BINAP = 2,2′-bis-
(diphenylphosphino)-1,1′-binaphthyl] was required for the
less reactive vinyl acetate.
This Lewis acid-promoted strategy was also used to
synthesize unusual yet stable oxetene derivatives. Mikami and
co-workers284,285 demonstrated that alkynylsilanes bearing
electron-rich p-methoxyphenyl groups underwent the formal
[2+2] cycloaddition to aﬀord oxetenes with high ee when a
chiral cationic BINAP−Pd complex was used (Scheme 69).
Alkynes bearing aliphatic and aromatic groups gave the desired
oxetanes in good to excellent yields and ee.284 A variety of other
conjugated alkynes were also compatible, including 1-naphthyl-,
heteroaryl-, and vinyl-substituted alkynes. Remarkably, an
ynamide was also able to undergo this transformation in
excellent yield and ee, and the catalyst loading could be lowered
to 0.5 mol %. These unusual oxetenes could undergo a variety
of transformations, including reduction of the double bond with
Pd/C and H2 to give oxetane 198 (Scheme 70).
284
5. SYNTHESIS OF OXETANE DERIVATIVES FROM
OXETANE-CONTAINING BUILDING BLOCKS
Partly due to interest in the pharmaceutical industry, a number
of oxetane building blocks have recently been developed and
become increasingly available. In turn, this has furthered the
exploration of oxetanes in drug discovery. An increasing
selection of oxetane building blocks, largely 3-substituted
examples, are now readily available from commercial suppliers
Table 17. Eﬀect of Normal and Slug Flow Conditions on Eﬃciency of Paternò−Bu ̈chi Cyclization
energy eﬃciencies
reactor yield (%) irradiation time (s) %·W−1·h−1 %·W−1·h−1·cm−2
batch 40 180 1.60 0.561
normal ﬂow 39 30 9.36 0.596
slug ﬂowa 45 15 21.6 1.376
aUsing H2O and substrate solution.
Scheme 68. Synthesis of 2-Triﬂuoromethyloxetanes via
Transition Metal-Catalyzed Formal [2+2] Cycloaddition
Scheme 69. Synthesis of Chiral, Stable Oxetene Derivatives
through Formal [2+2] Cycloaddition Mediated by a Chiral
BINAP−Pd Complex
Scheme 70. Reduction of Triﬂuoromethylated Oxetene to
the Corresponding Oxetane
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(Figure 15). Certain examples, particularly modiﬁcations of
oxetan-3-one, and 3-hydroxyoxetane are inexpensive, yet other
simple substitution patterns remain very costly, for example,
oxetane-3-carboxylic acid.
Reactions of 3-hydroxyoxetane 199 were demonstrated by
Baum et al.286 in 1983 via the tosylate, formed by use of
aqueous sodium hydroxide and tosyl chloride (Scheme 71).
Reaction of 3-(tosyloxy)oxetane 200 with sodium azide yielded
3-azidooxetane 201 in 86% yield. Subsequent reaction with
triphenylphosphine and then ammonolysis with liquid
ammonia gave 3-aminooxetane 202 in excellent 96% yield.
Oxidation to 3-nitrooxetane 203 was successful with m-CPBA.
This could be then converted to the 3,3-dinitrooxetane by use
of aqueous methanol and tetranitromethane.286
Simple 3-bromo, iodo, and tosylate examples have been
shown to be eﬀective electrophiles for N-alkylation, especially
on N-heteroaromatic compounds, with nucleophilic substitu-
tion occurring at the four-membered ring by an SN2
mechanism.287 Recent examples include applications in
medicinal chemistry and in the preparation of substrates for
ring-opening reactions (Scheme 72;288,289 also see section
3.1.3.1 for additional examples of similar reactions on more
substituted substrates).
Nonetheless, outside the patent literature, there remain
relatively few reactions on these simple substrates that maintain
the oxetane ring. An example is oxidation of oxetane-3-
methanol to the aldehyde, which has been achieved with Dess−
Martin periodinane290,291 or PCC.292 This section will give an
overview of the transformations available on key oxetane
building blocks and provide examples of their use in drug
discovery eﬀorts, including a survey of examples from the
patent literature.
5.1. Carreira’s Oxetan-3-one
Oxetan-3-one was originally reported in 1973;5,287 however,
studies from Carreira and co-workers63,65 since 2006 have
developed this unit as an attractive electrophilic building block
for the incorporation of oxetanes. There have been a large
number of examples since, exploiting this ketone in reactions to
incorporate an oxetane into a selection of important molecules.
In 1991, prior to Carreira’s studies, Kozikowski and Fauq293
published a route to synthesize oxetane-containing amino acid
derivatives as inhibitors for the glycine binding site of the N-
methyl-D-aspartate (NMDA) receptor complex (Scheme 73).
Oxetan-3-one was identiﬁed as a key intermediate and was
synthesized in ﬁve steps from epichlorohydrin. A Strecker
synthesis was then used to deliver the desired amino acid
derivatives. Base hydrolysis of aminonitrileoxetane 204 at 95 °C
for 2.5 h, followed by hydrogenolysis over Pd(OH)2, delivered
the amino acid 205 (Scheme 73). Alternatively, base hydrolysis
at 50 °C for 30 min and then hydrogenolysis over Pd(OH)2
resulted in the amino carboxamide.
Carreira and co-workers63,64 developed a general procedure
for synthesis of 3-aryloxetan-3-ols from halogenated aromatic
species, through a halogen−lithium exhange and then addition
to oxetan-3-one (Scheme 74). This has been shown to be
general for a large number of aromatic and hetereoaromatic
groups, including but not limited to pyridine, pyrimidine,
pyrazole, and ortho-, meta-, and para-substituted phenyl-
Figure 15. Some commercially available oxetane-containing building
blocks.
Scheme 71. Synthesis of 3-Amino- and 3-Nitrooxetane
Scheme 72. SN2 Reactions on Simple Oxetane Building
Blocksa
aEstrada et al.288; Sun and co-workers.289
Scheme 73. Synthesis of Two Oxetane Amino Acid
Derivatives via Oxetan-3-one
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containing examples.289,294−309 Similarly, alkynyl289,310−312 and
vinyl313,314 organometallics have been added directly.
The 3-hydroxy group has provided a useful handle for further
reactions, making 3-aryloxetan-3-ols interesting reactive inter-
mediates. The earliest demonstration of replacement of a
tertiary alcohol at the 3-position of an oxetane with a suitable
nucleophile was in 2006 by Carreira and co-workers.63
Fluorination by stoichiometric DAST was achieved in yields
between 40% and 47% (Scheme 75). Subsequently, this
methodology has been adopted and reported in numerous
industrial medicinal chemistry patents for synthesis of 3-
ﬂuorooxetanes.315−339 Fluorinating agents such as Xtal-
Fluor325,326 and Deoxo-Fluor327−329 have also been found to
be applicable for this transformation. The reaction has been
shown to be tolerant of various preinstalled aryl substituents,
with good yields (>70%) being reported for p-cyano-,330−332 m-
iodo-,333 and p-bromophenyl334,335 and pyridyl336−338 exam-
ples. Additionally, examples have been reported with
pyrimidines,329 pyrazoles,339,326 and more complex dia-
ryls.340−342 Chlorination of an oxetan-3-ol was also shown to
be feasible; use of methanesulfonyl chloride and triethylamine
at 55 °C formed the desired 3-chlorooxetane in 42% yield
(Scheme 76).64 This remains the only example of this
transformation.
Acid-mediated dehydroxylation of 3-aryloxetan-3-ols has
been successfully achieved by use of triﬂuoroacetic acid and
triethylsilane as the hydride donor (Scheme 77a).64 Although
this reaction worked well for the p-anisyl derivative, neither the
unsubstituted phenyl nor the 2,4-dimethylphenyl variants gave
the desired product. A more general route was developed as a
three-step, one-pot synthesis via the tosylate (Scheme 77b).63 A
low reaction temperature was required to prevent ring opening
of the oxetane.64
In 2013, scientists at Hoﬀman-La Roche343 reported in a
patent an example of a four-step synthesis of dehydroxylated
oxetane 208 from oxetan-3-ol 206 (Scheme 77c). Near-
quantitative conversion to the xanthate 207 was realized, with
subsequent conversion to 3-aryloxetane 208 achieved in 38%
yield by a Barton−McCombie deoxygenation with azobisiso-
butyronitrile (AIBN) and tributylstannane.
To generate 3-aminooxetanes, oxetan-3-one has been widely
used in reductive amination sequences (also see section
5.3).344−349 Hamzik and Brubaker350 demonstrated the
preparation of 3-aminooxetanes through condensation of
oxetan-3-one and tert-butylsulﬁnimine (Bus), followed by
addition of various organometallic reagents to imine 209
(Scheme 78a). Generation of an aziridine from the same imine
with dimethyloxosulfonium methylide aﬀorded aziridine 210 as
an alternative electrophile. The activated aziridine opened
preferentially, rather than the oxetane, generating 3-function-
alized 3-aminooxetanes. The Bus group could be successfully
removed with 4 N HCl in methanol in a short reaction time;
longer reaction times gave ring opening with chloride. In a
similar approach, Ellman and co-workers351 described the Rh-
catalyzed addition of aryl boroxines to the oxetane Bus-
aldimines (Scheme 78b). The addition was tolerant of various
functional groups on the aryl substituent, including phenol,
ketone, and acetamide groups, though interestingly, omission of
the phosphine ligand was required for a bromoaryl derivative to
minimize side reactions.
Brady and Carreira352 reported the synthesis of 3-amino-
oxetanes by nucleophilic addition to N,O-acetals derived from
oxetan-3-one. Alkynyl, vinyl, allyl, and allenyl triﬂuoroborates
were added eﬀectively by use of BF3·OEt2 to open the aminal,
with tetrabutylammonium bromide included to solubilize the
boron reagents (Scheme 79).
In the initial studies of Carreira and co-workers,63 oxetan-3-
one was used to prepare a series of oxetane Michael acceptors,
which have proven to be valuable building blocks in their own
right. The synthesis of α,β-unsaturated ester 211 and aldehyde
212 was achieved by a Wittig reaction with the corresponding
stabilized ylide reagents (Scheme 80).63 Additionally, nitro-
alkene 213 was synthesized by condensation with nitro-
methane.
These unsaturated units 211−213 underwent conjugate
addition with various nucleophiles including amines, organo-
cuprates, arylboronic acids, and vinylboronic acids, allowing the
preparation of various 3,3-disubstituted oxetanes (Scheme
81).63 The physicochemical properties of oxetane-containing
compounds 2−6 were compared to examine the inﬂuence of
the oxetane motif (see section 2). Carreira and co-workers65
also prepared the comparable α,β-unsaturated sulfonyl, nitrile,
and phosphonate oxetane derivatives. Vinyl sulfone derivative
214 enabled the preparation of 3-functionalized 3-methylox-
etane derivatives through reductive removal of the sulfonyl
group, for example, by the conjugate addition of amines,
followed by treatment with Mg/MeOH (Scheme 82).
Furthermore, conjugate addition reactions into acceptors,
such as 211, followed by a small number of additional synthetic
transformations, enabled the preparation of oxetane spirocycles
(Scheme 83).69,2 In these examples, the oxetane was shown to
be stable to a selection of organometallic reagents. An α-
ﬂuorinated derivative of 211 was prepared by Lequeux and co-
workers353 through a Julia−Kocienski reaction between oxetan-
3-one and ﬂuoromethylsulfones, which was used to prepared
ﬂuorine-containing 3,3-disubstituted oxetanes.
Scheme 74. Sample Synthesis of a 3-Aryloxetan-3-ol by
Organometallic Addition
Scheme 75. Fluorination of Oxetan-3-ol by Use of
Diethylaminosulfur Triﬂuoride
Scheme 76. Chlorination of 3-Phenyloxetan-3-ol by Use of
Methanesulfonyl Chloride and Triethylamine
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Diederich and co-workers354 showed that incorporation of a
pendant oxetane improved the water solubility of 216, an
inhibitor of the enzyme IspE (4-diphosphocytidyl-2C-methyl-D-
erythritol kinase, EC 2.7.1.148), targeting the treatment of
diseases such as malaria and tuberculosis (Scheme 84). The key
step in synthesis of 216 was conjugate addition of 5-
iodocytosine 215 to Michael acceptor 211, which gave 33%
yield. Subsequent Sonogashira cross-coupling aﬀorded 216 with
a yield of 71%. Similarly, the synthesis of oxetanylthalidomide
by Carreira and co-workers80 (Table 2, section 2) involved
conjugate addition of an amine to a nitrooleﬁn derived from
oxetanone.
In 2014, Ellman and co-workers355 reported catalytic
enantioselective addition of thioacids to an oxetane-containing
nitroalkene using bifunctional organocatalyst 217 (Scheme
85a). Michael addition into the oxetane-containing nitroalkene
Scheme 77. Dehydroxylation of Oxetan-3-ols
Scheme 78. Preparation of 3-Aminooxetanes by Addition to an Iminea
a(a) Hamzik and Brubaker350; (b) Ellman and co-workers351.
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and subsequent enantioselective protonation led to the
synthesis of 1,2-nitrothioacetate products in high yields and
enantioselectivities for various substrates. Biomedically relevant
1,2-aminosulfonic acids were accessed via a high-yielding two-
step route with complete retention of ee (Scheme 85b). Very
recently, related work on conjugate addition, and subsequent
enantioselective protonation, of pyrazol-5-ones to oxetane-
containing trisubstituted nitroalkenes was reported.356
Carreira and co-workers357 and Shipman and co-workers358
simultaneously reported the use of oxetan-3-one to generate
peptide mimics, with an aminooxetane providing a bioisostere
for the amide linkage (Scheme 86). Peptides often confer poor
properties as drug candidates because they are easily cleaved.
Oxetanes may reduce the propensity for cleavage, providing an
opportunity for new peptidomimetics with improved proper-
ties. In both cases, amine conjugate addition to nitrooleﬁn 213
was used to introduce amino acid units. Shipman and co-
workers359 recently reported an adaptation of this approach to
generate oxetane-containing diketopiperazine derivatives. Very
recently, Jørgensen and co-workers360 reported an organo-
Scheme 79. Nucleophilic Addition of Carbon Nucleophiles
onto Spirocyclic Oxetanes
Scheme 80. Synthesis of Oxetane Michael Acceptors
Scheme 81. Synthesis of 3,3-Diaryloxetanes via Conjugate
Addition to Oxetane-Derived α,β-Unsaturated Ester,
Aldehyde, and Nitroalkene
Scheme 82. Conjugate Addition to Vinyl Sulfone 214 and
Reductive Removal
Scheme 83. Synthesis of Oxetane-Containing Spirocyclic
Compounds Involving Conjugate Additiona
aR = piperonyl.
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catalyzed cycloaddition to oxetanyl nitrooleﬁns to generate
spirocyclohexene-oxetane scaﬀolds.
Oxetan-3-one has been used in a number of complexity-
generating reactions to incorporate oxetanes into interesting
structural types. Shipman and co-workers361 have used this unit
in the Passerini reaction (Scheme 87a) and also in the Pictet−
Spengler reaction362 (Scheme 87b). Harrity and co-workers363
applied their sydnone cycloadditions to an oxetane-containing
motif in both intermolecular and intramolecular cycloadditions
to form oxetane-containing pyrazole derivatives (Scheme 88).
Bode and co-workers364 have developed a powerful one-step
protocol for synthesis of saturated N-heterocycles, using stannyl
amine reagents in combination with aldehydes (SnAP
protocol). This approach has been expanded to spirocyclic
saturated N-heterocyclic examples, using ketones.365 Signiﬁ-
cantly, oxetan-3-one was used in a key example to form an
oxetane-containing spirocyclic piperazine (Scheme 89). Con-
densation of SnAP reagent 218 with oxetan-3-one generated an
imine, which underwent Cu-catalyzed radical cyclization to
form spirocyclic heterocycle 219.
In 2015, Sooś and co-workers366 showed that oxetan-3-one
(as well as other four-membered cyclic ketones) would undergo
selective direct cross-aldol reactions with other ketones, such as
cyclopentanone, promoted by pyrrolidine (Scheme 90). The
selectivity was attributed to the inherent angle strain of oxetan-
3-one and relief of this strain during the conversion of C(sp2)
to C(sp3). When unsymmetrical acyclic ketone butan-2-one
was employed, L-proline was used as the organocatalyst at 80
°C to overcome the formation of a stable enamine adduct, but a
mixture of regioisomers was obtained (1.5:1).
5.2. Cross-Coupling of Oxetane Building Blocks
Synthesis of aryloxetanes has been greatly expanded by the use
of 3-iodooxetane in transition-metal cross-coupling reactions.
In 2008, Duncton et al.79 (Evotec) demonstrated the use of 3-
iodooxetane in cross-coupling reactions with a series of
arylboronic acids (Scheme 91). Under conditions developed
by Gonzaĺez-Bobes and Fu367 for the cross-coupling of alkyl
halides, a Ni-catalyzed Suzuki reaction achieved the coupling of
3-iodooxetane and also 3-iodoazetidines in moderate yields.
The transformation was tolerant of various aryl groups but was
unsuccessful with heterocyclic derivatives.
Zhang and Yang,368 in 2015, developed a milder Ni-catalyzed
Suzuki cross-coupling reaction of alkyl halides and arylboronic
acids, using K2CO3 as the base instead of the more standard Li/
KOtBu or Na/KHMDS. In the substrate scope, 3-iodooxetane
was found to be a viable substrate, forming the aryloxetane
product in 68% yield (Scheme 92).
To incorporate an oxetan-3-yl group into heteroaromatic
bases, Duncton et al.369 reported a Minisci reaction involving
generation of the oxetane radical (Scheme 93). The reaction
likely proceeded via addition of an oxetane radical to the
protonated heterocycle, followed by rearomatization. Although
the yields were generally low, the reaction proved tolerant of a
number of diﬀerent functional groups. Various N-heterocycles
were successfully employed in the reaction, leading to
synthetically useful yields, including quinoline, isoquinoline,
pyridine, pyridazine, benzothiazole, benzimidiazole, quinoxa-
line, quinazoline, and phthalazine examples. Of particular note,
due to the existing functionality present, were the hydroquinine
and geﬁtinib derivatives 220 and 221.
Molander and co-workers370 recently extended copper-
catalyzed borylation methodology to prepare various hetero-
cyclic triﬂuoroborates, several of which could be applied in a
Minisci reaction with heteroaromatics. Several heterocyclic
triﬂuoroborates were prepared from iodoheterocycles, including
3-iodooxetane (Scheme 94). The oxetane derivative was not
demonstrated in the Minisci reaction; indeed, there are no
reactions reported to date with oxetane boronates.
Molander et al.371 established a Ni-catalyzed reductive
coupling of saturated heterocyclic bromides with aryl and
heteroaryl bromides. The reaction was developed by employing
a high-throughput experimentation approach to screen Ni
sources, ligands, additives, and solvents for the coupling of N-
Boc-4-bromopiperidine with 4-bromoanisole. The scope of the
saturated heterocycles included coupling of 3-bromooxetane
with 4-bromoanisole in a yield of 43% (Scheme 95). Reaction
conditions were reoptimized for heteroaromatic coupling
partners, which had given poor yields under the previously
developed conditions. Hence, the cross-coupling of N-Boc-5-
bromoindole with 3-bromooxetane proceeded in 36% yield.
Very recently, Buchwald and co-workers372 reported a system
for Lipshutz−Negishi cross-coupling under aqueous conditions,
Scheme 84. Oxetane-Containing IspE Inhibitor with
Improved Aqueous Solubility
Scheme 85. Catalytic Enantioselective Synthesis of (a) 1,2-
Nitrothioacetates and (b) 1,2-Aminosulfonic Acids
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which included the coupling of 3-bromooxetane in high yields.
A new ligand (VPhos) and Pd precatalyst were developed for
coupling of alkyl bromides, particularly saturated heterocycles,
and aromatic and heteroaromatic bromides and chlorides. Ley
and co-workers373 published two examples of 3-aryloxetanes
synthesized in two steps from oxetan-3-one via a sulfonyl
hydrazone intermediate 223 and subsequent metal-free
coupling with boronic acids (Scheme 96). The reaction was
optimized on N-Boc-piperidinone-derived tosyl hydrazine with
4-chlorophenylboronic acid. Replacement of the tosyl group of
Scheme 86. Oxetane Peptidomimetics Formed via Conjugate Additiona
aShipman and co-workers358; Carreira and co-workers357.
Scheme 87. (a) Passerini and (b) Pictet−Spengler Reactions
Involving Oxetan-3-one
Scheme 88. Inter- and Intramolecular Sydnone
Cycloadditions
Scheme 89. Synthesis of Spirocyclic Piperazine-Oxetane by
Use of SnAP Reagents
Scheme 90. Strain-Driven Direct Cross-Aldol Reaction with
Oxetan-3-one
Scheme 91. Ni-Catalyzed Suzuki Coupling of 3-
Iodooxetanea
aDuncton et al.79
Scheme 92. Ni-Catalyzed Suzuki Cross-Coupling Reaction of
3-Iodooxetane and Arylboronic Acidsa
aZhang and Yang.368
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the hydrazone with a p-methoxyphenyl sulfonyl group, by use
of 222, improved the observed yields.
Harrity and co-workers374 prepared oxetane sulﬁnate salt 225
from 3-iodooxetane in a high-yielding three-step process
(Scheme 97). Interestingly the sulfonate salt could be displaced
from the pyridylsulfone 224 with a thiolate nucleophile in
preference to oxetane ring opening. The sulﬁnate salts could be
coupled with electron-rich indoles to introduce a sulfonyl group
at the indole 3-position (226) by use of I2 in MeOH.
5.3. Applications in Medicinal Chemistry
The readily available oxetane units discussed above have
recently found extensive use in medicinal chemistry. This
section will cover the use of oxetanes in biologically active
compounds prepared in drug discovery eﬀorts. We will discuss
examples where oxetanes have been used as part of an extensive
screening and optimization approach. In most of these
examples, the oxetane-containing example is the most bioactive
compound and/or has the most desirable physicochemical
properties as a potential therapeutic.
In 2011, Kinoshita et al.346 reported the development of a
highly potent and selective anaplastic lymphoma kinase (ALK)
inhibitor as a promising therapeutic for cancer. The
incorporation of an oxetane group, via reductive amination of
oxetan-3-one, led to a signiﬁcant improvement in the in vitro
clearance level in mouse and human liver microsomes when
compared to an isopropyl group at the same position (227,
Figure 16). The N-oxetan-3-ylpiperidin-4-yl derivative had
good metabolic stability and strong antitumor eﬃcacy against
KARPAS-299, a NPM-ALK-positive ALCL cell line. In an
extension of this study, the introduction of an ethyl substituent
on the phenyl ring (228) led to an almost 2-fold increase in
potency against KARPAS-299, proposed to be a result of
improved ALK selectivity over oﬀ-target kinases.347
Stepan et al.82,83 explored arylsulfonamides as potential γ-
secretase inhibitors toward treatment options for Alzheimer’s
disease. Lead compound 229 contained a cyclohexyl sub-
stituent and displayed good potency but suﬀered from poor
metabolic stability and solubility (Figure 17; also see section 2).
Incorporation of an oxetane resulted in the greatest improve-
ment in metabolic stability and lipophilicity. Overall, 2,4,4-
Scheme 93. Fe-Catalyzed Synthesis of Heteroaryloxetanes
from 3-Iodooxetane
Scheme 94. Preparation of Oxetane Triﬂuoroborate
Scheme 95. Ni-Catalyzed Reductive Coupling of 3-
Bromooxetane
Scheme 96. Metal-Free Coupling of Boronic Acids with
Saturated Heterocycles by Use of Sulfonyl Hydrazones
Scheme 97. Preparation and Indole Coupling Reactions of
Oxetane Sulﬁnate Salts
Figure 16. Highly potent ALK inhibitors.
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trisubstituted analogue 231 was the most stable γ-secretase
inhibitor of the series.
Dowling et al.81 at AstraZeneca described a series of 5-
anilinopyrazolo[1,5-a]pyrimidine inhibitors of CK2 kinase
(Figure 9, section 2). An N-oxetanyl group was used in place
of a N-cyclopropyl group to reduce lipophilicity without the
introduction of a basic group. Although the oxetane examples
were potent CK2 inhibitors, they were 10-fold less active than
cyclopropyl counterparts.
Scott et al.375 at AstraZeneca developed a series of G-protein
coupled receptor (GPCR) 119 agonists as a potential diabetes
treatment. Initial development led to the discovery of a tert-
butyl carbamate-containing compound that, although potent,
suﬀered from nonideal aqueous solubility (24 μM). In order to
improve this, a number of carbamates were examined.
Replacing the tert-butyl group with a 3-substituted oxetane
resulted in a dramatic increase in aqueous solubility to >2200
μM, over twice as soluble as the THF equivalent; however,
these examples showed a reduction in potency. Addition of a
methyl group to the oxetane increased the activity; ethyl and
isopropyl groups did not further increase potency but led to an
increase in metabolic instability. The alkyl substituent was
revealed to be the site of metabolism, and to circumvent this,
triﬂuoromethyloxetane-containing 233 was synthesized, which
increased potency while maintaining a desirable solubility of
110 μM (Scheme 98). This was incorporated via pentaﬂuor-
ophenyl carbonate 232, developed speciﬁcally for this trans-
formation after more standard approaches had failed.
Pei et al.376 at Genentech developed a potent and selective
oxetane-containing mammalian target of rapamycin (mTOR)
inhibitor as a potential future cancer treatment. An advanced
tetrahydroquinazoline lead molecule was further optimized to
reduce the unfavorable time-dependent inhibition of cyto-
chrome P450 (CYP). This was achieved by replacing an N-
substituted pyrimidine 234 with an N-substituted oxetane 235,
which prevented the interaction with CYPs via the pyrimidine
unit (Figure 18). The oxetane unit, introduced by reductive
amination of oxetan-3-one, reduced the basicity of the nitrogen
atom compared to alkyl groups. It also led to lower hERG
liability while maintaining the high potency of the initial
advanced lead molecule. Following selection of the oxetane as
the drug development candidate, further modiﬁcation was
carried out, replacing the tetrahydroquinazoline scaﬀold with a
bicyclic pyrimidoaminotropane 236.344 The oxetane unit was
re-evaluated on this new backbone and compared to other
substituents, and it was found to still possess the most desirable
properties to be brought forward as a clinical candidate.
Leucine-rich repeat kinase 2 (LRRK2) is a gene related to
Parkinson’s disease that has stimulated signiﬁcant interest
within neuroscience research. Estrada et al.288 reported the
development of highly potent, selective, and brain-penetrant
small-molecule inhibitors of LRRK2 (Figure 19a). The lead
compound was optimized to establish 237, with a pendent
oxetane motif, as one of the best inhibitors, with an IC50 value
of 19 nM.
Jadhav et al.377 at Lilly discovered a series of noncovalent
inhibitors of cathespin S, useful as a potential treatment of
abdominal aortic aneurysm. Following a medium-throughput
screen, several hits were identiﬁed and one was selected for
modiﬁcation to improve its potency and physical properties. A
key aspect of this modiﬁcation process was replacing the N-
methyl group on piperazine with an N-oxetanyl unit to
modulate the basicity of the nitrogen atom and to lower the
overall lipophilicity. This modiﬁcation, along with others, led to
the development of clinical candidate 238 (Figure 19b).
Zhang, Geng, and co-workers348 developed 2,4-diarylamino-
pyrimidine analogues with a ﬂexible amino acid side chain that
are potent inhibitors against wild-type and mutant ALK kinases
as a potential treatment against crizotinib-resistant non-small-
cell lung cancer. Variation of the substitution of the primary
amino group was studied, and it was found that use of a
substituted piperazine, one of which contained pendant oxetane
(239, Scheme 99), generated highly potent and selective ALK
inhibitors. A primary amino acetamide proved to be more
Figure 17. Comparison of metabolic stability of lead compound 229
compared to oxetane-containing analogues. CLint,app (milliliters per
minute per kilogram), shown in parentheses, is total intrinsic clearance
obtained from scaling in vitro HLM half-lives.
Scheme 98. Preparation of Triﬂuoromethyl-Substituted
Oxetane GPCR119 Agonist
Figure 18. Potent and selective mTOR inhibitors.
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active (ALK IC50 = 2.7 nM vs 4.9 nM for the oxetane) and this
was chosen for further evaluation.
Phillips et al.349 at Novartis developed GPCR TGR5
agonists, an attractive target for type 2 diabetes treatment
and for chronic inﬂammation. An oxetane unit was used as part
of a survey of alkyl substituents on a piperazine ring (240,
Scheme 100). Although the oxetane unit successfully mitigated
the issue of hERG risk and retained target potency, CYP3A4
inhibition and metabolic stability were not improved, so this
example was not taken forward.
Schoenfeld et al.378 at Hoﬀmann-La Roche developed a
series of hepatitis C virus inhibitors. An advanced lead structure
was developed containing a tert-butyl group, which was
succeptible to metabolic oxidation. An oxetane replacement
showed similar activity. However, the increase in polarity led to
reduced intrinsic permeability, so it was not advanced further
(241, Figure 20a). The oxetane was synthesized via a C−O
bond-forming step from the corresponding diol under
Mitsonobu conditions.
Gonzalez et al.379 (Amgen) utilized a 3-sulfonyl oxetane
during variation of the N-alkyl substituent of a series of
morpholinone inhibitors of the MDM2−p53 interaction.
Disruption of MDM2 binding to p53 can reactivate the p53
pathway in tumor cells to allow cell cycle arrest and apoptosis.
The 3-sulfonyl oxetane example 242 provided inhibitors with
reduced cellular potency when compared to the more eﬀective
tert-butyl sulfone derivative (Figure 20b).
A novel class of γ-secretase modulators was developed by
Austin et al.380 at Satori Pharmaceuticals as a potential
treatment of Alzheimer’s disease. An initial hit was identiﬁed
from an extract of black cohosh root and developed to improve
metabolic stability. A range of esters and carbamates was
synthesized as bioisosteres to replace a glycoside moiety in
order to improve chemical stability and decrease the topological
polar surface area (tPSA) and HBD count. Oxetane examples
were studied but did not prove to be potent inhibitors (243,
Figure 21). Ultimately, increased activity correlated with
increased basicity and hence nitrogen-containing groups,
including azetidines, proved most potent. During an earlier
structure−activity relationship study,381 N-oxetanyl-substituted
Figure 19. (a) Inhibitor of LRRK2. (b) Cathespin S inhibitor.
Scheme 99. 2,4-Diarylaminopyrimidine Analogues as Potent
Inhibitors against Wild-Type and Mutant ALK Kinases
Scheme 100. GPCR TGR5 Agonists for Potential Type 2
Diabetes Treatment
Figure 20. (a) Oxetane-containing hepatitis C virus inhibitor. (b) 3-
Sulfonyl oxetane inhibitor of MDM2.
Figure 21. γ-Secretase modulators with improved metabolic stability.
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morpholine derivatives were utilized to examine the eﬀects of
varying other key parts of the structure.
Procopiou et al.382 at GlaxoSmithKline reported the
development of a series of indazole arylsulfonamides as CC
chemokine receptor 4 (CCR4) antagonists. A modiﬁed ligand
lipophilicity index (LLEAT), which combined lipophilicity,
potency, and size and made comparisons to conventional
ligand eﬃciency, was used as a metric to compare analogues.
Oxetane amides 244 and 245 had inferior LLEAT values
compared to an acetamide group (Figure 22). The solubility
increased for 244 and for THF and THP analogues but 245
was similar to the acetamide, attributed to the greater exposure
of the oxygen in 244.
Dineen et al.383 (Amgen) identiﬁed a potent inhibitor of β-
site amyloid precursor protein cleaving enzyme (BACE1).
Previously reported aminooxazoline xanthene scaﬀold 246 was
modiﬁed to improve BACE1 potency and prevent oﬀ-targert
hERG channel activity. Principally this was achieved by
incorporating a N atom in the 4-position of the xanthene
core and by replacing the 5-pyrimidyl group with a 2-ﬂuoro-3-
pyridyl analogue (Figure 23). To further reduce hERG activity,
the side chain at the 4-position was modiﬁed. An alkynyl side
chain with a pendant methoxy group proved eﬀective,
maintaining BACE1 potency while reducing hERG binding
aﬃnity (247, Figure 23). However, oxidative demethylation of
the methoxy group resulted in poor metabolic stability. An
oxetane group was successfully incorporated to reduce this
oxidative dealkylation, resulting in a compound with good
stability in human and rat liver microsomes (248, Figure 23).
Additionally, the oxetane unit was found to be stable in the
presence of glutathione.
Plancher and co-workers384 at Hoﬀmann-La Roche devel-
oped a series of 5-hydroxyindole-based histamine 3 receptor
inverse agonists as a potential treatment for obesity. A 3-
oxetanyl unit was assessed during modiﬁcation of the basic
piperidine side chain (249, Figure 24a). The oxetane led to the
largest reduction in basicity with a pKa of 6.4, compared with
9.7 for isopropyl, 9.1 for cyclobutyl, and 7.7 for cyclopropyl.
The oxetane-containing example retained potent hH3R binding
(Ki = 23 nM), although it suﬀered from poor microsomal
clearance.
Samuelsson and co-workers385 described a series of HIV-1
protease inhibitors with a number of diﬀerent substituents
containing hydrogen-bond acceptors. The isopropyl group
from the L-Val methyl side chain, reported previously,386 was
replaced with a 3-oxetane (250), an ethoxymethyl, and a 1-
methyl-substituted ethoxymethyl in order to “extend” a H-bond
acceptor from the original position of the isopropyl (Figure
24b). This was designed to promote a positive interaction with
the nitrogen of the Asp-30 residue of the HIV-1 protease
backbone. Although the oxetane increased the tPSA and led to
a signiﬁcant lowering of logP, there was a considerable loss of
potency compared to the original isopropyl group. The
structural rigidity of the oxetane was proposed to be the
cause of the loss in potency, forcing the oxygen atom to point
away from the N−H of Asp-30 residue.
Heﬀron et al.387 at Genentech undertook an in silico design
approach in the development of inhibitors of phosphatidylino-
sitol 3-kinase (PI3K), a target for potential cancer treatment, in
particular, glioblastoma multiforme (GBM) brain tumors.
Previous PI3K inhibitors discovered by Genentech suﬀered
from poor penetration of the blood−brain barrier (BBB) due to
high eﬄux. In order to improve the physicochemical properties
of these inhibitors to increase BBB penetration, a central
nervous system multiparameter optimization (CNS MPO) was
utilized. In silico correlation of the CNS MPO score with
desirable eﬄux ratios, and subsequently with the probability of
metabolic stability, resulted in a very narrow range of
physicochemical properties. Thus, a small number of molecules
were selected for synthesis, including a number of oxetane-
containing examples. One of the two key candidates discovered,
a 3-methoxy-substituted oxetane (251, Figure 24c), was
subjected to testing in mice; it successfully inhibited tumor
growth beyond the BBB and was taken forward for further
study toward clinical application.
Lewcock, Siu, and co-workers388 have recently developed a
series of inhibitors of dual leucine zipper kinase (DLK,
MAP3K12), prominent in the regulation of neuronal
degradation. Following the discovery of an initial hit through
high-throughput screening, optimization led to oxetane 252 as
a potent and selective DLK inhibitor (Figure 24d). A key aspect
of the optimization was to reduce the lipophilicity and basicity
of the analogues. An oxetane was successfully used to reduce
the basicity of a key piperidine to limit eﬄux, important for a
brain penetrant, while maintaining good metabolic stability.
The bioactivity of this compound was shown in a number of
animal models of neurodegenerative diseases.
5.4. Survey of Oxetanes in Drug Discovery Patents
The use of oxetanes disclosed in the patent literature has
increased dramatically in the last 5 years. In this section, we
examine the synthesis of oxetane-containing compounds that
appeared in international or U.S. patents for use in medicinal
chemistry or drug discovery programs. Here, oxetane-
containing molecules from these patents are collated to include
structure, source of the oxetane building block used, and
bioactivity including any available data, along with the patent
Figure 22. Oxetane-containing indazole CCR4 antagonists.
Figure 23. 4-Azaxanthene BACE1 inhibitors containing a pendent
oxetane.
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number and company (Table 18). In the cases where there are
multiple examples of oxetanes in a given patent, an example has
been selected, usually the most bioactive compound in the
target screen if the data were available.
One particular patent warrants further discussion. The
original patent, ﬁled by Hoﬀmann-La Roche, described the
preparation of benzothiazepines and analogues for the
treatment of respiratory syncytial viral (RSV) infection.389 In
this patent, the authors describe the synthesis of a large number
of oxetane-containing compounds, several of which are
reported to have very low IC50 values in comparison to other
non-oxetane-containing examples. This new class of RSV
inhibitors displayed EC50 values as low as 0.2 nM. Compound
255 (Scheme 101) was shown to have a less potent EC50 value
of 5 nM. Despite this, a recently disclosed patent describes the
scale-up process for the synthesis of >5 kg of this compound.390
The scale-up route begins with oxidation of [3-(bromomethyl)-
oxetan-3-yl]methanol 253 to the corresponding carboxylic acid,
followed by carbamate formation and amination to form 254. A
double amination with 2,4-dichloroquinazoline was then carried
out, ﬁrst with the primary aminooxetane fragment at the 4-
position, followed by the benzothiazepine. Deprotection of the
carbamate under acid conditions furnished 5.82 kg of 255
(Scheme 101).
6. FUNCTIONALIZATION OF INTACT OXETANE
DERIVATIVES THROUGH METALATED AND
RADICAL INTERMEDIATES
Recently a small number of examples of the functionalization of
intact oxetane rings at the 2-position have emerged, involving
deprotonation of oxetane derivatives. Capriati and co-work-
ers442 reported the synthesis of 2-substituted phenyloxetanes by
formation of 2-lithio-2-phenyloxetane 256, which was chemi-
cally stable at −78 °C for up to 30 min (Scheme 102a). 2-
Phenyloxetane was regioselectively deprotonated by use of
sBuLi at −78 °C in THF and then trapped with reactive
electrophiles, including alkyl halides as well as aromatic and
aliphatic aldehydes and ketones, in good to excellent yields.
Employing enantiomerically enriched 2-phenyloxetane resulted
in racemic 2-substituted 2-phenyloxetanes in both polar (THF)
and nonpolar (hexane/TMEDA) solvents, the lithiated
intermediate being conﬁgurationally unstable. Reaction of the
lithiated intermediate with cyclopropylmethyl bromide gave the
butenyl-coupled product 257, which was cited as support for a
single-electron transfer mechanism, also being the cause of
racemization (Scheme 102b).
Bull and co-workers246 reported the regioselective lithiation
of 2-tolylsulfonyl oxetane, followed by reaction with electro-
philes to generate 2-substituted 2-sulfonyl oxetanes 258
(Scheme 103). Depending on the nature of the electrophile,
nBuLi or LiHMDS could be employed as the base, in THF at
−78 °C. These reaction conditions were developed to minimize
a concurrent ortho-lithiation of the aromatic ring, directed by
the sulfone moiety, that was particularly prominent when sBuLi
was employed.
Shipman and co-workers443 reported the enantioselective
synthesis of 2-substituted oxetan-3-ones by α-lithiation and
Figure 24. (a) Oxetane modulating the basicity of H3R agonists. (b) HIV-1 protease inhibitor. (c) Brain-penetrant 3-methoxy-substituted oxetane
PI3K inhibitor. (d) Potent and selective DLK kinase inhibitor.
Scheme 101. Large-Scale Preparation of Benzothiazepine
RSV Inhibitors
Scheme 102. Formation and Reactivity of 2-Lithio-2-
phenyloxetane
Scheme 103. Functionalization of 2-Arylsulfonyl Oxetanes
via Lithation of the Oxetane Ring
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alkylation of the (S/R)-1-amino-2-methoxymethylpyrrolidine
(SAMP/RAMP) hydrazones 259 derived from oxetan-3-one444
(Table 19). Deprotonation of hydrazone 259 with tBuLi to
form the azaenolate, followed by electrophilic trapping,
accessed 2-alkylated oxetanes 260 in good yields and
diastereoselectivities. By use of ozone or oxalic acid, the
alkylated hydrazones 260 were converted to the corresponding
enantioenriched oxetan-3-ones 261 with ee values of up to
84%. Synthesis of a 2,2-disubstituted oxetan-3-one was achieved
in 90% ee by a one-pot sequential metalation/alkylation
protocol. Furthermore, 2,4-disubstituted examples could be
accessed by thermal isomerization of the hydrazone conﬁg-
uration. Notably, there are no examples of the direct
deprotonation of oxetane itself to form 2-metalated oxetane.
Oxetanes have recently been shown to be powerful directing
groups for ortho-lithiation on aromatic rings. Capriati and co-
workers445 ﬁrst developed this feature of the oxetane ring in
2012, using 2-methyl-2-phenyloxetane 262, without a benzylic
proton, for regioselective synthesis of functionalized 2-
aryloxetanes (Scheme 104). Treatment of oxetane 262 with
Table 18. continued
aSee refs 391, 392, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419,
420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, and 441.
Table 19. Enantioselective Synthesis of 2-Substituted
Oxetan-3-ones
entry electrophile (RX) yield 260 (%) yield 261 (%) ee (%)
1 BnBr 73 79 74
2 BrCH2CHCHPh 57 77 84
3 CH3(CH2)7I 60 85 83
4 ICH2CH2CH2OTBS 68 60 84
5 PhCHO 62 92a 54, 2b
a1:1 dr. b(S,R) = 54; (S,S) = 2.
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sBuLi in Et2O resulted in lithiation of the ortho position of the
aryl ring, which was reacted with a variety of electrophiles
including aldehydes, ketones, Me3SiCl, and Bu3SnCl in good
yields. Alternatively, biaryl compounds could be accessed in one
pot with a Li−B exchange followed by Suzuki cross-coupling
with aryl and heteroaryl bromides. The oxetane substituent was
shown to be as powerful a directing group as the
dimethylaminomethyl group but not as eﬀective as a sulfonyl
group.445 This allowed functional groups known to be weak
directing groups to be present on the aromatic ring without
aﬀecting the regioselectivity of the metalation.
Rouquet et al.446 reported the regioselective ortho-function-
alization of 3-oxetanylpyridines. Treating 3-(2-methyloxetan-2-
yl)pyridine 263 with 1.4 equiv of nBuLi in the presence of
TMEDA at −78 °C in Et2O resulted in lithation at the pyridine
C4 position (Scheme 105). A wide range of electrophiles was
employed to generate the 4-functionalized pyridines, including,
for example, diphenyl disulﬁde. The reaction was carried out on
a gram scale, with methyl tert-butyl ether as the solvent and I2
as the electrophile, to aﬀord the 4-iodopyridine derivative in
67%.
There have been two recent reports of radical functionaliza-
tion at the 2-position of oxetane itself, maintaining the ring
intact.447−449 Ravelli et al.447 reported the functionalization of
oxetane through C−H activation by decatungstate photo-
catalyst TBADT, [(n-Bu)4N]4[W10O32], and addition to an
electron-poor oleﬁn (Table 20). Oxetane (3 equiv relative to
the oleﬁn) was irradiated in the presence of TBADT (2 mol %)
in acetonitrile to generate the oxetane α-oxy radical. Substituted
oxetanes were generated by use of terminal oleﬁns and those
with β-substituents. Employing oleﬁns with two electron-
withdrawing substituents resulted in good yields despite the
increased steric hindrance. 3,3-Dimethyloxetane was also
successfully employed in the reaction to form 2,3,3-
trisubstituted derivatives.447
When a 2-substituted oxetane was used, in the presence of a
nonhindered oleﬁn, a mixture of 2,2- and 2,4-disubstituted
regioisomers was formed. When a bulky substituent (e.g., tBu)
was present at C2 of the oxetane, reaction at the secondary
radical was preferred (Scheme 106a). This was suggested to be
due to a decreased reaction rate allowing back-hydrogen
transfer to occur. Functionalization at the 3-position could be
achieved by employing oxetanecarbaldehyde 264 (Scheme
106b).447
Jin and MacMillan448 recently developed a visible-light-
promoted photoredox catalytic method for direct α-arylation of
dialkyl ethers with electron-deﬁcient heteroarenes. Use of a
highly tuned Ir-based photocatalyst in the presence of a
persulfate salt generated an α-oxyalkyl radical, which underwent
Minisci-type coupling with heteroarenes in excellent yields
(Scheme 107a). The scope of the dialkyl ether component
included a number of THFs, 1,4-dioxane, and 1,3-dioxolane as
well as acyclic dialkyl ethers, which were all coupled with
isoquinoline (77−93% yields). Most signiﬁcant, however, was
the use of oxetane as a substrate. Under the standard reaction
conditions, an oxetanyl radical was generated; however, it
underwent a ring-opening polymerization reaction. Modiﬁca-
tion of the reaction conditions by using MeCN as the sole
solvent under more dilute conditions (0.05 vs 0.1 M), along
with addition of (nBu)4NCl to solubilize the persulfate anion,
Scheme 104. Exploiting Ortho-Directing Ability of the
Oxetane Ring To Access Functionalized 2-Aryloxetanes
Scheme 105. Ortho-Metalation on Pyridine Directed by an
Oxetane
Table 20. Photocatalytic Synthesis of Oxetane Derivatives
Scheme 106. Regioselectivity of Alkylation of Oxetane by
Use of Decatungstate Photocatalyst
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led to successful coupling of oxetane and isoquinoline, albeit in
a yield of 42% (Scheme 107b).
7. SYNTHESIS AND REACTIVITY OF
2-METHYLENEOXETANES
7.1. Synthesis of 2-Methyleneoxetanes
2-Methyleneoxetanes, oxetanes that bear an exocyclic CC
double bond at the 2-position, have been known since the late
1960s. The ﬁrst examples of 2-methyleneoxetanes were
synthesized by the Paterno−̀Büchi reaction. In 1966, Arnold
and Glick450 showed that excited-state carbonyl derivatives
could be added to allenes under a high-pressure mercury arc
lamp. Low yields were obtained and the major product of these
reactions tended to be the bis-spirocyclic oxetanes (1,6-
dioxaspiro[3.3]heptanes). Around the same time, Hammond
and co-workers451,452 extended the Paterno−̀Büchi reaction
with allenes and carbonyl compounds to include xanthone and
benzaldehyde (Scheme 108a). The yields of the product
oxetanes were higher, presumably due to the oxetane
derivatives being more stable, but bis-spirocyclic oxetanes
were also isolated. The use of ﬂuorenone also aﬀorded 2-
methyleneoxetane 265; however, this was always isolated with
the isomeric ketone 266 formed as a result of a rearrangement
aided by the similar excitation energy of ﬂuorenone and 2-
methyleneoxetane 265 (Scheme 108b).451,452
In the 1970s, Hudrlik et al.453,454 prepared the parent 2-
methyleneoxetane 270 through a retro-Diels−Alder reaction
(Scheme 109). A lengthy synthesis commenced with a Diels−
Alder reaction between anthracene and α-acetoxyacrylonitrile
to aﬀord 267, followed by several transformations to aﬀord diol
268. The primary alcohol was activated with MsCl and the
crude reaction material was cyclized under Williamson
etheriﬁcation conditions (KOtBu/tBuOH), aﬀording spirocy-
clic oxetane 269. Pyrolysis of oxetane−anthracene adduct by
heating at 330−350 °C gave a mixture of products including 2-
methyleneoxetane 270 (10%) along with other products (271−
274) and remaining starting material.454
Hudrlik and Mohtady455 also demonstrated that 2-methyl-
eneoxetanes could be synthesized through intramolecular O-
alkylation of enolates (Scheme 110). Treatment of ketone 275
with KH aﬀorded 2-benzylideneoxetane 276 through O-
alkylation, along with cyclobutanone 277 from C-alkylation.
Each of the compounds in this synthetic route was taken
through crude, so the yields for ﬁnal products are estimated.
The gem-dimethyl group was essential to facilitate cyclization.
With no further investigations reported for over 20 years, in
1996 Dollinger and Howell456 reported a new approach to 2-
methyleneoxetanes through methylenation of β-lactones
(Scheme 111). Good yields were achieved with the Petasis
Scheme 107. Direct α-Arylation of Ethers by Photoredox
Catalysis−Minisci Reaction Sequence
Scheme 108. 2-Methyleneoxetanes from Xanthone,
Benzaldehyde, and Fluorenone
Scheme 109. First Synthesis of 2-Methyleneoxetane 270
Scheme 110. Synthesis of 2-Methyleneoxetanes via
Intramolecular O-Alkylation of Enolates
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reagent to generate varied substituted methyleneoxetanes,
whereas with the more Lewis acidic Tebbe reagent the product
could not be isolated. Howell has used this method extensively
for preparation of 2-methyleneoxetanes and in numerous
studies on their reactivity (see section 7.2).
A 2-methyleneoxetane analogue of Orlistat (278), a
pancreatic lipase inhibitor, was prepared in 20% yield by use
of the Petasis reagent to react at the β-lactone (Scheme
112).457−459 This analogue was then directly compared against
Orlistat in an assay against porcine pancreatic lipase (PPL) with
tributyrin as the substrate.459,460 Comparative IC50 values
showed that analogue 278 displayed activity against PPL, albeit
lower than Orlistat (IC50 = 1.7 mg·mL
−1 vs IC50 = 0.4 mg·
mL−1), and preliminary kinetic studies suggested irreversible
inhibition. Despite the lower activity of the methyleneoxetane
analogue, this was a signiﬁcant result, as the carbonyl group of
Orlistat was believed to be integral to both interaction and
reaction with pancreatic lipase.
In an alternative approach, Fang and Li461 reported the
synthesis of 2-methyleneoxetanes by Cu-catalyzed intra-
molecular O-vinylation. γ-Bromohomoallylic alcohols such as
279 were prepared through a Sn-mediated Barbier reaction.
When 1,10-phenanthroline ligands were used with CuI for the
Ullmann cyclization, good yields of the desired 2-methyleneox-
etane 280 were observed (Scheme 113). Only alkyne 281 was
observed in the absence of a ligand, formed by direct
elimination of HBr.
Primary, secondary, and tertiary alcohols were all good
substrates under these cyclization conditions (Scheme 114),
with the order of reactivity of secondary alcohols being aliphatic
> allylic > benzylic. The conﬁguration of a substituted CC
double bond was retained in the cyclization, but the presence of
the additional substituent required higher temperatures. γ-
Chlorohomoallylic alcohol analogues were unreactive under the
reaction conditions. The reaction was successful for other ring
sizes, and interestingly, competition experiments established
that the 4-exo ring closure was preferred over ring closure to
form ﬁve- or six-membered rings. This was proposed to be due
to precoordination of the Cu catalyst to the alkoxide prior to
oxidative addition, leading to the formation of a favorable ﬁve-
membered ring structure containing Cu, following oxidative
addition. Interestingly, the equivalent Pd-catalyzed reactions
favor the 5-exo-ring closure.461
In 2011, Saunders and Miller462 showed that formal
cycloadditions of allenoates and 2,2,2-triﬂuoroacetophenones
could be achieved to form either dihydrofurans or 2-
alkylideneoxetanes when Lewis basic catalysts were used.
While phosphines catalyzed the [3+2] cycloaddition to give
the dihydrofurans, 1,4-diazobicyclo[2.2.2]octane (DABCO)
catalyzed the formal [2+2] cycloaddition to form 2-
alkylideneoxetanes 282 (Scheme 115).
Scheme 111. Synthesis of 2-Methyleneoxetanes via
Methylenation of β-Lactones
Scheme 112. Synthesis of 2-Methyleneoxetane Analogue of
Orlistat
Scheme 113. Synthesis of 2-Methyleneoxetanes through Cu-
Catalyzed O-Vinylation
Scheme 114. Sample Scope of Cu-Catalyzed Intramolecular
Ullman Coupling
Scheme 115. Synthesis of 4-Triﬂuoromethyl-2-
methyleneoxetanes via Lewis Base-Catalyzed Formal [2+2]
Cycloaddition
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The reaction was successful with various aryl substituents: 4-
halo-substituted aromatics were well tolerated, but low yields
were obtained with electron-rich aryl substituents. Ketones that
did not possess a triﬂuoromethyl group were unreactive.
Substitution at the γ-position of the allenic esters was also
viable, with oxetane 283 formed in 51% yield (2.9:1 dr). The
proposed mechanism involved addition of DABCO to the
allenoate, followed by γ-addition to the ketone (Scheme 116).
The subsequent oxyanion could undergo conjugate addition
onto the β-carbon, re-forming the enolate, which then
eliminated DABCO. Though the reaction progressed when
catalytic amounts of DABCO were used, the optimized
conditions used stoichiometric amounts to obtain higher yields.
At around the same time, Ye and co-workers463 reported a
similar reaction that used catalytic quantities of DABCO (20
mol %) in THF at 0 °C to form 2-alkylideneoxetanes 284
(Table 21). Again, electron-rich ketones gave lower yields, and
some sterically bulky ester groups (Cy and t-Bu) were tolerated
on the allenoate.
In 2012, an asymmetric version of this Lewis base-catalyzed
formal [2+2] cycloaddition was reported (Scheme 117).464 The
optimized conditions used 20 mol % β-isocupreidine 285 as
catalyst and 10 equiv of water as an additive in THF at −15 °C
for 6 days. High yields and good to excellent ee were obtained
with a variety of substrates including both electron-rich and
electron-deﬁcient aromatics. As well as triﬂuoromethylaryl
ketones, the reaction worked similarly with a pentaﬂuoroethyl
ketone (286) and with a pentyltriﬂuoromethyl ketone (287).
The proposed role of water was to stabilize the transition state
for γ-addition of the extended enolate to the ketone through
formation of a six-membered hydrogen-bonded ring with the
hydroxy group of the catalyst.
A formal [2+2] cycloaddition was developed by Selig et al.465
to form more substituted 2-alkylideneoxetanes through the
incorporation of additional substituents on the allenoate. By use
of 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), a highly active
nitrogen Lewis base,466 for allenoate activation, a variety of γ-
substituted allenoates were transformed into highly substituted
2-alkylideneoxetanes (Scheme 118). All four possible isomers
were formed during the reaction, but increasing the steric bulk
of the γ-substituent led to increased formation of the Z isomer.
Electron-rich ketone substrates gave higher yields than
electron-deﬁcient ketones, due to the electron-deﬁcient ketones
undergoing addition reactions with TBD itself, poisoning the
catalyst. An α,γ-disubstituted allenoate was also a viable
substrate, forming a highly substituted oxetane in good yield
and diastereoselectivity with a slightly higher catalyst loading
(30 mol %) and a longer reaction time (288).
7.2. Reactivity of 2-Methyleneoxetanes
The reactivity of 2-methyleneoxetanes can be separated into
two types: (i) ring opening of the oxetane and (ii)
functionalization of the CC double bond. Ring-opening
reactions include conversion to homopropargylic alcohols
through elimination,467 nucleophilic attack with carbon or
heteroatom nucleophiles at C4 to generate ketones,468,469 and
reductive ring opening of 4-aryl derivatives by use of Li/4,4′-di-
tert-butylbiphenyl (DTBB) to generate ketones.470,471 Certain
2-methyleneoxetanes have also been reported to undergo a
conversion to α,β-unsaturated methyl ketones at high temper-
atures (Scheme 119).472 The incorporation of a silyl group at
the 3-position of the ring in 289 enhanced the reaction, which
was proposed to occur by alkene isomerization through oxetene
291, followed by a 4π-electron electrocyclic ring opening to
give ketone 290.
The ﬁrst example of functionalization of the exocyclic CC
double bond of a 2-methyleneoxetane, such as 292, was
reported in 1998 through epoxidation to form 1,5-
dioxaspiro[3.2]hexanes (e.g., 293, Scheme 120).393 By use of
anhydrous, acetone-free dimethyldioxirane (DMDO) to
Scheme 116. Proposed Mechanism for Lewis Base-Catalyzed
Formal [2+2] Cycloaddition of Allenoates and 2,2,2-
Triﬂuoroacetophenones
Table 21. Selected Examples of 2-Alkylideneoxetanes
Synthesized by Use of Catalytic Amounts of DABCO
entry R Ar yield (%)
1 Et 3-MeC6H4 73
2 Et 2-thienyl 47
3 Cy Ph 79
4 tBu Ph 60
Scheme 117. Asymmetric Formal [2+2] Cycloaddition with
β-Isocupreidine 285 as Catalyst
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provide neutral conditions,473 quantitative yields of the
sensitive spirocycles were obtained from a variety of substituted
2-methyleneoxetane derivatives. Moderate diastereoselectivity
was observed with one substituent at the C3 position, but an
additional substituent at C3 or any substitution at the C4
position lowered the dr.
The internal acetal of these spirocycles, such as 294,
underwent hydrolysis in the absence of acid to aﬀord ketones
such as 295 in very high yields (Scheme 121a).393 This
reactivity was then reported for a variety of nucleophiles:
oxygen nucleophiles gave good yields of hydroxy ketones,
thiophenol was slow to react but the sodium thiolate gave a
good yield, imidazole gave low yields, and ring opening
followed by reduction to a 1,3-diol occurred with LiAlH4
(Scheme 121b).474 Unexpectedly, the use of DIBAL gave
nucleophilic attack at the internal position of the epoxide to
leave the oxetane ring intact (296). Coordination of the Lewis
acid to the epoxide oxygen was proposed with participation of
an oxetane oxonium ion. Ring opening of the epoxide, leaving
the oxetane ring intact, also occurred with nucleophiles such as
TMSN3 (297) and AlMe3 (298).
A detailed study of heteroaromatic nucleophiles was
undertaken with the epoxide of 3-phenyl-2-methyleneoxetane
293 which related pKa of the nucleophile to the reaction
product.475 Both imidazole and TMS-imidazole gave oxetane
ring opening, pyrrole and indole did not react, and 1,2,4-
triazole and its TMS-linked analogue also caused oxetane ring
opening. However, 1,2,3-triazole gave the 2,2-disubstituted
oxetane, as did benzotriazole, TMS-benzotriazole, and tetrazole.
This study concluded that more acidic nucleophiles formed the
2,2-disubstituted oxetanes, potentially due to activation of the
Scheme 118. Use of TBD as Lewis Base Catalyst for Synthesis of Highly Substituted 2-Alkylideneoxetanes
Scheme 119. Tandem Alkene Isomerization/Electrocyclic
Ring Opening of 2-Methyleneoxetanes
Scheme 120. Epoxidation of 2-Methyleneoxetanes: Synthesis
of 1,5-Dioxaspiro[3.2]hexanes
Scheme 121. Nucleophilic Ring Opening of 1,5-
Dioxaspiro[3.2]hexanes
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epoxide so that intramolecular oxonium formation could occur
more easily. Howell and co-workers475 therefore investigated
other Lewis acids, and the addition of Mg(OTf)2 with 1,2,4-
triazole, which originally gave oxetane ring opening (299), gave
2,2-disubstituted oxetane formation (300, Scheme 122).
The tandem ring opening of 1,5-dioxaspiro[3.2]hexanes was
utilized in synthesis of the challenging sphingoid base of
glycosphingolipids.476 1,5-Dioxaspiro[3.2]hexane 301 was
prepared in three steps from N-Boc-protected L-serine (Scheme
123). Addition of a higher-order cuprate led to formation of
ketone 302 through nucleophilic attack at the least hindered
epoxide carbon, which was converted to D-erythro-dihydros-
phingosine 303 in two steps. 1,5-Dioxaspiro[3.2]hexane 301
also underwent facile epoxide ring opening with acetic acid, and
subsequent functionalization converted ketone 304 to D-xylo-
phytosphingosine 305 in six steps. A similar strategy was used
in the synthesis of epi-oxetin, involving a DIBAL opening of
epoxide 306 (Scheme 124).477
In 2012, ring opening of spirocyclic epoxide 307 was used to
generate hydroxymethyloxetane 308 as a possible intermediate
in the synthesis of Laureatin.478 However, treatment of
derivative 309 with NBS instead mediated a rearrangement,
forming epoxytetrahydrofuran 310 in a 51% yield (Scheme
125).
Howell and co-workers479 also examined the reactivity of the
enol ether of 2-methyleneoxetanes with haloelectrophiles,
intending to trap the intermediate oxonium ion. Treatment
of oxetane 311 with KOtBu, followed by the addition of I2, gave
the ﬁrst example of a [2.2.0] fused ketal, 312, in 40% yield
(Scheme 126).
A similar strategy was used to access oxetane-containing
psico-nucleosides, that is, with a hydroxymethyl group adjacent
to the base, related to the natural product oxetanocin A. This
was achieved through electrophilic addition of F+ followed by
nucleophilic attack of the nucleobase (Scheme 127).480 From 2-
methyleneoxetane 313, selectﬂuor gave a good yield for
nucleobase incorporation, but both N7 (314) and competing
N9 alkylation (315) occurred. After multiple puriﬁcations, 314
was obtained as a 37:63 mixture (α:β epimers, 42% yield) and
315 as a 23:77 mixture (α:β epimers, 34% yield), with both
favoring the desired β-isomers. Oxetane-containing psico-
nucleosides 316 and 317 were then prepared through a
substitution reaction with ammonia, followed by deprotection
of the silyl ethers.480
Cyclopropanation of the exocyclic CC double bond of 2-
methyleneoxetanes was achieved to form 4-oxaspiro[2.3]-
hexanes (Scheme 128).481 Using ZnEt2 and CH2CI2 in the
modiﬁcation by Furukawa et al.482 of the Simmons−Smith
reaction gave a good yield of spirocyclic cyclopropanes,
providing the reaction temperature was not raised above
0 °C, across a variety of substituted oxetanes. Bekolo and
Howell481 showed that 4-oxaspiro[2.3]hexanes underwent
rearrangement when treated with BF3·OEt2 (Scheme 129).
For example, treatment of oxetanes 318−320 with BF3·Et2O
led to three diﬀerent products being formed: cyclobutanone
321, THF 322, and cyclopentanone 323. The reaction was
proposed to proceed via ring opening to form carbocationic
intermediates, which could rearrange through cyclopropane
Scheme 122. Synthesis of 2,2-Disubstituted Oxetane 300 by
Use of Mg(OTf)2 and 1,2,4-Triazole
Scheme 123. Synthesis of D-erythro-Dihydrosphingosine and
D-xylo-Phytosphingosine by Tandem Ring Opening of 1,5-
Dioxaspiro[3.2]hexane
Scheme 124. Synthesis of epi-Oxetin through DIBAL
Opening of 1,5-Dioxaspiro[3.2]hexanea
aBlauvelt and Howell.477
Scheme 125. Unexpected Rearrangement of Oxetane 309
Aﬀording Epoxytetrahydrofuran
Scheme 126. Synthesis of [2.2.0]-Fused Ketal
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opening and hydride shifts, with the pathway inﬂuenced by the
substitution on the oxetane ring.
Oxaspirohexanes that were synthesized from 2-methyleneox-
etanes also underwent rearrangement catalyzed by Zeise’s
Pt(II) dimer.483 Monosubstituted as well as 5,6-trans-
disubstituted oxaspirohexanes rearranged in good yields via a
platinacyclobutane intermediate (Scheme 130). 5,6-cis-disub-
stituted oxaspirohexanes ring-opened to aﬀord allyl chlorides as
the major product.
8. RING-OPENING AND RING-EXPANSION
REACTIONS OF OXETANES
In an apparent contradication with the stability required of the
oxetane ring in many medicinal chemistry applications, the
strain present in the ring (106 kJ·mol−1) renders oxetanes
useful synthetic intermediates.31,32 This section considers
reactions that result in ring opening of oxetanes, through
attack at the 2-position releasing the ring strain, and also ring-
expansion reactions that form larger heterocyclic systems. Here,
ring expansion is deﬁned as when the oxygen atom from the
oxetane ring remains in the new ring structure formed in the
relevant reaction; ring opening is the term used when the
oxetane O-atom is not in the new ring, even if a ring is formed.
Readers are also directed to recent reviews by Malapit and
Howell,7 on aspects of using oxetanes in the preparation of
other heterocycles, and by Sun and co-workers,8 on
enantioselective oxetane ring-opening desymmetrization reac-
tions. Ring-opening reactions of oxetanones are not covered
speciﬁcally,5 and for ring-opening reactions of 2-methyleneox-
etanes, see section 7.
8.1. Ring-Opening Reactions of Oxetanes
Under acidic conditions, the oxetane ring can be opened with
simple nucleophiles, including hydrolysis to give 1,3-
glycols.484,485 Various nucleophiles have been employed,
including amines,486−489 KPPh2,
490 lithiated alkynes,491−493
TMSCN,494,495 allyl silanes,496 LiAlH4,
497 and azaenolates.498
Lithium enolates have been used to open mono- or
disubstituted oxetanes in the presence of BF3·OEt2.
499 Gassman
and Haberman495 reported the treatment of 2-substituted and
2,2-disubstituted oxetanes with TMSCN in the presence of zinc
iodide to aﬀord γ-hydroxyisonitriles 324 in yields of 73−94%,
by ring opening at the more substituted position (Scheme 131).
The isonitriles were converted into the corresponding γ-amino
alcohols 325 in 65−81%, following deprotection and
hydrolysis.
Organometallic reagents alone can open oxetane at higher
temperatures. In 1916, oxetane was treated with n-propylmag-
nesium bromide under reﬂux in ether/benzene, which resulted
in the formation of n-hexanol in 49% yield.500 This prompted
Scheme 127. Synthesis of Oxetane-Containing psico-
Nucleosides
Scheme 128. Cyclopropanation of 2-Methyleneoxetanes To
Form 2-Oxaspiro[2.3]hexanes
Scheme 129. Rearrangement of 4-Oxaspirohexanes
Catalyzed by BF3·Et2O
Scheme 130. Rearrangement of Oxaspirohexanes to 3-
Methylenetetrahydrofurans via Platinacyclobutane
Intermediate
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the seminal work by Searles501 on reaction of oxetane with
organometallic compounds. Oxetane, with a variety of aromatic
and aliphatic organometallic reagents, such as PhMgBr,
BnMgCl, and PhLi, was heated under reﬂux in benzene for 4
h to aﬀord the corresponding open-chain alcohols in moderate
to good yields (Table 22). It is notable that ring opening
occurred, whereas in the more strained epoxide, these
organometallic reagents would be likely to result in
deprotonation on the ring.502,503
Huynh et al.504 reported milder, room-temperature reaction
conditions for the opening of oxetane by Grignard reagents in
the presence of CuI (10 mol %) for 20 h. Grignard reagents,
including nBuMgCl, PhMgBr, and allyl-MgBr, successfully
reacted with oxetane with yields of 50−75%. High-temperature
reactions have also been reported.505
In 2008, Pineschi and co-workers506 developed a regiose-
lective ring opening of 2-aryloxetanes with aryl borates under
mild, neutral conditions. The use of enantiomerically pure 2-
phenyloxetane led to the formation of enantioenriched β-
aryloxy alcohols such as 327 or 328 with little reduction in ee.
This was proposed to occur via intramolecular delivery of the
aryloxy group in a six-membered transition state (329, Scheme
132), resulting in retention of conﬁguration at the reacting
center. When electron-rich aryl borates were used, the C-
alkylation product dominated, formed via a Friedel−Crafts
process, in low ee (326). A range of aryl borates could be used,
including a number of ortho-halo-substituted examples and a
catechol borate, in yields up to 86% and up to 86% ee (e.g.,
328, Scheme 132).
In 2002, Dussault et al.113 reported the regioselective Lewis
acid-catalyzed ring opening of oxetanes to aﬀord enantiomeri-
cally enriched 1,3-hydroperoxy alcohols and 1,3-peroxy alcohols
which could be converted into enantiomerically enriched 1,2,4-
trioxepanes. Enantioenriched oxetanes were treated with
ethereal H2O2 in the presence of Lewis acids to form
hydroperoxy alcohols. No reaction was observed when
MgCl2, ZnCl2, or BF3·OEt2 was employed, and the use of
TFA, CSA, BF3·OEt2, or H2SO4 resulted in signiﬁcant amounts
of 1,3-diol being formed. However, treating the oxetanes with
ethereal H2O2 in the presence of TMSOTf, Yb(OTf)3, or
Sc(OTf)3 resulted in the desired products 330 being formed in
good yields (Table 23). The reaction was extended to tertiary
oxetanes with alkyl hydroperoxides, such as t-BuOOH, cumyl-
OOH, and THP-OOH, to produce 3-peroxy alkanols in yields
of 39−51%.
Dai and Dussault507 reported the corresponding intra-
molecular reaction in 2005. Oxetanes 331 were treated with
O3 in methanol to give intermediate 332, which underwent a 5-
exo cyclization to aﬀord 1,2-dioxolanes 333 as a 1:1 mixture of
cis and trans isomers (Table 24). Interestingly, cyclization onto
a monosubstituted oxetane gave the desired product despite the
corresponding intermolecular reaction being unsuccessful. Alkyl
hydroperoxides were also generated by cobalt-mediated
reductive dioxygenation, such as from 334, which aﬀorded
triethylsilyl peroxide 335 in 80% yield (Scheme 133).
Scheme 131. Ring Opening of Oxetanes by Attack of an
Isonitrile Nucleophile
Table 22. Ring Opening of Oxetane with Organometallic
Reagents
entry Grignard reagent yield (%)
1 PhMgBr 84
2 CyMgBr 28
3 1-naphthyl-MgBr 80
4 i-PrMgCl 28
5 BnMgCl 83
6 PhLi 85
7 n-BuLi 28
Scheme 132. Ring Opening of 2-Aryloxetanes with Aryl Borates
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Deprotection with HF followed by 5-exo cyclization aﬀorded
1,2-dioxolane 336.507
Han and Wu508 reported the perhydrolysis of tertiary and
secondary oxetanes in the presence of a molybdenum species,
Na2MoO4-Gly, in H2O2/t-BuOMe. In addition to the desired
product 337, alcohol 338 (often not isolated) and elimination
product 339 were formed (Table 25). Diﬀerent diaster-
eoisomers showed diﬀerences in the stereoselectivity of the
reaction (Table 25, entries 3 and 4). Secondary oxetanes were
less reactive than tertiary oxetanes under the reaction
conditions; therefore a more acidic catalyst, PMA (phospho-
molybdic acid), was required.508
In 2014, Okamoto and co-workers509 reported the ring
opening of 2-substituted oxetanes by Fe-catalyzed reductive
magnesiation at the 2-position to aﬀord substituted 3-
oxidopropylmagnesium compounds such as 340 in excellent
yields. 2-Phenyloxetane was treated with a Grignard reagent in
THF in the presence of FeCl3 to form the ring-opened product
341 in 54% yield after workup, and this yield was increased to
99% by addition of a phosphine ligand (Scheme 134). Ring
opening occurred in high yields under modiﬁed conditions
when 2-alkyl, 2,2-diphenyloxetane, and 2,2-phenylmethylox-
etane substrates were used, but no reaction occurred when a
3,3-disubstituted oxetane was investigated.
The 3-oxidopropylmagnesium intermediates 342 were also
successfully quenched with electrophiles (Table 26). Okamoto
and co-workers509 proposed that the reaction proceeded via a
radical mechanism, involving a low-valent Fe species. This
proposal was supported by the loss of stereochemical
information when diastereomeric pairs of oxetanes were used.
In 2013, Okamoto and co-workers510 reported the reductive
ring-opening reaction of oxetanes catalyzed by a low-valent
titanium species, formed from a titanatrane complex (Scheme
135). Complex 344 was treated with Me3SiCl and Mg powder
to form a low-valent titanium alkoxide that, in the presence of
1,4-cyclohexadiene, reduced oxetanes to alcohols in good
yields. 3,3-Disubstituted oxetanes, 2-monoaryl and 2-monoalkyl
oxetanes, 2,2-disubstituted oxetanes, and spiro compounds
were all successfully reduced to the corresponding alcohols
(Table 27). Okamoto and co-workers510 proposed that the
oxetane coordinated to an intermediate Ti complex and then
underwent a single-electron transfer to generate a titanoxy
radical. This resulting radical could then abstract hydrogen
from 1,4-cyclohexadiene. The stability of this radical
intermediate aﬀected the regioselectivity of the reaction,
generally resulting in formation of the less-substituted alcohols
as the major products.
Murakami and co-workers,511 in 2013, showed that cyclo-
butanols underwent ring opening and addition to isocyanates
with a Rh catalyst. Conventionally, carbamates would be
formed when cyclobutanols are reacted with isocyanates, but
th i s combina t ion o f Rh ca ta l y s t and 1 ,1 ′ -b i s -
(diphenylphosphino)ferrocene (DPPF) ligand directed iso-
cyanate addition through the C-atom, generating amide
Table 23. Opening of Substituted Oxetanes with Hydrogen Peroxide To Access Hydroperoxy Alcohols
Table 24. Intramolecular Opening of Substituted Oxetanes
entry R R1 R2 yield (%)
1 Me Me H 57
2 C6H13 Me H 73
3 C6H13 H H 77
4 C6H13 Me Me 72
Scheme 133. Intramolecular Opening of Substituted Oxetanes with Alkyl Hydroperoxides
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derivatives. As part of the substrate scope, it was shown that
oxetanols were compatible with this Rh-catalyzed C-carbamoy-
lation (Scheme 136). The Rh-catalyzed C-carbamoylation of
oxetanols occurred in very good yields, and the stereochemical
integrity of an enantioenriched oxetanol (>98% ee; >20:1 dr)
was retained in ring-opened amide (>98% ee).
8.1.1. Intramolecular Ring Opening. The use of
intramolecular nucleophiles can be eﬀective in generating new
ring systems. In the total synthesis of (±)-gelsemine,
Danishefsky and co-workers512,513 utilized a Lewis acid-
mediated intramolecular oxetane ring-opening strategy with a
nitrogen nucleophile (Scheme 137).
In 1996, Bach and Kather514 reported intramolecular ring-
opening reactions of oxetanes 345 to give diastereomerically
pure sulfur, nitrogen, and oxygen heterocycles 346 (Table 28).
A Paterno−̀Büchi reaction of silyl enol ethers followed by a
Mitsunobu reaction generated oxygen-, sulfur-, or nitrogen-
containing precursors.514,515 Cyclization to six- and seven-
membered heterocycles was achieved by treatment with
organometallic reagents and heating. A tetrahydropyran was
synthesized in 54% yield by removing a pivaloyl protecting
group with MeLi in DME and then heating at reﬂux to promote
cyclization (Table 28, entry 1). However, the seven-membered
oxepane derivative could not be generated under the same
conditions, with only deprotection being observed (entry 2).
Replacing dimethoxyethane (DME) with high-boiling (162 °C)
Table 25. Perhydrolysis of Oxetanes in the Presence of Molybdenum Species
Scheme 134. Fe-Catalyzed Reductive Magnesiation of 2-
Phenyloxetane
Table 26. Electrophilic Trapping of Oxidopropylmagnesium
Compounds
Scheme 135. Formation of Primary Alcohols by Ring
Opening of Oxetanes
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diglyme allowed the oxepane derivative to be synthesized in a
32% yield as a mixture of diastereomers.515 Thiotetrahydropyr-
an and thiooxepane derivatives could be delivered as single
diastereoisomers by use of MeLi and MeMgBr, respectively
(entries 3 and 4). Similarly, use of MeMgBr yielded the
piperidine derivative in a synthetically useful 52% yield (entry
5). The Mg cation was thought to coordinate to the oxetane
oxygen, encouraging nucleophilic substitution.
Similarly, oxetane 347, prepared in three steps from 2-
hydroxyacetophenone by Paterno−̀Büchi reaction, could be
cyclized by use of MeLi to give a mixture of dihydrobenzofuran
derivatives 348 and 349, with the diol as the major product and
the monosilylated derivative as the minor product (Scheme
138).514,515 Treatment with MeMgBr gave the benzofuran
derivative 350, where the silyl ether was eliminated.
Grainger and co-workers516 examined the ring opening of
oxetanes to yield dihydrobenzofurans. A Paterno ̀−Büchi
reaction formed the oxetane moiety, and then acid-promoted
intramolecular cyclization occurred with a proximal arylme-
thoxy group acting as the nucleophile (Scheme 139). The use
of 10 equiv of HCl gave the bis-spirocyclic hydroxy products in
yields between 34% and 78%. Acetyl chloride could also be
used as a promoter to give acetate derivatives.
In 2012, Sun and co-workers517 reported the synthesis of
eight-membered lactones via a [6 + 2] cyclization process
between oxetane-containing benzaldehydes and ynol silyl
ethers. When oxetane 351 was treated with siloxy alkynes
352 in the presence of triﬂuoromethanesulfonimide as a Lewis
acid, eight-membered lactones 353 were formed (Table 29).
Nucleophilic attack on the aldehyde moiety of oxetane 351
resulted in an intramolecular oxetane ring-opening process.
Table 27. Radical Ring Opening of Oxetanes by Treatment
with Low-Valent Titanium Complex 344
Scheme 136. Rh-Catalyzed C-Carbamoylation of Oxetanols
and Isocyanates
Scheme 137. Oxetane Ring Opening in Total Synthesis of
(±)-Gelseminea
aDanishefsky and co-workers.512,513
Table 28. Scope of Ring-Opening Reactiona
entry n X PG reagent time (h) yield (%)
1 1 O Piv MeLi 6 54
2 2 O Piv MeLi 5 0
3 1 S Ac MeLi 4 91
4 2 S Ac MeMgBr 5 54
5 1 NTs H MeMgBr 5 52
aBach and Kather.514
Scheme 138. Intramolecular Cyclization to
Dihydrobenzofuran or Benzofuran Derivatives
Scheme 139. Synthesis of Bis-Spirocycles through Paternò−
Bu ̈chi Reaction and Acid-Promoted Intramolecular
Cyclization
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Oxetanes with aryl linkers substituted with an electron-
withdrawing or electron-donating group could be employed
in the reaction. Interestingly, when the oxetane ring was
substituted by an epoxide, a similar intermolecular reaction was
not observed. Instead an intermolecular homocyclization
between the oxirane and the aldehyde moiety occurred.
Yadav et al.518 utilized an acid-catalyzed oxetane ring-opening
approach to form a key substituted tetrahydropyran (THP)
skeleton in synthesis of the C1−C17 fragment of the polyether
natural product salinomycin. By use of a model substrate, the
desired regioselective ring opening was achieved with both
Lewis and Brønsted acids with MeOH as the solvent; however,
the methyl ether product was favored over THP. Switching to
an aprotic solvent (CH2Cl2) led to selective formation of the
THP, and the use of a 15:1 ratio of CH2Cl2:iPrOH resulted in
signiﬁcantly faster reaction times with either camphorsulfonic
acid or p-toluenesulfonic acid (entry 1, Table 30). The reaction
was viable for formation of a number of more complex THPs,
particularly those with multiple substituents (entries 2 and 3).
Formation of the key THP ring for the C1−C17 fragment of
salinomycin proceeded cleanly in 92% yield (entry 4). The
C1−C11 fragment of (+)-zincophorin was formed from the
corresponding oxetane in 83% yield in a similar manner (entry
5). Subsequent protecting-group manipulation allowed access
to the desired fragment.519
In 2015, Britton and co-workers520,521 reported a total
synthesis of the marine fungus-derived natural product
ascospiroketal, targeted due to potential biological activity. An
Ag(I)-promoted oxetane ring opening was used to install the
desired tricyclic structure. A brief screen of Ag(I) salts found a
combination of AgBF4 and Ag2O gave the best yield of 82%
with complete diastereoselectivity (Scheme 140). The complete
diastereoselectivity was attributed to the ability of the pro-R
oxetane transition structure to form bidentate chelation
between the oxygen of the oxetane ring and the oxygen of
the central ring to the Ag(I) salt (Scheme 140). This
stabilization is not available to the pro-S transition structure.520
The undesired spiroketal was readily epimerized by use of
ZnCl2 and MgO.
8.1.2. Enantioselective Ring Opening. Tomioka and co-
workers522 reported the ﬁrst example of enantioselective
desymmetrization of 3-substituted oxetanes, in 1997, by
treatment with organolithium reagents. 3-Phenyloxetane was
treated with PhLi, stoichiometric BF3·OBu2, and an external
chiral tridentate ligand 354 at −78 °C to aﬀord chiral alcohol
355 in a yield of 92% and ee of 47% (Scheme 141). n-
Butyllithium and lithum phenylacetylide also successfully gave
the corresponding alcohols in good yields but with low ee
values of 27% and 15%, respectively.
Catalytic enantioselective ring opening of 3-substituted
oxetanes, by use of 2-mercaptobenzothiazoles 356 as
nucleophiles with chiral phosphoric acid catalyst 358, was
reported in 2013 by Sun and co-workers8,289 (Scheme 142).
Substituted and unsubstituted mercaptobenzothiazoles were
Table 29. Intramolecular Ring Opening of Oxetane
Resulting in Formation of Eight-Membered Lactones
Table 30. Acid-Catalyzed Tetrahydropyran Formation by
Intramolecular Oxetane Ring Opening: Natural Product
Fragmentsa
aConditions: CSA (1 equiv), CH2Cl2/iPrOH (15:1), 0 °C to rt, 2−2.5
h. bReaction was run for 48 h. cReaction was run overnight.
Scheme 140. Oxetane Ring-Opening Step in Total Synthesis
of Ascospiroketal
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used and could generate tertiary or quaternary chiral centers in
the products 357. Low catalyst loadings of 2.5 mol % were
employed, and broadly excellent enantioselectivities of 71−99%
ee were obtained.
In 2009, Loy and Jacobsen523 reported the intramolecular
enantioselective ring opening of 3-substituted and 3,3-
disubstituted oxetanes catalyzed by Co−salen complex 359 or
360 (Scheme 143). Bimetallic catalyst 360 (n = 1) showed
enhanced reactivity compared to monomeric catalyst 359, likely
due to cooperative interaction between (salen)Co motifs.
Tetrahydrofurans were formed in high yields of 89−93% and
excellent ee values (96−99%) when oligomeric catalyst 360 was
employed (Table 31). Alkyl and phenyl substitution at the 3-
position of oxetane was tolerated under the reaction conditions,
aﬀording THFs with quaternary stereocenters. Phenolic
substrates were also tolerated; however, a higher catalyst
loading was required to attain good enantioselectivity.
Sun and co-workers8 have recently reported several examples
of intramolecular enantioselective oxetane ring opening. In
2013, the intramolecular ring opening of oxetanes to access
chiral 1,2,3,4-tetrahydroisoquinolines was described (Scheme
144).524 Reaction of aldehydes 361 with anilines in the
presence of a Hantzsch ester (364) and enantiopure chiral
phosphoric acid 363 aﬀorded tetrahydroisoquinolines 362 in
excellent yields and high enantioselectivities. This reaction was
successful with a range of electron-donating and electron-
withdrawing aryl aldehydes. With 3,3-disubstituted oxetanes,
the product with a quaternary center (365) was formed with an
excellent yield of 94% but moderate enantioselectivity (56%
ee).
By a similar principle, Sun and co-workers525 reported the
asymmetric three-component aza-Diels−Alder reaction of
indoles using a chiral phosphoric acid catalyst and an oxetane
ring as the directing group. Oxetane-tethered aldehydes 366
were combined with indoles 367 and arylamines 368 in the
presence of catalyst 363 to aﬀord a variety of polycyclic
alkaloid-like products 369 (Table 32).
Yang and Sun526 described the enantioselective synthesis of
1,4-dioxanes via intramolecular desymmetrization of oxetanes
in 2016. 3,3-Disubstituted oxetanes 370 were treated with a
chiral phosphoric acid catalyst 372 of the same type to access
chiral 1,4-dioxanes 371 bearing a quaternary stereocenter
(Table 33). Alkyl and aryl substituents were tolerated as
substituents at the 3-position of the oxetane ring; however, the
presence of a triﬂuoromethyl substituent retarded the reaction,
and an increase in temperature was required to obtain
conversion. Increased steric hindrance in close proximity to
the alcohol functional group did not aﬀect the reaction
Scheme 141. Enantioselective Ring Opening of 3-Substituted
Oxetanes with Stoichiometric Chiral Ligand
Scheme 142. Enantioselective Ring Opening of 3-Substituted Oxetanes with Mercaptobenzothiazoles
Scheme 143. Co-Catalyzed Intramolecular Ring Opening of
3-Substituted Oxetanes
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eﬃciency or enantioselectivity. When the oxygen atom in the
side chain was replaced with a carbon atom (373), other
oxaheterocycles 374 were synthesized in yields of 89−94% and
ee values of 68−91% (Scheme 145). Very recently, the same
group reported an enantioselective opening of 3-substituted
oxetanes, with chloride as a nucleophile, to generate function-
alized γ-chlorohydrins.527 Trimethoxychlorosilane was used as
the chloride source in the presence of wet molecular sieves for a
controlled release of HCl.
8.1.3. Ring Opening of Oxetan-3-one Derivatives. The
last ﬁve years has seen reports of the conversion of oxetan-3-
one to a variety of heterocycles. Carreira and co-workers528
developed a formation of isoxazoles via a base-mediated
rearrangement of 3-(nitromethylene)oxetanes. The use of
iPr2EtN in THF resulted in clean conversion to the isoxazole.
This was proposed to occur by deprotonation of the oxetane to
form a strained oxetene intermediate, which could undergo ring
opening by the nitronate anion followed by dehydration to
furnish the isoxazole-4-carboxaldehyde 375. A one-pot cascade
reaction was then successfully developed, starting with a Henry
reaction between (2-nitroethyl)benzene and oxetan-3-one
(Scheme 146). Subsequent mesylation and elimination of the
corresponding oxetan-3-ol, and then rearrangement, furnished
the 3-benzylisoxazole-4-carboxaldehyde. The scope of the
isoxazole-4-carboxaldehyde products at the 3-postion was
quite varied. The phenyl group could be replaced with
electron-rich and electron-deﬁcient aromatic and heteroaro-
matic groups, aliphatic groups, remote esters, and terminal
alkenes, as well as protected alcohols and amines. Aryl
substitution at the 3-position was also viable starting from
arylnitromethanes.
Carreira and co-workers529 generated a series of morpho-
lines, thiomorpholines, and piperazines from oxetan-3-one via
N,O-, N,S-, and N,N-acetals derived from oxetan-3-one.529 The
acetals were treated with TMSCN in the presence of catalytic
indium triﬂate to form saturated nitrogen-containing hetero-
cycles (Table 34). This involved a Strecker reaction with
TMSCN to introduce the nitrile and then activation of the
oxetane by the Lewis acid to promote intramolecular
cyclization, which proceeded in excellent yields and dr.529
Reaction of triﬂuoroborate nucleophiles with similar N,O-
acetals, promoted by BF3·OEt2, generated aminooxetanes (see
Scheme 79, section 5).352 These products were shown to
undergo ring opening to produce substituted morpholine rings.
This two-step process could also be performed in one pot; for
example, aminals 376 were converted to benzomorpholines
377 by employing an excess of BF3·OEt2 with substituted
alkynyl potassium triﬂuoroborates (Table 35).
Orr and co-workers530 reported the microwave-mediated
condensation of oxetan-3-one with primary amides or
thioamides to aﬀord (hydroxymethyl)oxazoles 378 and
(hydroxymethyl)thiazoles 379 (Table 36). A range of aromatic
substituents as well as tertiary and secondary alkyl groups were
Table 31. Scope of Enantioselective Intramolecular Ring-
Opening Reaction of 3-Substituted and 3,3-Disubstituted
Oxetanes
Scheme 144. Asymmetric Ring Opening of 3-Substituted Oxetanes by Use of Aromatic Amines and Chiral Phosphoric Acid
Catalyst
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tolerated under the reaction conditions. The mechanism was
proposed to involve ﬁrst the opening of oxetan-3-one, followed
by condensation.
8.2. Ring-Expansion Reactions of Oxetanes
There have been investigations over many years into the ring
expansion of oxetanes to generate larger oxygen heterocycles.
In particular, oxetanes react with diazo compounds, which can
aﬀord mixtures of products resulting from ring expansion and
ylide formation with protonation or rearrangement.531,532 In
the 1960s, Nozaki et al.533,534 found that, when treated with a
diazo compound in the presence of a chiral copper chelate, 2-
Table 32. Catalytic Asymmetric Multicomponent Aza-Diels−Alder Reaction
Table 33. Enantioselective Synthesis of 1,4-Dioxanes via
Oxetane Desymmetrization
entry R R′
cat loading
(mol %)
time
(h)
yield 371
(%)
ee
(%)
1 Me H 2 12 93 98
2 iPr H 3 36 95 92
3a CF3 H 10 60 92 98
4 HO(CH2)4 H 5 12 99 97
5 vinyl H 5 8 93 96
6 allyl H 3 12 89 98
7 Ph H 5 30 98 92
8 Me Me 5 12 92 94
aReaction was run at 60 °C.
Scheme 145. Enantioselective Synthesis of Alternative
Oxaheterocycles
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phenyloxetane would undergo ring expansion to give a mixture
of cis/trans THF derivatives. In 1994, Ito and Katsuki535
reported asymmetric ring expansion of oxetanes to THFs. Aryl
oxetanes were treated with t-butyl diazoacetate in the presence
of a chiral bipyridyl Cu complex to aﬀord the THFs in yields of
31−40%. Interestingly, whereas racemic 2-(phenyl)oxetane
aﬀorded a 1:1 mixture of trans- and cis-t-butyltetrahydrofuran-
2-carboxylates, (R)-2-phenyloxetane preferentially aﬀorded the
trans isomer while reaction with (S)-2-phenyloxetane aﬀorded
the cis isomer preferentially.536−539
In 2001, Lo and Fu111 published conditions for asymmetric
ring expansion of oxetanes to THFs using diazo esters in the
presence of a Cu(I)/bis(azaferrocene) catalyst, giving excellent
diastereo- and enantiocontrol over the newly generated
stereocenter (Scheme 147). Both the cis and trans diaster-
eoisomers could be synthesized simply by swapping the
enantiomer of the bis(azaferrocene) ligand [(R,R)-381 gave
trans-380 in 98% ee, while (S,S)-381 gave cis-380 in 95% ee].
Lacour and co-workers540 described the formation of a
number of interesting functionalized 15-membered macrocycles
via Rh-catalyzed condensation of a single α-diazo-β-keto ester
with three oxetane molecules (Scheme 148). The reaction
proceeded under mild conditions at 20 °C, with catalyst loading
of just 1 mol % Rh2(OAc)4 and oxetane as the solvent, forming
the macrocycle in yields up to 84%. Diﬀerent ester substituents
were well-tolerated (R1 = Me, Et, tBu, allyl; R2 = Me), as were
diﬀerent ketone substituents (R2 = Et, Pr, Ph, iPr; R1 = Et),
giving excellent yields (55−84%) of the macrocylic products
(382). Substituted oxetanes such as 3,3′-dimethyl- and 3,3′-
Scheme 146. Cascade Formation of Isoxazoles by
Rearrangement of Oxetanes
Table 34. Conversion of Oxetan-3-one into Saturated
Nitrogen Heterocycles via Formation of Intermediate
Spirocycles
entry X R R1 yield (%) dr
1 O H iPr 92 >20:1
2 O H Me 80 >20:1
3 O H Ph 97 >16:1
4 O Et H 80
5 O Ph H 79
6 NTs H Et 67
7 S H H 41
8 S Bn Bn 89 2:1
Table 35. One-Pot Ring Expansion of Spirocyclic Oxetanes
entry R yield 377 (%)
1 p-Cl-C6H4 85
2 Ph 69
3 H 81
4 TMS 75
5 Cy 64
6 (CH2)3Cl 82
Table 36. Microwave-Mediated Synthesis of Oxazoles and
Thiazoles
yield (%)
entry R 378, X = O 379, X = S
1 Ph 36 64
2 cyclohexyl 17 63
3 tBu 14 40
4 3-F3C-Ph 24 36
5 4-MeO-Ph 15 50
Scheme 147. Asymmetric Ring Expansion of 2-Aryloxetanes
by Use of Cu(I)/Bis(azaferrocene) Catalyst
Scheme 148. Macrocyclization of Oxetanes with α-Diazo-β-
keto Esters
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diethyloxetanes could be used to form the corresponding
substituted macrocycles in 65% and 51% yield, respectively.
The reaction was proposed to proceed via initial addition of
oxetane oxygen to the Rh-carbenoid, generated from the α-
diazo-β-keto ester, to form an oxetane ylide (383, Scheme 148).
This oxetane unit then propagates the reaction through the
electrophilic carbon at the oxetane 2-position, with two further
oxetane units adding before trapping with the keto carbonyl
becomes favored to furnish the macrocycle.
In 1999, Larksarp and Alper541 reported the cycloaddition of
vinyloxetanes with heterocumulenes as a method to access 1,3-
oxazines. 2-Vinyloxetane 384 was reacted with an isocyanate or
a carbodiimide in the presence of palladium(0) catalyst and a
phosphine ligand (Scheme 149). Alper proposed that the
reaction proceeded via a π-allyl palladium intermediate, formed
by addition of the vinyloxetane to the palladium complex,
followed by reaction with the isocyanate or carbodiimide. The
reaction yields were lower when isocyanates were used, possibly
due to a faster rate of dimerization of the isocyanate than the
rate of dimerization of carbodiimide, relative to the rate of
cyclization. Bicyclic oxazines could be accessed from the
cycloaddition of bicyclic vinyl oxetanes with isocyanates or
carbodiimides but required a pressurized reactor.
Njardarson and co-workers542 have reported the ring
expansion of vinyl-substituted oxetanes 385 in the presence
of diazo compounds 386 and catalytic Cu(tfacac)2. Both the
[2,3] ring-expansion product 387 and the [1,2] insertion
product 388 were observed in good combined yields, with the
product ratio dependent on which diazo substrate was used
(Scheme 150). The formation of an oxonium ylide
intermediate was crucial for formation of both products.
In subsequent studies, Njardarson and co-workers543−546
reported the ring expansion of vinyloxetanes 389 to 3,6-
dihydro-2H-pyrans 390 in the presence of 1 mol % Cu(OTf)2
or 10 mol % triﬂic acid. Njardarson proposed that Cu(OTf)2
coordinated to the oxetane oxygen atom, prompting ring
opening, and the resulting allylic cation was then captured by
the oxygen atom in a 6-endo-trig cyclization. When a chiral
phosphoric acid catalyst 392 was employed, a chiral
dihydropyran 391 was synthesized with 90% ee but in reduced
yield (Scheme 151).
Treating vinyl oxetane 393 with diisopropyl dithiophosphate
resulted in nucleophilic ring opening to form 394 with Z-
selectivity, while a less nucleophilic reagent, diethyl phosphoric
acid, resulted in ring expansion to form the six-membered ring
395 (Scheme 152).547 Sterics played an important role in this
reaction, with substituents at the oleﬁn terminus inhibiting the
nucleophilic ring opening and enhancing the acid-catalyzed
pathway to form the ring-expanded product. No reaction was
observed when alkynyloxetanes were exposed to the reaction
conditions.
Alkynyloxetanes have been used in metal-catalyzed oxidative
cyclization reactions. Gagosz and co-workers548 showed that
when alkynyloxetane 396 was treated with a Cu(I) catalyst in
the presence of an oxidant, ring expansion occurred to form
both dihydrofuran 397 and lactone 398 (Table 37). Careful
Scheme 149. Synthesis of 1,3-Oxazines via Cycloaddition of
Vinyloxetanes with Isocyanates or Carbodiimides
Scheme 150. Ring Expansion of Vinyloxetanes to Medium-Sized Oxacycles
Scheme 151. Ring Expansion of Vinyloxetanes to 3,6-
Dihydro-2H-pyrans
Scheme 152. Z-Selective Ring Opening and Ring Expansion
of Vinyloxetanes
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tuning of the substituents on the pyridine N-oxide promoted
selective formation of either product. The use of a more
electron-deﬁcient 3-bromopyridine N-oxide favored dihydrofur-
an formation, being a better leaving group for 5-exo-trig
cyclization (entry 2). The more electron-rich 4-methoxypyr-
idine N-oxide favored lactone formation (entry 3). This ring
expansion was successful with a variety of alkynyloxetanes,
including both aryl and alkyl substitution at the 2-position as
well as methyl and phenyl groups at the 3-position of the
oxetane ring.
Formation of eight-membered heterocycles via Ni-catalyzed
reaction of oxetan-3-ones with 1,3-dienes was reported by
Louie and co-workers in 2013.549 Oxetan-3-one was treated
with 1,3-dienes in the presence of Ni(cod)2 and P(p-tolyl)3 to
aﬀord medium-sized rings (Scheme 153). The methodology
was also successful in reaction of azetidin-3-ones with 1,3-
dienes to form eight-membered N-heterocycles. Dienes with
benzyl and homobenzyl substituents were well-tolerated under
the reaction conditions, as were macrocyclic dienes.
In 2014, Liu and co-workers550 reported the [4 + 2]
cycloaddition of ynamides 399 with 2-aryloxetanes in the
presence of an Ag/Au complex to aﬀord six-membered 6-
amino-3,4-dihydro-2H-pyrans 400 (Scheme 154). Excellent
regioselectivity was observed due to the electrophilicity of the
Au−π-ynamides, which react with the oxetane nucleophiles.550
A variety of aryloxetanes and arylynamides were successfully
employed in the cycloaddition reaction.
In 2014, Yin and You551 reported an enantioselective
chlorination/ring-expansion cascade of cyclobutanols, accessing
chiral 2-alkyl-2-aryl cycloalkanones with excellent ee values by
use of 1,3-dichloro-5,5-dimethylhydantoin (DCDMH),
(DHQD)2PHAL as a catalyst, and N-Boc-L-phenylglycine
(NBLP) as a ligand. Yin and You also showed that oxetanols
401 were also compatible with this methodology, accessing
enantioenriched dihydrofuran-3(2H)-ones 402 in good yields
and excellent enantioselectivities (Scheme 155). Substrates
bearing halogenated aryl rings showed decreased reactivity
compared with more electron-donating substituted aromatics.
9. CONCLUSION
This review aims to provide an overview of the extensive recent
works involving oxetanes in synthesis and medicinal chemistry
and to highlight the continuing challenges. This interest has
been facilitated, and partly driven, by the emergence of
oxetanes for applications in medicinal chemistry. Oxetanes
Table 37. Cu(I)-Catalyzed Ring Opening of Alkynyloxetane 396 to Lactone and Dihydrofuran
entry R ratio (397:398) yield (%)
1 H 1.9:1 84
2 3-Br 1:0 85
3 4-OMe 0:1 74
Scheme 153. Nickel-Catalyzed Cycloaddition of 1,3-Dienes
with Oxetan-3-ones and Azetidin-3-ones
Scheme 154. Au- and Ag-Catalyzed [4 + 2] Cycloaddition of
Ynamides with Oxetanesa
aL = (o-biphenyl)(t-Bu)2P.
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present important opportunities to tune physicochemical
properties and increase the stability of a molecule, as well as
providing intellectual property novelty within a compact motif.
Thanks to the increasing commercial availability of oxetane-
containing building blocks, along with improved methods for
synthesis, oxetanes are likely to be increasingly used in
medicinal chemistry programs. However, to date it remains
challenging to target speciﬁc oxetane derivatives and to position
substituents and functional groups around the ring at
prescribed locations, especially for chiral nonracemic oxetanes.
These synthetic challenges continue to limit the full
exploitation of this ring system.
Williamson etheriﬁcation remains the most common
approach for oxetane synthesis, with cyclization from 1,4-
functionalized precursors providing a reliable strategy. How-
ever, the functionality that can be installed on the ring by this
approach is sometimes limited, and the synthesis of
(enantioenriched) cyclization precursors presents its own
challenge. An epoxide-opening and ring-closure sequence
with sulfoxonium ylides can take advantage of chiral epoxide
precursors to generate enantioenriched oxetanes. Sugars are
also valuable precursors to oxetanes but can require lengthy
sequences to unveil the heterocycle, with the stereochemical
outcome determined by the starting sugar. Alternative C−C
bond-forming cyclization methods are emerging that oﬀer the
potential to access new and valuable derivatives in relatively
short sequences and to provide oxetanes bearing more varied
functional groups. Increasing the options for cyclization
through alternative strategies that are applicable to a wide
array of substrates would be a valuable addition to the current
methodology.
The Paterno ̀−Büchi reaction continues to present a
conceptually attractive approach to bring together readily
available reactive partners to form oxetane rings. The
substituent requirements for photochemical activation have
perhaps limited the application of this methodology in
medicinal chemistry to date. However, this reaction presents
considerable scope for further development, likely to exploit
technological developments and engineering solutions to
facilitate the photochemistry. At the same time, small-
molecule-catalyzed formal [2+2] methods oﬀer a compelling
alternative, especially where chiral catalysts can be exploited to
generate enantioenriched products. The scope of recent
developments has been limited to highly electrophilic ketones,
such as triﬂuoromethyl ketones and closely related derivatives,
but oﬀers considerable potential upon extension to wider
classes of reagents.
One approach to access oxetane derivatives likely to see
extensive development in coming years is the functionalization
of intact oxetane rings, taking advantage of preformed oxetane
derivatives as building blocks and also allowing divergent
synthesis. To date this is not well-developed, with few bond-
forming reactions available, although SN2 reactions have been
demonstrated by use of good nucleophiles on oxetanes bearing
leaving groups. There is considerable potential for the
application of more (stereocontrolled) methods to attach
oxetane derivatives to target structures. Carreira’s oxetanone
has been widely embraced by synthetic and medicinal chemistry
communities, with simple reactions such as reductive amination
being very popular, as well as having applications in more
complex ketone chemistry and multicomponent reactions.
Simple cross-couplings of other oxetane units, such as halide
and boronic acid derivatives, are not well-developed, but some
important examples of cross-coupling at the oxetane 3-position
include Negishi cross-couplings and reductive coupling of an
oxetane halide with an aryl halide component. Furthermore,
only monosubstituted oxetane derivatives have been demon-
strated in these cross-coupling reactions.
Attempts to deprotonate oxetanes and form oxetanyl anions
have been limited to date, presumably due to the reactive
carbenoid nature of the deprotonated intermediate, and
stabilizing groups have been required in these limited examples.
Complementary radical methods have emerged recently by use
of oxetane itself. While these approaches have often used a large
excess of oxetane reagent, there is considerable potential for
method development and application to a wider range of
oxetane structures.
2-exo-Methyleneoxetanes present interesting precursors for
further reaction and another strategy to introduce groups onto
the oxetane ring, through activation of the oleﬁn and addition
of nucleophiles. Subtle reactivity diﬀerences between nucleo-
philes can lead to diﬀerent outcomes, potentially with ring
opening as a competing reaction pathway. Enantioselective
syntheses of alkylideneoxetanes have recently emerged through
formal [2+2] methods from allenes and ketones, with the
reaction scope to date limited to activated ketones.
The wide variety and number of oxetane compounds
appearing in the medicinal chemistry and patent literature
highlights the breadth of occurrence and the advantages
perceived from incorporation of this motif. Most commonly,
3-substituted oxetane derivatives are observed in these potential
medicinal compounds, being derived from simple building
blocks; 3-amino and 3-mono- or 3,3-disubstituted oxetane
derivatives (alkyl−alkyl or aryl−alkyl) are most prevalent.
Occasionally 2-substituted derivatives have been made, though
there are fewer available building blocks, and these derivatives
can introduce chirality and hence complexity. Nucleoside
analogues, containing fused and spirocyclic oxetanes, have also
shown interesting activity and proﬁles. However, it is apparent
that the oxetane structures are most commonly present as
pendant motifs. Further growth in the numbers of simple, small
oxetane building blocks that are readily available and can be
readily incorporated through simple linkages would certainly be
welcomed by medicinal chemists. Such small motifs, without
additional functionality to utilize in synthesis, are not trivial to
prepare in large quantities through current methods.
There continue to be important questions on the stability of
the oxetane motif in biological settings, which is crucial
Scheme 155. Asymmetric Chlorination/Ring Expansion of
Oxetanols
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information in the context of medicinal chemistry. In many
cases, high stability has been observed; however, this is likely to
be dependent on speciﬁc cases and surrounding molecular
structure and functional groups, and more studies are required.
For acid stability and stability to nucleophiles, a greater
understanding of structure−stability relationships, including the
eﬀect of diﬀerent substituents and substitution patterns on the
oxetane ring, as well as the eﬀects of other groups in the
molecule that may have stabilizing or destabilizing eﬀects,
would be very valuable. Such precompetitive information could
facilitate the more targeted installation of appropriate oxetane
derivatives, and the design of new derivatives that may oﬀer
improved properties. On the other hand, the small ring, being
unusual and not well recognized by the body, is unlikely to
present speciﬁc metabolic liabilities. Indeed, the beneﬁcial
increase in polarity upon incorporation of an oxetane provides a
general reduction of lipophilicity, often associated with an
increase in metabolic stability.
Oxetanes present considerable potential as isosteres. To date,
the majority of studies from Carreira concerned the
replacement of gem-dimethyl groups or carbonyl groups;
replacement of the carbonyl of thalidomide with an oxetane
to prevent racemization provides an elegant example. Peptide
mimics have recently appeared in the literature, in the form of
aminooxetanes, which show stability to enzymatic cleavage.
Other speciﬁc isosteres can be envisaged that could oﬀer
attractive properties, for example, speciﬁc ester or ketone
derivatives, which could be examined through direct pairwise
comparison. Furthermore, novel substituted oxetane derivatives
can readily provide access to new chemical space. More data
will inevitably emerge as usage in medicinal chemistry
continues and as new attractive building blocks and methods
facilitate further use, contributing to the body of knowledge on
the appropriateness of the oxetane ring in diﬀerent circum-
stances.
Powerful examples of the use of oxetanes as intermediates in
the synthesis of complex molecules and natural products have
been reported in the last ﬁve years. Exploitation of oxetanes as
reactive intermediates in this way provides a valuable
disconnection that is likely to be exploited more widely.
However, there remains space for fundamental studies on
methods for the ring opening of oxetanes. As a synthon,
oxetane is not yet close to being aﬀorded a similar proﬁle in
ring-opening reactions as the analogous epoxide, but it oﬀers
similar potential. The opening of enantioenriched oxetanes
provides valuable chiral building blocks, but nucleophilic
opening remains underexplored.
On the other hand, enantioselective opening of prochiral
oxetanes has taken great strides, through the desymmetrization
of prochiral 3-substituted and 3,3-disubstituted oxetanes. Very
high ee values have been obtained, and there are clear
opportunities for further development to extend the range of
nucleophiles and substrates, as well as to applying these
strategies to additional transformations that generate complex-
ity. Furthermore, the development of enantioselective kinetic
resolutions of racemic chiral derivatives would present
alternative approaches to enantioenriched building blocks.
It is feasible that improved understanding of oxetane ring
opening could lead to applications in medicinal chemistry, for
example, as covalent irreversible inhibitors with an oxetane
“warhead”. Alternatively, as a labeling tool in chemical biology,
subtle changes in oxetane structure may be able to promote
selective reactions, for example, with protein side chains.
Throughout this review, we have considered applications
toward biologically active compounds and medicinal chemistry.
Undoubtedly, improved access to oxetane derivatives and
understanding of ring opening will have impact in other ﬁelds,
such as polymer and materials science, through bespoke
oxetane monomers. The development of shorter and stereo-
controlled routes to oxetane derivatives, bearing a greater
variety of functionality around the ring, as well as novel readily
accessible oxetane building blocks, are required to develop the
applicability of the four-membered ring in these and other
ﬁelds. Numerous challenges remain in synthesis, reactivity, and
understanding of oxetane properties, but we expect further
exciting developments in coming years.
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(74) Burkhard, J. A.; Gueŕot, C.; Knust, H.; Carreira, E. M.
Expanding the Azaspiro[3.3]heptane Family: Synthesis of Novel
Highly Functionalized Building Blocks. Org. Lett. 2012, 14, 66−69.
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Alkyl Cyanobenzoates with Diphenylethene upon Direct versus
Charge-Transfer Excitation. J. Org. Chem. 2010, 75, 5461−5469.
(277) D’Annibale, A.; D’Auria, M.; Prati, F.; Romagnoli, C.; Stoia, S.;
Racioppi, R.; Viggiani, L. Paterno-̀Büchi Reaction versus Hydrogen
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(465) Selig, P.; Turocǩin, A.; Raven, W. Synthesis of Highly
Substituted Oxetanes via [2+2] Cycloaddition Reactions of Allenoates
Catalyzed by a Guanidine Lewis Base. Chem. Commun. 2013, 49,
2930−2932.
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00274
Chem. Rev. XXXX, XXX, XXX−XXX
CC
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